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1 RHEUMATOID ARTHRITIS
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease, which mainly 
affects the synovial joints. About 0.5 to 1% of adults suffer from this debilitating disease 
in western countries and about three times more women than men are affected.1 RA 
is characterized by the influx of immune cells into the joint, which leads to synovial 
hyperplasia, vascularization and in later stages damaged cartilage and bone. Patients 
suffer from swollen and painful joints and the progressive joint damage leads to functional 
decline over time. Furthermore, patients have an increased risk for co-morbidities such as 
cardiovascular diseases, certain types of cancer and depression.2 Since there is currently 
no cure for RA, early detection and good treatment are essential to minimize the disease 
burden in patients. To achieve these goals, it is crucial to understand the development 
and underlying immunopathogenesis. Therefore, this section provides an overview of the 
current knowledge in these two areas.
1.1 Development of RA
The diagnosis of RA is given to a patient at the moment they present to the rheumatologist 
with inflammatory arthritis in more than one joint and, depending on the number and 
type of joints affected, the presence of auto-antibodies, symptom duration longer than 6 
weeks and/or an abnormal acute-phase response.3 However, it is currently incompletely 
understood which processes precede this stage of clinically defined RA, although it is 
believed that multiple factors play a role in the development of RA. Based on these factors 
and studies in patients at risk for developing RA, five different phases leading up to RA 
diagnosis have been distinguished, although it should be noted that these phases do not 
necessarily occur in all patients or in this sequence, and can also occur simultaneously.4 
The first phase is the presence of genetic risk factors. Considering the high heritability rate 
of RA, which is estimated to be 50% for seropositive RA and 20% for seronegative RA5, 
genetic factors play an important role in the susceptibility to develop RA. The strongest 
genetic association is currently found in the HLA genes, where 5 amino acids explain 
12,7% of the heritability of RA.6
The second phase entails the exposure to environmental risk factors. These comprise 
a large number of factors, such as education level, weight, breastfeeding, air pollution, 
periodontal disease and ultraviolet light exposure.7 The latter is mainly related to the 
vitamin D serum level, which is inversely correlated with RA disease activity and may 
affect the risk of developing RA. However, the environmental risk factor that is most 
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strongly correlated with an increased risk of developing RA is smoking, where the number 
of cigarettes and the duration of smoking both contribute to the increased risk up to 20 
years after cessation.8 
Together, the genetic and environmental risk factors may lead to the third phase of the 
disease; systemic autoimmunity. This phase, which can already be identified years before 
disease onset, markers of autoimmune inflammation can be detected in the peripheral 
blood. The most extensively described markers are autoantibodies. Various types of 
autoantibodies have been described to be present predating RA diagnosis, including 
anti-carbamylated peptide antibodies (ACarPs), anti-PAD4-antibodies and anti-IgG4 hinge 
antibodies, but the best known are rheumatoid factor (RF) and anti-citrullinated peptide 
antibodies (ACPA).7 Rheumatoid factor is directed against the Fc part of IgG and is found 
in 50-80% of patients and 10% of healthy individuals.9-10 ACPA are directed against 
citrullinated peptides, such as α-enolase, fibrinogen, vimentin, filaggrin and collagen type 
I and II, and are highly specific for RA.10 Citrullination is the process where an arginine 
in the protein is changed into a citrulline by peptidylarginine deiminases (PADs) and 
which occurs mainly during apoptosis.11 However, certain environmental risk factors 
can increase the level of citrullinated proteins and thereby increase the likelihood of 
citrullinated peptides to be detected by the immune system. For example, the amount 
of citrullinated proteins is increased in the lungs in response to smoking or other air 
pollutants.12-13 Furthermore, citrullination is increased in neutrophils in response to A. 
actinomycetemcomitans, one of the bacteria associated with periodontitis.14 Of note, 
during apoptosis PAD enzymes may not only citrullinate proteins inside the apoptotic 
cells. They may also leak out and citrullinate proteins in their environment, thereby 
providing even more sources for an immune response in RA.15
Next to the presence of autoantibodies, the systemic autoimmunity phase is also 
characterized by elevated levels of cytokines and chemokines, such as monocyte 
chemotactic protein (MCP)-1, tumor necrosis factor (TNF)-α, interleukin (IL)-6, soluble 
TNF receptor II, granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-1β 
and IL-10.16-20 Interestingly, the concentration of cytokines increases towards the diagnosis 
of RA.8, 16, 21 Additionally, there is epitope spreading and altered glycosylation of the 
autoantibodies, of which the latter recently was shown to be essential for pathogenicity 
of autoantibodies.21-23
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In the next phases there is a conversion from systemic autoimmunity to local joint 
inflammation, which is usually the start of clinical presentation. In the fourth phase, 
defined as symptoms without clinical arthritis, patients have complaints such as pain and 
morning stiffness but without evidence of synovitis on imaging and clinical evaluation. 
In the fifth phase, which is unclassified arthritis, there is clinical evidence of synovitis, 
but the patient does not (yet) meet the criteria set for the RA diagnosis.4
In 60% of the unclassified arthritis patients, the joint inflammation will resolve. However, 
in the remaining 40% the inflammation becomes chronic and they will be diagnosed 
with RA within three years after the first symptoms. Notably, 90% of ACPA positive 
unclassified arthritis patients will progress to RA, making ACPA positivity a clear risk 
factor for developing RA.24
1.2 The immunopathogenesis of RA
In recent years, research focus has shifted from the established phase of RA towards the 
earlier phases. It is thought that there is a ‘window of opportunity’ in which treatment is 
most effective, since symptom duration is associated with drug-free sustained remission 
and radiographic progression.25 Therefore, early detection may limit the risks of chronic 
synovitis and may even provide a cure for the disease. In order to do that, it is important 
to understand the underlying immunological processes. Due to extensive research, a 
picture is beginning to emerge in which both cells from the immune system and joint 
stromal cells play an important role in disease pathogenesis. Through cell-cell interaction 
and production of pro-inflammatory cytokines, these cells activate each other and 
thereby fuel a chronic inflammation. Although anti-inflammatory factors, such as IL-10 
and soluble TNF receptors, are produced by the RA pannus and somewhat limit the 
inflammation26-27, they are not sufficient to completely control the immune system and 
restore joint homeostasis.
Since there is still debate on the order in which cells are activated28, we here provide an 
overview of the various cell types that can be found in the pannus of RA joints and the 
roles they may play in the onset, development and chronicity of RA. An overview of their 
interactions is displayed in figure 1. 
Antigen-presenting cells
The normal adaptive immune response starts with antigen-presenting cells (APCs), such 
as dendritic cells (DCs) but also macrophages and B cells. These cells scavenge the body 
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for foreign intruders and can present specific parts of the intruders as peptides on their 
major histocompatibility complex (MHC) molecules. The antigens can be sensed by 
highly specific T cells, which will initiate an immune cascade with the goal to eradicate 
the intruder. 
In the context of RA, APCs can initiate the autoimmune response by presenting self-
antigens instead of foreign antigens, such as citrullinated or carbamylated peptides. 
Interestingly, the HLA-DR variant that is associated with increased RA susceptibility 
encodes an MHC class II molecule with higher avidity for citrullinated peptides than 
for native peptides.29 This may explain the increased RA susceptibility for individuals 
carrying this specific HLA-DR allele, and could also explain the further increase in 
susceptibility when these patients also smoke and hence have higher levels of citrullinated 
proteins in their lungs.30 
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Figure 1. Schematic overview of the cellular interactions mediated by different proinflammatory cytokines 
in RA. The interaction between immune cells and joint-residing cells in RA is shown. TNFα is produced by 
almost all immune cells and affects many immune cells and joint cells. During the inflammatory process a 
counter reaction of regulatory and anti-inflammatory factors will also be induced (not depicted in this figure).
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APCs are also efficient producers of pro-inflammatory cytokines such as IL-6, IL-23 
and TNFα, to drive differentiation of the antigen-specific T cells and to further activate 
other APCs, but also synovial fibroblasts. Chemokines such as IL-8 are produced to 
attract more immune cells, such as monocytes, thereby further activating inflammation. 
Macrophages and DCs are found in high levels in the synovium and synovial fluid of RA 
patients.31-32 Notably, DCs in the synovial fluid are distinct from DCs in the blood and are 
also called inflammatory DCs.33 Furthermore, the levels of macrophages in the synovium 
are correlated with disease activity and decrease during successful antirheumatic 
treatment.34-35 These data suggest that APCs such as DCs and macrophages not only 
play a role in the initiation of the inflammatory response, but they also contribute to the 
perpetuation of the inflammation. 
T cells
T cells can roughly be divided into three groups; (1) cells with a T cell receptor (TCR) 
consisting of an α and β chain (TCRαβ) and the coreceptor CD4, (2) cells with TCRαβ 
and the coreceptor CD8 and (3) cells with a TCR consisting of a γ and δ chain.
CD4+ T cells, also called T-helper (Th) cells, are activated in the normal immune 
response once their highly specific TCR recognizes an antigen presented on MHC class 
II molecules by an APC presenting antigens on their MHC class II molecules. A second 
signal via interaction between CD28 on T cell and CD80 and CD86 on the APC ensures 
survival of the T cell. Depending on the cytokines secreted by the APC, the Th cells then 
differentiate towards several types of effector cells. IL-12 leads to the differentiation of 
a Th1 cell, whereas IL-4 directs towards Th2 cells and the combination of transforming 
growth factor (TGF)-β or IL-1β, IL-6 and IL-23 induces a Th17 phenotype. These Th cells 
can then propagate the immune response through activation of B cells and production 
of pro-inflammatory chemokines and cytokines to activate and attracts other immune 
cells. Of note, when there is only TGFβ in the environment during antigen-presentation, 
the Th cells will become a regulatory T cell (Treg) and suppress inflammation. After the 
infection is cleared, most Th cells will die but some will become memory Th cells in 
order to clear the intruder faster during the next infection.
CD8+ T cells are known for their cytotoxic activity and are activated when their TCR 
recognizes the antigen presenting on an MHC class I molecules of an APC. These cells 
then start producing lytic enzymes, such as granzymes and perforin, which will kill 
the infected cells. Furthermore, they will also produce pro-inflammatory cytokines like 
13
Introduction
interferon (IFN)-γ and TNFα. Similar to Th cells, also CD8+ T cells will form memory 
cells after the infection is cleared.
The γδ T cells are somewhat different than the Th and C8+ T cells, in that they do not 
require stimulation from an APC to get activated. Instead, they are activated by small 
nonpeptide phosphoantigens. Upon activation, γδ T cells can induce DC maturation, 
produce pro-inflammatory cytokines and help B cells.
Since the APCs in RA present self-antigens instead of foreign antigens, the reaction 
mounted by T cells is directed against self-tissue. This is a reaction that should normally 
be suppressed by deletion of autoreactive T cells during thymic development. However, 
in RA patients this tolerogenic mechanism is defective and autoreactive T cells are able 
to initiate the autoimmune response.
Although γδ T and CD8+ T cells are both found in the synovium of RA patients and their 
normal functions provide clues that they may play a role in synovial inflammation36-37, 
it is thought that Th cells play the major role in RA pathogenesis. This is partly due to 
the correlation between HLA-DR haplotypes and RA susceptibility, since HLA-DR is 
an MHC class II molecule and hence activates the Th cells. Although all Th cells can 
activate B cells to further induce the immunological cascade, it seems that not all Th 
cells are equally important in the development of RA. Classically it was thought that 
Th1 cells were the most pathogenic cells in autoimmune diseases such as RA, but the 
discovery of IL-23 has placed the Th17 cells at the center of attention.38 Several studies in 
experimental arthritis models have suggested a role for Th17 cells in the development of 
arthritis, such decreased severity of collagen-induced arthritis upon deletion of IL-17A, 
the signature cytokine of Th17 cells.39 Furthermore, mice deficient in IL-23 or IL-17R 
are protected against developing arthritis.40-41 In human RA, Th17 cells and IL-17A are 
elevated compared to healthy controls and are correlated with disease activity.42-43
Functionally, the difference in pathogenicity between Th17 cells and other Th subsets 
could lie in the activation of synovial fibroblasts. CCR6+ memory Th (memTh) cells, 
which include Th17 cells but not Th1 or Th2 cells, are specifically able to activate synovial 
fibroblasts from RA patients. This interaction creates a pro-inflammatory feedback loop 
that promotes the production of pro-inflammatory cytokines such as IL-17A, IL-6 and 
IL-8, but also tissue-destructive matrix metalloproteases.43 Another important mechanism 
by which Th17 cells contribute to RA disease pathogenesis is through modulation of 
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plasma cells. A recent study has shown that specifically IL-23-activated Th17 cells reduce 
the expression of St6gal1, a sialyltransferase, in plasma cells via IL-21 and IL-22. As a 
result, autoantibodies produced by these plasma cells have reduced sialic acid residues and 
become pathogenic, resulting in autoimmune synovial inflammation.23 These data may 
also explain the disappointing results in clinical trials targeting IL-17A or its receptor in 
established RA patients, since the role for Th17 cells may lie predominantly in disease 
onset.38
All the Th cells discussed so far have a pro-inflammatory role and could thereby contribute 
to synovial inflammation. However, there may also be a role for the regulatory T cells 
(Tregs). These cells normally inhibit inflammation via production of the anti-inflammatory 
cytokine IL-10 and inhibiting proliferation of other Th cells. Their importance in RA 
is demonstrated in murine experimental arthritis, where Treg-depletion aggravates 
arthritis and administration of antigen-specific regulatory cells cures and protects from 
arthritis.44-45 
Interestingly, Tregs are specifically decreased during active disease in RA patients 
and patients have a higher Th17/Treg ratio than healthy controls.46 This immunological 
imbalance may play an important role in the chronic inflammation and normalization is 
an important therapeutic challenge.
B cells and antibody production
B cells are activated through interaction with Th cells via their antigen-specific B 
cell receptor (BCR). Upon activation they will proliferate and undergo class switch 
recombination and somatic hypermutation of their BCR. This results in highly specific 
memory B cells and most importantly; large amounts of plasma cells which secrete 
antibodies towards the antigen. In addition, activated B cells secrete cytokines such as 
IL-6 to stimulate other immune cells.
Similar to T cells, B cells should normally not be activated by self-antigens because 
the autoreactive B cells are mostly removed during their development. In RA patients, 
for an unknown reason there is a break of tolerance leading to an increased amount of 
autoreactive B cells in the peripheral blood of RA patients.47 These autoreactive B cells 
can contribute to RA development by the production of high-affinity autoantibodies, such 
as ACPA or RF which are associated with the risk of developing RA. There are various 
mechanisms through which these auto-antibodies can contribute to the disease progress 
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in RA. First, it has been shown that ACPAs specific for citrullinated vimentin activate 
osteoclastogenesis, which starts bone loss but also induces pain and the production of 
IL-8.48 IL-8 acts as a chemokine and can attract immune cells such as neutrophils and 
macrophages, which may start the pro-inflammatory cascade leading up to chronic 
synovitis. Furthermore, autoantibodies can bind autoantigens to form immune complexes, 
which attracts complement and thereby drives the inflammation.49
Next to their antibody production, B cells can also contribute to inflammation through 
antigen-presentation, as described in the APC section, and through cytokine production. 
IL-6 is one of the cytokines that is produced by B cells upon activation and which is 
important for the development of Th17 cells and activation of other immune cells.50 
Importantly, synovial fluid B cells from RA patients also produce RANKL, which is 
important for osteoclast differentiation and thus contributes to the bone loss observed 
in patients.51 
Innate immune cells
Although the adaptive immune response appears to play a major role in starting RA 
pathogenesis, also immune cells of innate origin contribute to the ongoing synovial 
inflammation.
During a normal immune response, innate immune cells form the first line of defense. 
They fight pathogens through phagocytosis, complement activation and lytic cell death. 
Furthermore, they activate the adaptive immune system via antigen-presentation as 
discussed previously. 
In RA synovial inflammation, especially macrophages play a significant role. Next 
to their function as APC, as described earlier in this chapter, macrophages are potent 
producers of pro-inflammatory cytokines such as TNFα, IL-1 and IL-6. Furthermore, they 
produce matrix metalloproteases (MMPs) that mediate tissue destruction, reactive oxygen 
species and chemokines to recruit other immune cells.52 Finally, the macrophages from 
RA synovial tissues are capable of promoting neovascularization, an important process 
in the formation of the inflammatory pannus in RA.53 It is hypothesized that these pro-
inflammatory macrophages differentiate from the monocytes that invaded the RA tissue, 
rather than representing aberrantly activated tissue-resident macrophages.54
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Mast cells and neutrophils are two other innate immune cell types which can be found 
in the RA synovial tissue. They are thought to contribute to RA pathogenesis through 
the production of pro-inflammatory cytokines, prostaglandins, chemokines and reactive 
oxygen species.52 However, recently a new role has been hypothesized for neutrophils 
in RA pathogenesis. Neutrophils can create neutrophil extracellular traps (NETs) via a 
process called NETosis, which is normally used to trap and kill microbes. However, these 
NETs also contain high amounts of citrullinated histones and could therefore provide a 
source of autoantigens to which other immune cells react.55
Synovial fibroblasts
Next to the immune cells, also the local joint cells play an important role in RA 
pathogenesis. In a synovial joint, the non-articular surfaces are lined with a 1 to 3 cells 
thick layer called the synovium. The synovium consists of fibroblast-like synoviocytes, 
or synovial fibroblasts, and tissue-resident macrophages. In RA patients, the synovial 
cells start hyperproliferating, producing pro-inflammatory cytokines, chemokines and 
tissue-destructive enzymes and there is vascular growth in the synovium. Furthermore, 
the fibroblasts start presenting antigens that further aggravate synovial inflammation.56
Already in 1996 it was demonstrated that the synovial fibroblasts from RA patients 
(RASF) have an activated invasive and destructive phenotype which they maintain over 
longer periods of time after isolation from the arthritic joint.57 New studies suggest that 
this change in phenotype already occurs very early in the disease; RASF from early 
RA patients do not exhibit the suppressive functions anymore that RASF from healthy 
individuals or patients with resolving arthritis have. Later, in the established disease, 
the RASF even stimulate inflammation by activating synovial endothelium to attract 
immune cells.58 Interestingly, it was recently shown that synovial fibroblasts differ in their 
phenotype depending on the joint they originate from. For example, synovial fibroblasts 
from lower extremities such as knees and ankles respond stronger to TNFα than those 
from upper extremities such as shoulders and hands. Also, hand synovial fibroblasts 
produce more MMP13 than shoulder and knee synovial fibroblasts.59 Thereby, these cells 
could contribute to the symmetric joint inflammation that is observed in RA, further 
demonstrating their importance in disease pathogenesis. Since gene expression patterns 
that discern these groups of fibroblasts are similar between knees of RA patients and 
healthy controls, it is postulated that the differences are intrinsic and not due to disease.59 
This phenomenon could be related to the aberrant epigenetic signatures in RASF, as 
described for DNA methylation and histone modifications.60
17
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Due to the increased recognition for the role of synovial fibroblasts in RA, they have also 
become interesting therapeutic targets.61 This emerging field will expand over the coming 
years and more studies will further increase our knowledge on the role and the potential 
therapeutic targeting of RASF.
Chrondrocytes and osteoclasts
Two important features of RA are damaged cartilage and bone erosions, which are largely 
mediated by chondrocytes and osteoclasts, respectively.
Although synovial fibroblasts and macrophages are potent producers of MMPs that mediate 
cartilage destruction, this cannot explain the cartilage damage in the deep zones of the 
cartilage not directly adjacent to the pannus.62-63 Therefore, it is thought that chondrocytes 
may also play a crucial role in joint damage. In a healthy joint, chondrocytes reside in the 
cartilage and maintain a balance between cartilage degradation and synthesis of cartilage 
components. However, in RA they are stimulated by pro-inflammatory cytokines such as 
IL-1 and TNFα.64 In response, they release MMPs and other proteases that tip the balance 
towards cartilage degradation. Furthermore, chondrocytes start producing IL-6, PGE2 
and chemokines to further aggravate the ongoing inflammation.64
While chondrocytes are mediators of cartilage damage in RA, osteoclasts are responsible 
for the bone erosions in this disease. Under homeostatic conditions, the bone-resorbing 
osteoclasts are in equilibrium with the bone-forming osteoblasts. During inflammation, 
osteoclasts are highly activated through the increased abundance of RANKL expressed 
by immune cells and synovial fibroblasts, leading to an increased RANKL/OPG balance. 
Furthermore, TNFα is also capable of directly promoting osteoclastogenesis independent 
of RANKL. This increased activation leads to increased bone resorption at the site of 
the pannus.65
2 TREATMENT OF RHEUMATOID ARTHRITIS
Before the development of the modern RA medication, patients were treated with non-
steroidal anti-inflammatory drugs (NSAIDs), hydroxychloroquine, gold or steroids and 
bed rest, which were not very effective or quite toxic. Luckily, that situation has greatly 
improved by the introduction of methotrexate and later by the biological disease-modifying 
antirheumatic drugs (bDMARDs), or ‘biologicals’. Here we will give an overview of the 
current treatment protocols, how they intervene in the immune pathogenesis as described 
above, and the opportunities to improve the current therapies.
1
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2.1 Current treatment
The goal of all RA treatment is to achieve sustained disease remission or low disease 
activity if remission is not possible due to longstanding disease. In order to reach 
remission as early as possible, it is important that an RA patient is treated as soon 
as the diagnosis is made.66 According to the most recent EULAR recommendations, 
patients are first treated with methotrexate (MTX) or another conventional DMARD 
(cDMARD) such as sulfasalazine when patients have a contraindication for MTX.66 When 
there is no improvement in disease activity within three months after the start of the 
treatment, or when the treatment goal is not reached after six months, other drugs can 
be added to the MTX therapy. Usually patients are started on a bDMARD which targets 
the cytokine TNFα. Although this is only one of the cytokines in the immunological 
processes described above, the success rate of this therapy indicates that TNFα plays a 
central role in the inflammatory cascade. This has fueled the hypothesis that there is a 
hierarchical cytokine structure in RA, with certain cytokines being central in driving 
the joint inflammation.67
If TNFα-targeting treatment is not effective in bringing down disease activity, other 
bDMARDs are available that inhibit IL-6-mediated signaling, another key pathway in the 
hierarchical cytokine structure, via inhibition of IL-6R, suppress T cell activation through 
mimicking CTLA4 or deplete B cells by targeting CD20. Recently, also so-called targeted, 
or non-biological, DMARDs have been approved which interfere in the Janus Kinase 
(JAK) pathways. The JAKs are important in the downstream signaling of many cytokines, 
including IL-6, IL-23 and IFNγ, and thereby target multiple pro-inflammatory pathways 
simultaneously. Although they are currently not in the first line of treatment, that may 
change in the future since their route of administration may be preferred by patients (oral 
versus injection) and there are indications that they work equally well in monotherapy as 
in combination with MTX.68 Finally, patients are treated with glucocorticoids (GC), such 
as prednisone and dexamethasone, as a bridging therapy when a new treatment is started 
or a patient switches to a different treatment. These GCs quickly resolve inflammation, 
but due to their side effects they should be tapered and preferably stopped as soon as 
clinically possible. Of note, these GCs are often combined with vitamin D supplements 
to prevent the osteoporotic side effects of the GCs.
2.2 Improving RA treatment: restore the immunological imbalance
Although the current treatment protocol has improved the quality of life of many RA 
patients, there is also a large group of patients who do not respond sufficiently to these 
19
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therapies or who become resistant over time. Also, there is still no cure for the disease. 
Therefore, it is important to keep working on better treatments and preferably a way to 
cure or prevent RA. 
One way to achieve this goal is to normalize the immunological imbalance that is present 
in autoimmune diseases such as RA. An important sign of the immunological imbalance 
in RA is the increased level and activity of the Th17 cells, combined with the decreased 
level and functionality of Tregs. Therefore, inhibiting the activity of Th17 cells could be 
an important step towards normalizing the immunological balance in early RA patients.
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Figure 2. The pathogenic role of CCR6+ memTh cells in RA synovial inflammation. (Upper panel) Current 
knowledge on the potential pathogenic effects of CCR6+ memTh cells, including RASF activation, direct 
and indirect macrophage activation, B cell modulation and indirect cartilage and bone destruction. (Lower 
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 on this pro-inflammatory system, by inhibiting CCR6+ memTh pathoge-
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Interestingly, we have previously shown that the pro-inflammatory activity of CCR6+ 
memTh cells, which include Th17 cells and several other IL-17A-producing subpopulations, 
can be efficiently inhibited by the active vitamin D metabolite 1,25(OH)
2
D
3
.69 Furthermore, 
1,25(OH)
2
D
3
 can also inhibit the pro-inflammatory loop between CCR6+ memTh cells 
and synovial fibroblasts, which could prevent the establishment of chronic synovial 
inflammation (figure 2).70 In line with these findings, it has been shown that 1,25(OH)
2
D
3
 
can suppress both the incidence and progression of experimental arthritis and other 
autoimmune diseases.71-73 
Combining these data with the correlation between serum vitamin D levels and the 
incidence and severity of RA,74-75 vitamin D seems like an interesting tool to modulate 
the unbalanced immune system through targeting Th17 cells. However, supplementing 
high doses of 1,25(OH)
2
D
3
 is clinically limited due to the high risk of severe side effects 
due to hypercalcemia. 
Therefore, it is of great interest to understand how 1,25(OH)
2
D
3
 modulates CCR6+ memTh 
cells, including Th17 cells, and how it can contribute to inhibiting arthritis. Using this 
knowledge, we can circumvent the need for high levels of vitamin D supplementation and 
directly target the relevant pathways.
3 AIMS OF THE THESIS
In this thesis we aim to explore the mechanisms by which vitamin D can modulate 
CCR6+ memTh cells, including Th17 cells, and how this could contribute to alleviating 
RA disease activity. 
Therefore, we first provide an overview of the current knowledge concerning vitamin D in 
autoimmune diseases (Chapter 2), including an overview of the clinical trials performed 
in this context and the immunomodulatory effects that have been described.
Since 1,25(OH)
2
D
3
-treatment can prevent onset and progression of experimental arthritis, 
we then examined how 1,25(OH)
2
D
3
 modulated Th17 differentiation in the context of this 
disease model in Chapter 3. 
For investigating the effects of 1,25(OH)
2
D
3
 on Th17 cells in human RA, CCR6+ memTh 
cells are used. However, CCR6+ Th cells are a heterogeneous group of cells, which consist 
of various subpopulations. Currently it is unknown whether these subpopulations are 
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separate cell types and if they are all equally susceptible to modulation by 1,25(OH)
2
D
3
. 
These issues are addressed in Chapter 4.
Previously, it has been shown that 1,25(OH)
2
D
3
 inhibits the pro-inflammatory activity 
of the CCR6+ memTh cells. In Chapter 5 we further explored the phenotypical changes 
in CCR6+ memTh cells from healthy controls and RA patients that are induced by 
1,25(OH)
2
D
3
. In order for these phenotypical changes to be useful in clinical practice, 
the effects need to be maintained in a pro-inflammatory environment even in the absence 
of 1,25(OH)
2
D
3
. Chapter 6 describes this functional stability of the effect of 1,25(OH)
2
D
3
 
under various stimuli.
Given the immunomodulatory properties of 1,25(OH)
2
D
3
, it is of interest to find direct 
clinical uses for vitamin D supplementation. Chapter 7 describes the immunomodulatory 
potential of 1,25(OH)
2
D
3
 in combination with dexamethasone in the pro-inflammatory 
loop between CCR6+ memTh cells and RASF and how this combination could increase 
effectiveness of TNFα-blocking therapies.
Since all previous studies were performed in vitro and these do not always reflect the 
complexity of the human body, in Chapter 8 we investigated the clinical correlation 
between serum vitamin D levels and the treatment response on etanercept, a widely-used 
TNFα-blocking agent.
1
22
Chapter 1
REFERENCES
1. Scott, D. L.; Wolfe, F.; Huizinga, T. W., Rheumatoid arthritis. Lancet 2010, 376 (9746), 1094-
108.
2. Dougados, M., Comorbidities in rheumatoid arthritis. Curr Opin Rheumatol 2016, 28 (3), 
282-8.
3. Aletaha, D.; Neogi, T.; Silman, A. J.; Funovits, J.; Felson, D. T.; Bingham, C. O., 3rd; 
Birnbaum, N. S.; Burmester, G. R.; Bykerk, V. P.; Cohen, M. D.; Combe, B.; Costenbader, 
K. H.; Dougados, M.; Emery, P.; Ferraccioli, G.; Hazes, J. M.; Hobbs, K.; Huizinga, T. W.; 
Kavanaugh, A.; Kay, J.; Kvien, T. K.; Laing, T.; Mease, P.; Menard, H. A.; Moreland, L. W.; 
Naden, R. L.; Pincus, T.; Smolen, J. S.; Stanislawska-Biernat, E.; Symmons, D.; Tak, P. P.; 
Upchurch, K. S.; Vencovsky, J.; Wolfe, F.; Hawker, G., 2010 rheumatoid arthritis classification 
criteria: an American College of Rheumatology/European League Against Rheumatism 
collaborative initiative. Ann Rheum Dis 2010, 69 (9), 1580-8.
4. Gerlag, D. M.; Raza, K.; van Baarsen, L. G.; Brouwer, E.; Buckley, C. D.; Burmester, G. 
R.; Gabay, C.; Catrina, A. I.; Cope, A. P.; Cornelis, F.; Dahlqvist, S. R.; Emery, P.; Eyre, S.; 
Finckh, A.; Gay, S.; Hazes, J. M.; van der Helm-van Mil, A.; Huizinga, T. W.; Klareskog, 
L.; Kvien, T. K.; Lewis, C.; Machold, K. P.; Ronnelid, J.; van Schaardenburg, D.; Schett, 
G.; Smolen, J. S.; Thomas, S.; Worthington, J.; Tak, P. P., EULAR recommendations for 
terminology and research in individuals at risk of rheumatoid arthritis: report from the Study 
Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis 2012, 71 (5), 638-41.
5. Frisell, T.; Holmqvist, M.; Kallberg, H.; Klareskog, L.; Alfredsson, L.; Askling, J., Familial 
risks and heritability of rheumatoid arthritis: role of rheumatoid factor/anti-citrullinated 
protein antibody status, number and type of affected relatives, sex, and age. Arthritis Rheum 
2013, 65 (11), 2773-82.
6. Raychaudhuri, S.; Sandor, C.; Stahl, E. A.; Freudenberg, J.; Lee, H. S.; Jia, X.; Alfredsson, 
L.; Padyukov, L.; Klareskog, L.; Worthington, J.; Siminovitch, K. A.; Bae, S. C.; Plenge, R. 
M.; Gregersen, P. K.; de Bakker, P. I., Five amino acids in three HLA proteins explain most 
of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 2012, 44 
(3), 291-6.
7. Karlson, E. W.; van Schaardenburg, D.; van der Helm-van Mil, A. H., Strategies to predict 
rheumatoid arthritis development in at-risk populations. Rheumatology (Oxford) 2016, 55 
(1), 6-15.
8. Costenbader, K. H.; Feskanich, D.; Mandl, L. A.; Karlson, E. W., Smoking intensity, duration, 
and cessation, and the risk of rheumatoid arthritis in women. Am J Med 2006, 119 (6), 503 
e1-9.
23
Introduction
9. Mannik, M.; Nardella, F. A.; Sasso, E. H., Rheumatoid factors in immune complexes of 
patients with rheumatoid arthritis. Springer Semin Immunopathol 1988, 10 (2-3), 215-30.
10. Conigliaro, P.; Chimenti, M. S.; Triggianese, P.; Sunzini, F.; Novelli, L.; Perricone, C.; 
Perricone, R., Autoantibodies in inflammatory arthritis. Autoimmun Rev 2016, 15 (7), 673-83.
11. Witalison, E. E.; Thompson, P. R.; Hofseth, L. J., Protein Arginine Deiminases and Associated 
Citrullination: Physiological Functions and Diseases Associated with Dysregulation. Curr 
Drug Targets 2015, 16 (7), 700-10.
12. Catrina, A. I.; Ytterberg, A. J.; Reynisdottir, G.; Malmstrom, V.; Klareskog, L., Lungs, joints 
and immunity against citrullinated proteins in rheumatoid arthritis. Nat Rev Rheumatol 2014, 
10 (11), 645-53.
13. Makrygiannakis, D.; Hermansson, M.; Ulfgren, A. K.; Nicholas, A. P.; Zendman, A. J.; 
Eklund, A.; Grunewald, J.; Skold, C. M.; Klareskog, L.; Catrina, A. I., Smoking increases 
peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination 
in BAL cells. Ann Rheum Dis 2008, 67 (10), 1488-92.
14. Konig, M. F.; Abusleme, L.; Reinholdt, J.; Palmer, R. J.; Teles, R. P.; Sampson, K.; Rosen, A.; 
Nigrovic, P. A.; Sokolove, J.; Giles, J. T.; Moutsopoulos, N. M.; Andrade, F., Aggregatibacter 
actinomycetemcomitans-induced hypercitrullination links periodontal infection to 
autoimmunity in rheumatoid arthritis. Sci Transl Med 2016, 8,369 369ra176.
15. Vossenaar, E. R.; Radstake, T. R.; van der Heijden, A.; van Mansum, M. A.; Dieteren, C.; 
de Rooij, D. J.; Barrera, P.; Zendman, A. J.; van Venrooij, W. J., Expression and activity of 
citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann 
Rheum Dis 2004, 63 (4), 373-81.
16. Deane, K. D.; O’Donnell, C. I.; Hueber, W.; Majka, D. S.; Lazar, A. A.; Derber, L. A.; 
Gilliland, W. R.; Edison, J. D.; Norris, J. M.; Robinson, W. H.; Holers, V. M., The number of 
elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts 
time to diagnosis in an age-dependent manner. Arthritis Rheum 2010, 62 (11), 3161-72.
17. Rantapaa-Dahlqvist, S.; Boman, K.; Tarkowski, A.; Hallmans, G., Up regulation of monocyte 
chemoattractant protein-1 expression in anti-citrulline antibody and immunoglobulin M 
rheumatoid factor positive subjects precedes onset of inflammatory response and development 
of overt rheumatoid arthritis. Ann Rheum Dis 2007, 66 (1), 121-3.
18. Jorgensen, K. T.; Wiik, A.; Pedersen, M.; Hedegaard, C. J.; Vestergaard, B. F.; Gislefoss, 
R. E.; Kvien, T. K.; Wohlfahrt, J.; Bendtzen, K.; Frisch, M., Cytokines, autoantibodies and 
viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: 
case-control study nested in a cohort of Norwegian blood donors. Ann Rheum Dis 2008, 67 
(6), 860-6.
1
24
Chapter 1
19. Karlson, E. W.; Chibnik, L. B.; Tworoger, S. S.; Lee, I. M.; Buring, J. E.; Shadick, N. 
A.; Manson, J. E.; Costenbader, K. H., Biomarkers of inflammation and development of 
rheumatoid arthritis in women from two prospective cohort studies. Arthritis Rheum 2009, 
60 (3), 641-52.
20. Kokkonen, H.; Soderstrom, I.; Rocklov, J.; Hallmans, G.; Lejon, K.; Rantapaa Dahlqvist, 
S., Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. 
Arthritis Rheum 2010, 62 (2), 383-91.
21. Sokolove, J.; Bromberg, R.; Deane, K. D.; Lahey, L. J.; Derber, L. A.; Chandra, P. E.; Edison, 
J. D.; Gilliland, W. R.; Tibshirani, R. J.; Norris, J. M.; Holers, V. M.; Robinson, W. H., 
Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid 
arthritis. PLoS One 2012, 7 (5), e35296.
22. Rombouts, Y.; Ewing, E.; van de Stadt, L. A.; Selman, M. H.; Trouw, L. A.; Deelder, A. 
M.; Huizinga, T. W.; Wuhrer, M.; van Schaardenburg, D.; Toes, R. E.; Scherer, H. U., Anti-
citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior 
to the onset of rheumatoid arthritis. Ann Rheum Dis 2015, 74 (1), 234-41.
23. Pfeifle, R.; Rothe, T.; Ipseiz, N.; Scherer, H. U.; Culemann, S.; Harre, U.; Ackermann, J. A.; 
Seefried, M.; Kleyer, A.; Uderhardt, S.; Haugg, B.; Hueber, A. J.; Daum, P.; Heidkamp, G. 
F.; Ge, C.; Bohm, S.; Lux, A.; Schuh, W.; Magorivska, I.; Nandakumar, K. S.; Lonnblom, E.; 
Becker, C.; Dudziak, D.; Wuhrer, M.; Rombouts, Y.; Koeleman, C. A.; Toes, R.; Winkler, T. H.; 
Holmdahl, R.; Herrmann, M.; Bluml, S.; Nimmerjahn, F.; Schett, G.; Kronke, G., Regulation 
of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. 
Nat Immunol 2017, 18 (1), 104-113.
24. van Gaalen, F. A.; Linn-Rasker, S. P.; van Venrooij, W. J.; de Jong, B. A.; Breedveld, F. C.; 
Verweij, C. L.; Toes, R. E.; Huizinga, T. W., Autoantibodies to cyclic citrullinated peptides 
predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a 
prospective cohort study. Arthritis Rheum 2004, 50 (3), 709-15.
25. van Nies, J. A.; Krabben, A.; Schoones, J. W.; Huizinga, T. W.; Kloppenburg, M.; van der 
Helm-van Mil, A. H., What is the evidence for the presence of a therapeutic window of 
opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 2014, 
73 (5), 861-70.
26. Katsikis, P. D.; Chu, C. Q.; Brennan, F. M.; Maini, R. N.; Feldmann, M., Immunoregulatory 
role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994, 179 (5), 1517-27.
27. Brennan, F. M.; Gibbons, D. L.; Cope, A. P.; Katsikis, P.; Maini, R. N.; Feldmann, M., TNF 
inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell 
cultures: evidence of feedback control of TNF action. Scandinavian journal of immunology 
1995, 42 (1), 158-65.
25
Introduction
28. Firestein, G. S.; McInnes, I. B., Immunopathogenesis of Rheumatoid Arthritis. Immunity 
2017, 46 (2), 183-196.
29. Hill, J. A.; Southwood, S.; Sette, A.; Jevnikar, A. M.; Bell, D. A.; Cairns, E., Cutting edge: 
the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the 
rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003, 
171 (2), 538-41.
30. Klareskog, L.; Stolt, P.; Lundberg, K.; Kallberg, H.; Bengtsson, C.; Grunewald, J.; Ronnelid, J.; 
Harris, H. E.; Ulfgren, A. K.; Rantapaa-Dahlqvist, S.; Eklund, A.; Padyukov, L.; Alfredsson, 
L., A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR 
(shared epitope)-restricted immune reactions to autoantigens modified by citrullination. 
Arthritis Rheum 2006, 54 (1),.38-46
31. Harding, B.; Knight, S. C., The distribution of dendritic cells in the synovial fluids of patients 
with arthritis. Clin Exp Immunol 1986, 63 (3), 594-600.
32. Smeets, T. J.; Kraan, M. C.; Galjaard, S.; Youssef, P. P.; Smith, M. D.; Tak, P. P., Analysis 
of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired 
synovial biopsy specimens from the cartilage-pannus junction in patients with RA. Ann 
Rheum Dis 2001, 60 (6), 561-5.
33. Segura, E.; Touzot, M.; Bohineust, A.; Cappuccio, A.; Chiocchia, G.; Hosmalin, A.; Dalod, 
M.; Soumelis, V.; Amigorena, S., Human inflammatory dendritic cells induce Th17 cell 
differentiation. Immunity 2013, 38 (2), 336-48.
34. Haringman, J. J.; Gerlag, D. M.; Zwinderman, A. H.; Smeets, T. J.; Kraan, M. C.; Baeten, D.; 
McInnes, I. B.; Bresnihan, B.; Tak, P. P., Synovial tissue macrophages: a sensitive biomarker 
for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005, 64 (6), 
834-8.
35. Tak, P. P.; Smeets, T. J.; Daha, M. R.; Kluin, P. M.; Meijers, K. A.; Brand, R.; Meinders, A. 
E.; Breedveld, F. C., Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue 
in relation to local disease activity. Arthritis Rheum 1997, 40 (2), 217-25.
36. Su, D.; Shen, M.; Li, X.; Sun, L., Roles of gammadelta T cells in the pathogenesis of 
autoimmune diseases. Clin Dev Immunol 2013, 2013, 985753.
37. Carvalheiro, H.; da Silva, J. A.; Souto-Carneiro, M. M., Potential roles for CD8(+) T cells in 
rheumatoid arthritis. Autoimmun Rev 2013, 12 (3), 401-9.
38. Lubberts, E., The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol 2015, 11 
(7), 415-29.
39. Nakae, S.; Nambu, A.; Sudo, K.; Iwakura, Y., Suppression of immune induction of collagen-
induced arthritis in IL-17-deficient mice. J Immunol 2003, 171 (11), 6173-7.
1
26
Chapter 1
40. Murphy, C. A.; Langrish, C. L.; Chen, Y.; Blumenschein, W.; McClanahan, T.; Kastelein, 
R. A.; Sedgwick, J. D.; Cua, D. J., Divergent pro- and antiinflammatory roles for IL-23 and 
IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198 (12), 1951-7.
41. Corneth, O. B.; Mus, A. M.; Asmawidjaja, P. S.; Klein Wolterink, R. G.; van Nimwegen, M.; 
Brem, M. D.; Hofman, Y.; Hendriks, R. W.; Lubberts, E., Absence of interleukin-17 receptor 
a signaling prevents autoimmune inflammation of the joint and leads to a Th2-like phenotype 
in collagen-induced arthritis. Arthritis Rheumatol 2014, 66 (2), 340-9.
42. Leipe, J.; Grunke, M.; Dechant, C.; Reindl, C.; Kerzendorf, U.; Schulze-Koops, H.; Skapenko, 
A., Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010, 62 (10), 2876-85.
43. van Hamburg, J. P.; Asmawidjaja, P. S.; Davelaar, N.; Mus, A. M.; Colin, E. M.; Hazes, J. M.; 
Dolhain, R. J.; Lubberts, E., Th17 cells, but not Th1 cells, from patients with early rheumatoid 
arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines 
upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis 
Rheum 2011, 63 (1),.73-83
44. Frey, O.; Petrow, P. K.; Gajda, M.; Siegmund, K.; Huehn, J.; Scheffold, A.; Hamann, A.; 
Radbruch, A.; Brauer, R., The role of regulatory T cells in antigen-induced arthritis: 
aggravation of arthritis after depletion and amelioration after transfer of CD4+CD25+ T 
cells. Arthritis Res Ther 2005, 7 (2), R291-301.
45. Asnagli, H.; Martire, D.; Belmonte, N.; Quentin, J.; Bastian, H.; Boucard-Jourdin, M.; Fall, P. 
B.; Mausset-Bonnefont, A. L.; Mantello-Moreau, A.; Rouquier, S.; Marchetti, I.; Jorgensen, 
C.; Foussat, A.; Louis-Plence, P., Type 1 regulatory T cells specific for collagen type II as an 
efficient cell-based therapy in arthritis. Arthritis Res Ther 2014, 16 (3), R115.
46. Wang, W.; Shao, S.; Jiao, Z.; Guo, M.; Xu, H.; Wang, S., The Th17/Treg imbalance and 
cytokine environment in peripheral blood of patients with rheumatoid arthritis. Rheumatol 
Int 2012, 32 (4), 887-93.
47. Samuels, J.; Ng, Y. S.; Coupillaud, C.; Paget, D.; Meffre, E., Impaired early B cell tolerance 
in patients with rheumatoid arthritis. J Exp Med 2005, 201 (10), 1659-67.
48. Harre, U.; Georgess, D.; Bang, H.; Bozec, A.; Axmann, R.; Ossipova, E.; Jakobsson, P. 
J.; Baum, W.; Nimmerjahn, F.; Szarka, E.; Sarmay, G.; Krumbholz, G.; Neumann, E.; 
Toes, R.; Scherer, H. U.; Catrina, A. I.; Klareskog, L.; Jurdic, P.; Schett, G., Induction of 
osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J 
Clin Invest 2012, 122 (5), 1791-802.
49. Tan, E. M.; Smolen, J. S., Historical observations contributing insights on etiopathogenesis 
of rheumatoid arthritis and role of rheumatoid factor. J Exp Med 2016, 213 (10), 1937-50.
50. Bugatti, S.; Vitolo, B.; Caporali, R.; Montecucco, C.; Manzo, A., B cells in rheumatoid 
arthritis: from pathogenic players to disease biomarkers. Biomed Res Int 2014, 2014, 681678.
27
Introduction
51. Yeo, L.; Toellner, K. M.; Salmon, M.; Filer, A.; Buckley, C. D.; Raza, K.; Scheel-Toellner, 
D., Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid 
arthritis. Ann Rheum Dis 2011, 70 (11), 2022-8.
52. McInnes, I. B.; Schett, G., The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365 
(23), 2205-19.
53. Koch, A. E.; Polverini, P. J.; Leibovich, S. J., Stimulation of neovascularization by human 
rheumatoid synovial tissue macrophages. Arthritis Rheum 1986, 29 (4), 471-9.
54. Kurowska-Stolarska, M.; Alivernini, S., Synovial tissue macrophages: friend or foe? RMD 
Open 2017, 3 (2), e000527.
55. Corsiero, E.; Pratesi, F.; Prediletto, E.; Bombardieri, M.; Migliorini, P., NETosis as Source 
of Autoantigens in Rheumatoid Arthritis. Front Immunol 2016, 7, 485.
56. Tran, C. N.; Davis, M. J.; Tesmer, L. A.; Endres, J. L.; Motyl, C. D.; Smuda, C.; Somers, 
E. C.; Chung, K. C.; Urquhart, A. G.; Lundy, S. K.; Kovats, S.; Fox, D. A., Presentation of 
arthritogenic peptide to antigen-specific T cells by fibroblast-like synoviocytes. Arthritis 
Rheum 2007, 56 (5), 1497-506.
57. Muller-Ladner, U.; Kriegsmann, J.; Franklin, B. N.; Matsumoto, S.; Geiler, T.; Gay, R. E.; 
Gay, S., Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal 
human cartilage when engrafted into SCID mice. Am J Pathol 1996, 149 (5), 1607-15.
58. Filer, A.; Ward, L. S. C.; Kemble, S.; Davies, C. S.; Munir, H.; Rogers, R.; Raza, K.; Buckley, 
C. D.; Nash, G. B.; McGettrick, H. M., Identification of a transitional fibroblast function in 
very early rheumatoid arthritis. Ann Rheum Dis 2017.
59. Frank-Bertoncelj, M.; Trenkmann, M.; Klein, K.; Karouzakis, E.; Rehrauer, H.; Bratus, A.; 
Kolling, C.; Armaka, M.; Filer, A.; Michel, B. A.; Gay, R. E.; Buckley, C. D.; Kollias, G.; 
Gay, S.; Ospelt, C., Epigenetically-driven anatomical diversity of synovial fibroblasts guides 
joint-specific fibroblast functions. Nat Commun 2017, 8, 14852.
60. Ospelt, C.; Gay, S.; Klein, K., Epigenetics in the pathogenesis of RA. Semin Immunopathol 
2017, 39 (4), 409-419.
61. Jones, D. S.; Jenney, A. P.; Swantek, J. L.; Burke, J. M.; Lauffenburger, D. A.; Sorger, P. K., 
Profiling drugs for rheumatoid arthritis that inhibit synovial fibroblast activation. Nat Chem 
Biol 2017, 13 (1),.38-45
62. Mitchell, N. S.; Shepard, N., Changes in proteoglycan and collagen in cartilage in rheumatoid 
arthritis. The Journal of bone and joint surgery. American volume 1978, 60 (3), 342-8.
63. Dodge, G. R.; Poole, A. R., Immunohistochemical detection and immunochemical analysis 
of type II collagen degradation in human normal, rheumatoid, and osteoarthritic articular 
cartilages and in explants of bovine articular cartilage cultured with interleukin 1. J Clin 
Invest 1989, 83 (2), 647-61.
1
28
Chapter 1
64. Otero, M.; Goldring, M. B., Cells of the synovium in rheumatoid arthritis. Chondrocytes. 
Arthritis Res Ther 2007, 9 (5), 220.
65. Jung, S. M.; Kim, K. W.; Yang, C. W.; Park, S. H.; Ju, J. H., Cytokine-mediated bone 
destruction in rheumatoid arthritis. Journal of immunology research 2014, 2014, 263625.
66. Smolen, J. S.; Landewe, R.; Bijlsma, J.; Burmester, G.; Chatzidionysiou, K.; Dougados, M.; 
Nam, J.; Ramiro, S.; Voshaar, M.; van Vollenhoven, R.; Aletaha, D.; Aringer, M.; Boers, 
M.; Buckley, C. D.; Buttgereit, F.; Bykerk, V.; Cardiel, M.; Combe, B.; Cutolo, M.; van Eijk-
Hustings, Y.; Emery, P.; Finckh, A.; Gabay, C.; Gomez-Reino, J.; Gossec, L.; Gottenberg, J. 
E.; Hazes, J. M. W.; Huizinga, T.; Jani, M.; Karateev, D.; Kouloumas, M.; Kvien, T.; Li, Z.; 
Mariette, X.; McInnes, I.; Mysler, E.; Nash, P.; Pavelka, K.; Poor, G.; Richez, C.; van Riel, 
P.; Rubbert-Roth, A.; Saag, K.; da Silva, J.; Stamm, T.; Takeuchi, T.; Westhovens, R.; de 
Wit, M.; van der Heijde, D., EULAR recommendations for the management of rheumatoid 
arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. 
Ann Rheum Dis 2017, 76 (6), 960-977.
67. Livshits, G.; Kalinkovich, A., Hierarchical, imbalanced pro-inflammatory cytokine networks 
govern the pathogenesis of chronic arthropathies. Osteoarthritis Cartilage 2018, 26 (1), 7-17.
68. Burmester, G. R.; Pope, J. E., Novel treatment strategies in rheumatoid arthritis. Lancet 2017, 
389 (10086), 2338-2348.
69. Colin, E. M.; Asmawidjaja, P. S.; van Hamburg, J. P.; Mus, A. M.; van Driel, M.; Hazes, J. M.; 
van Leeuwen, J. P.; Lubberts, E., 1,25-dihydroxyvitamin D3 modulates Th17 polarization and 
interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. 
Arthritis Rheum 2010, 62 (1), 132-42.
70. van Hamburg, J. P.; Asmawidjaja, P. S.; Davelaar, N.; Mus, A. M.; Cornelissen, F.; van 
Leeuwen, J. P.; Hazes, J. M.; Dolhain, R. J.; Bakx, P. A.; Colin, E. M.; Lubberts, E., TNF 
blockade requires 1,25(OH)2D3 to control human Th17-mediated synovial inflammation. 
Ann Rheum Dis 2012, 71 (4), 606-12.
71. Lemire, J. M.; Archer, D. C., 1,25-dihydroxyvitamin D3 prevents the in vivo induction of 
murine experimental autoimmune encephalomyelitis. J Clin Invest 1991, 87 (3), 1103-7.
72. Cantorna, M. T.; Hayes, C. E.; DeLuca, H. F., 1,25-Dihydroxycholecalciferol inhibits the 
progression of arthritis in murine models of human arthritis. J Nutr 1998, 128 (1),.68-72
73. Cantorna, M. T.; Munsick, C.; Bemiss, C.; Mahon, B. D., 1,25-Dihydroxycholecalciferol 
prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J 
Nutr 2000, 130 (11), 2648-52.
74. Lin, J.; Liu, J.; Davies, M. L.; Chen, W., Serum Vitamin D Level and Rheumatoid Arthritis 
Disease Activity: Review and Meta-Analysis. PLoS One 2016, 11 (1), e0146351.
29
Introduction
75. Hiraki, L. T.; Arkema, E. V.; Cui, J.; Malspeis, S.; Costenbader, K. H.; Karlson, E. W., 
Circulating 25-hydroxyvitamin D level and risk of developing rheumatoid arthritis. 
Rheumatology (Oxford) 2014, 53 (12), 2243-8.
1
Chapter 2
Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential
Chapter 2
Vitamin D in Autoimmunity: Molecular 
Mechanisms and Therapeutic Potential
Wendy Dankers1,2, Edgar M. Colin1,3, Jan Piet van Hamburg1,2, and 
Erik Lubberts1,2*
Departments of 1Rheumatology and 2Immunology, Erasmus MC, University 
Medical Center, Rotterdam, The Netherlands; 3Department of Rheumatology, 
ZGT, Almelo, The Netherlands 
Frontiers in Immunology 2017, 7:697
32
Chapter 2
ABSTRACT
Over the last three decades it has become clear that the role of vitamin D goes beyond the 
regulation of calcium homeostasis and bone health. An important extra-skeletal effect 
of vitamin D is the modulation of the immune system. In the context of autoimmune 
diseases, this is illustrated by correlations of vitamin D status and genetic polymorphisms 
in the vitamin D receptor with the incidence and severity of the disease. These correlations 
warrant investigation into the potential use of vitamin D in the treatment of patients 
with autoimmune diseases. In recent years several clinical trials have been performed to 
investigate the therapeutic value of vitamin D in multiple sclerosis, rheumatoid arthritis, 
Crohn’s disease, type I diabetes and systemic lupus erythematosus. Additionally, a second 
angle of investigation has focused on unraveling the molecular pathways used by vitamin 
D in order to find new potential therapeutic targets. This review will not only provide 
an overview of the clinical trials that have been performed, but also discuss the current 
knowledge about the molecular mechanisms underlying the immunomodulatory effects of 
vitamin D and how these advances can be used in the treatment of autoimmune diseases. 
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1 INTRODUCTION
Autoimmune diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and 
Crohn’s disease, result from an aberrant activation of the immune system whereby the 
immune response is directed against harmless self-antigens. This results in inflammation, 
tissue damage and loss of function of the affected organs or joints. With the increasing 
prevalence of autoimmunity in the Western countries 1, also the societal burden of these 
diseases increases. Although the treatment of autoimmune diseases has improved due to 
the development of so-called biologics like tumor necrosis factor alpha (TNFα) inhibitors, 
a large proportion of patients is still not adequately responding to these treatments.2 
Therefore it is still important to improve current therapies or to uncover new treatment 
options.
In this context, the immunomodulatory effects of vitamin D provide opportunities to 
enhance the treatment of autoimmune diseases. Firstly, given the high prevalence of 
vitamin D deficiency in patients suffering from autoimmunity, vitamin D supplementation 
might decrease disease severity or augment the therapeutic effect of current medication. 
Secondly, knowing the molecular mechanisms underlying the immunomodulatory effects 
could lead to the discovery of new potential therapeutic targets. Therefore, this review 
will explore the advances that have been made in both clinical trials and molecular 
studies. In addition, it will give an overview of the challenges that still remain before the 
immunomodulatory effects of vitamin D can be utilized in clinical practice.
2 VITAMIN D METABOLISM, SIGNALING AND FUNCTION
Vitamin D, or cholecalciferol, is a secosteroid hormone that can be obtained from dietary 
sources, but that is predominantly synthesized in the skin from 7-dehydroxycholesterol 
in response to UV light (figure 1). Cholecalciferol is bound by vitamin D binding protein 
(DBP) and transported to the liver. In the liver various cytochrome p450 (Cyp) vitamin 
D hydroxylases convert cholecalciferol into 25(OH)D
3
. Cyp2R1 is considered to be the 
primary 25-hydroxylase responsible for this process. Subsequently DBP transports 
25(OH)D
3
 to the kidneys, where the 1α-hydroxylase Cyp27B1 converts 25(OH)D
3
 into 
1,25(OH)
2
D
3
. 1,25(OH)
2
D
3
, also called calcitriol, is the active vitamin D metabolite. To 
control calcitriol concentrations, the 24-hydroxylase Cyp24A1 hydroxylates 25(OH)
D
3
 or 1,25(OH)
2
D
3
 at C-24, yielding the less active metabolites 24,25(OH)
2
D
3
 and 
1,24,25(OH)
3
D
3
, respectively.3 The level of 1,25(OH)
2
D
3
 is therefore mainly determined 
by the balance between Cyp27B1 and Cyp24A1. Two proteins that are important for 
2
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regulating this balance are fibroblast growth factor 23 (FGF23) and parathyroid hormone 
(PTH). FGF23 shifts the balance towards Cyp24A1 and therefore inactivation of vitamin D 
signaling, and is induced by high concentrations of 1,25(OH)
2
D
3
 and low serum phosphate. 
On the other hand, PTH favors the balance towards Cyp27B1 and activation of vitamin 
D signaling. PTH is inhibited by high concentrations of 1,25(OH)
2
D
3 
and induced by low 
serum calcium (figure 1).3
1,25(OH)
2
D
3
 initiates its signaling cascade by binding to the vitamin D receptor (VDR), 
which is a nuclear receptor that acts as a transcription factor. VDR binds to vitamin D 
responsive elements (VDREs) in the DNA, mostly to so-called DR3-type VDREs that are 
characterized by two hexameric core binding motifs separated by 3 nucleotides. In the 
absence of ligand, VDR is mostly bound to non-DR3-type VDREs and is associated with 
co-repressor proteins. When 1,25(OH)
2
D
3
 binds to VDR, this induces a conformational 
change leading to the formation of two new protein interaction surfaces. One is for binding 
with heterodimeric partners to facilitate specific DNA binding, such as retinoid X receptor 
(RXR), and the other is for recruitment of co-regulatory complexes that will exert the 
genomic effects of VDR.4 Furthermore, there is a shift in binding to primarily DR3-type 
VDREs.5 Interestingly, although RXR has multiple binding partners, specifically with 
VDR it will bind to the DR3-type elements. This indicates that the heterodimerization of 
VDR and RXR is important for functioning of the VDR.6 However, research in colorectal 
cancer cells has shown that 25% of the VDR binding sites are not enriched for RXR.7 
No direct data on colocalization of VDR and RXR in immune cells has been reported, 
although Handel et al. found a significant overlap between VDR in CD4+ T cells and RXR 
in a promyelocytic leukemia cell line.8 Therefore it is currently unknown whether the rate 
of VDR/RXR colocalization differs between cell types. Also, the functional consequence 
of VDR binding with or without RXR remains to be understood.    
The best known function of 1,25(OH)
2
D
3
 is the maintenance of calcium homeostasis by 
facilitating the absorption of calcium in the intestine. However, in the presence of low 
1,25(OH)
2
D
3
 levels, calcium will be mobilized from the bone rather than the intestine. 
If these conditions are prolonged, this may lead to osteomalacia and rickets, both well-
known clinical signs of vitamin D deficiency. An overview of the current knowledge on 
the role of vitamin D signaling in calcium homeostasis was recently given by Carmeliet et 
al. and will not be discussed here.9 The first hint that vitamin D might also be important 
for extraskeletal health came from mycobacterial infections like tuberculosis, in which 
vitamin D was used as a treatment before antibiotics were discovered.10 The discovery 
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Figure 1. Vitamin D metabolism. The metabolic pathway of vitamin D. Red arrows indicate inhibition, green 
arrows indicate induction.
that the VDR is expressed in almost all human cells has further increased the attention 
for the extraskeletal effects of vitamin D. As a result, vitamin D deficiency has now not 
only been linked to bone health, but also for example cancer, cardiovascular diseases and 
autoimmune diseases.9
3 VITAMIN D AND AUTOIMMUNE DISEASES
Since the discovery of the VDR on blood lymphocytes 11, 12, the effects of vitamin D on 
the immune system and immune-related diseases became the subject of a large number 
of studies. In this context, it was discovered that supplementation with 1,25(OH)
2
D
3
 could 
prevent both the initiation and progression of experimental autoimmune encephalomyelitis 
(EAE) and collagen-induced arthritis (CIA), experimental models of MS and RA, 
respectively.13-15 In addition, VDR deficiency aggravated arthritis severity in human TNFα 
transgenic mice.16 Similarly, vitamin D deficiency increased enterocolitis severity in IL-10 
knock-out (KO) mice, which are used as a model system for inflammatory bowel diseases 
2
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(IBD). Treatment with 1,25(OH)
2
D
3
 decreased disease symptoms in both the IL-10 KO 
mice and in the dextran sulfate sodium (DSS)-induced colitis model.17, 18 Finally, treatment 
with 1,25(OH)
2
D
3
 reduced the incidence of diabetes in non-obese diabetic (NOD) mice 19, 
20 and the severity of systemic lupus erythematosus in MRL/1 mice.21
These studies in experimental autoimmune models underscore the need to examine 
whether there is a protective role for vitamin D in human autoimmune diseases. In the 
last decades numerous studies have investigated the link between vitamin D and the 
incidence and severity of autoimmune diseases. One of the first indications was the 
correlation between increasing MS prevalence and increasing latitude, and consequently 
with decreasing sunlight exposure. Exceptions to this gradient can at least partially be 
explained by genetic variants (like the HLA-DRB1 allele) or lifestyle differences, such 
as high fish consumption.22 The relation between latitude and disease prevalence was 
also found for other autoimmune diseases such as type I diabetes mellitus (T1D) and 
IBD.23, 24 Further strengthening the link between sun exposure and autoimmunity is the 
finding that the risk of developing MS is correlated with the month of birth, with for the 
northern hemisphere a higher risk in April and a lower risk in October and November.25, 26 
Importantly, this correlation can only be found in areas where the UV exposure changes 
during the year.25
Next to UV exposure, vitamin D can also be obtained from dietary sources and 
supplements. A meta-analysis by Song et al. found that the incidence of RA is inversely 
correlated with vitamin D intake, both when considering dietary intake and supplements 
or supplements alone.27 In addition, vitamin D supplementation in early childhood 
might reduce the risk of developing T1D up to 30% depending on the supplementation 
frequency.28, 29 Also the effect of maternal vitamin D intake on the risk of T1D in the 
offspring has been investigated, but due to the limited amount of studies there is currently 
not sufficient evidence to prove a correlation.29 
Investigating the correlation between vitamin D intake and prevalence of autoimmunity is 
challenging because the measurements of dietary intake and UV exposure are often based 
on estimations. Therefore, it might be more useful to analyze the correlation between the 
serum 25(OH)D
3
 level and autoimmunity. Indeed, in many autoimmune diseases patients 
have a lower serum 25(OH)D
3
 than healthy controls.30-36 In addition, patients with a lower 
25(OH)D
3
 level are implicated to have higher disease activity.32, 35, 37 Although it is not clear 
whether the lower 25(OH)D
3
 level also increases the risk of autoimmunity, the study by 
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Hiraki et al. suggests there is a strong correlation between the risk of developing RA and 
the 25(OH)D
3
 level between 3 months and 4 years before diagnosis.38 It should be noted 
that all these studies merely demonstrate correlations, so it is still under debate whether 
the low 25(OH)D
3
 level is the cause or the result of the autoimmune disease. 
Another line of evidence that indicates a role for vitamin D in human autoimmunity 
is the correlation with polymorphisms in the VDR. There are four well-known VDR 
polymorphisms that have been extensively studied for their potential role in autoimmunity: 
ApaI, BsmI, TaqI and FokI. All of these polymorphisms have been associated with the 
risk of developing an autoimmune disease, although it differs between diseases and 
polymorphisms whether it is protective or a risk factor. Also, ethnicity plays a role in the 
correlation between the polymorphisms and autoimmune diseases.39-47
In summary, autoimmune diseases are correlated with 25(OH)D
3
 serum levels, vitamin 
D intake, UV exposure and VDR polymorphisms. Furthermore, 1,25(OH)
2
D
3
 suppresses 
disease in experimental autoimmune models. Although these data do not prove a 
causal relationship between vitamin D and autoimmune diseases, they warrant further 
investigation into whether at-risk individuals and patients could benefit from vitamin D 
supplementation.
4 VITAMIN D AS A THERAPEUTIC AGENT IN HUMAN  
AUTOIMMUNE DISEASES
Despite the beneficial effects of 1,25(OH)
2
D
3
 supplementation in experimental autoimmune 
models, the application of vitamin D derivatives in clinical practice is currently limited to 
topical use for the treatment of psoriasis.48 The systemic use of vitamin D in the treatment 
of other autoimmune diseases is still under investigation. Table 1 gives an overview of the 
placebo-controlled clinical trials investigating the effect of vitamin D supplementation 
in autoimmune diseases other than psoriasis. Here we discuss these trials and what this 
means for the therapeutic potential of vitamin D in each of these autoimmune diseases.
4.1 Multiple Sclerosis (MS)
In the field of MS, several trials have been performed in which cholecalciferol was given 
to the patients, but the results are contradictory. Beneficial effects of cholecalciferol 
supplementation that have been reported include decrease in expanded disability status 
scale (EDSS), decrease in MRI lesions, increased functionality and reduced relapse 
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rates.49, 50 Importantly, cholecalciferol has an added effect when used as a supplement to 
interferon β (IFNβ) treatment.50 On the other hand, two other trials reported no difference 
in any of these parameters.51, 52 Vitamin D supplementation might also be important in 
the pre-MS stage, since cholecalciferol supplementation decreased the conversion rate of 
optic neuritis to chronic MS.53 
Due to the small sample size (no more than 35 patients per group) of these trials, it is 
difficult to draw conclusions from these data. Although the effect of cholecalciferol on 
conversion to chronic effect appears promising, this was only one study with 13 treated 
patients and 11 placebo controls. Therefore, more research is necessary to determine 
whether therapy with cholecalciferol is beneficial for MS patients.
4.2 Rheumatoid Arthritis (RA)
Despite the beneficial effect of 1,25(OH)
2
D
3
 supplementation on experimental arthritis.15 
there are to date only three randomized trials investigating the effect of supplementation 
on disease activity in rheumatoid arthritis. Although the studies performed by Salesi 
et al. and Dehghan et al. suggest a beneficial effect on disease activity and relapse 
rate respectively, neither results reach statistical significance.54, 55 However, Dehghan 
et al. point out that for every ten patients treated with cholecalciferol, relapse would 
be prevented in one patient. Considering the costs and safety profile of cholecalciferol 
supplementation, this might be worth following up. Ergocalciferol, the less potent fungal 
equivalent of human cholecalciferol, had no effect on disease activity and was associated 
with worse patient-related health assessments.56 Similarly to studies in MS, the major 
limitation in the three RA studies is the group size, which limits the power of the analyses. 
Therefore no definitive conclusion can be drawn yet whether vitamin D can be used as 
a therapeutic agent in RA.
4.3 Crohn’s Disease (CD)
Crohn’s disease (CD) is a subtype of the inflammatory bowel diseases and investigated 
intensively for the effect of vitamin D supplementation. However, the difficulty with 
this disease is that the intestinal inflammation may lead to decreased absorption of the 
supplemented vitamin D. Nevertheless, for adult patients cholecalciferol supplementation 
might reduce the risk of relapses, although the difference does not reach statistical 
significance (p =0.06).57 Correspondingly, cholecalciferol prevented further increase of 
intestinal permeability, which may be an early marker of relapse.58 This is even more 
pronounced when the patients are stratified based on their serum 25(OH)D
3
 level. 
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Additionally, patients with a serum level above 75 nmol/L have significantly lower 
serum levels of C-reactive protein (CRP, a marker of inflammation) and a non-significant 
decrease in disease activity as measured with Crohn’s Disease Activity Index.58 These 
studies used 1,200-2,000 IU cholecalciferol daily in adults, but in children there is no 
difference in disease activity between supplementing 400 and 2,000 IU daily despite a 
serum 25(OH)D
3
 level that is 25 nmol/L higher in the latter group.59 
When compared to RA and MS, the results for adult CD are more consistently showing 
a beneficial effect of cholecalciferol treatment. Since group sizes are again small, more 
research is required to confirm these data.
4.4 Type I Diabetes Mellitus (T1D)
In contrast to the other autoimmune diseases where cholecalciferol supplementation is 
investigated, in T1D almost all trials use 1,25(OH)
2
D
3
 or an analogue. Both forms appear 
to delay, but not prevent, the progression of β cell destruction in three studies.60-62 On 
the other hand, no effect of 1,25(OH)
2
D
3
 on T1D was observed in studies performed by 
Bizzarri et al. and Walter et al..63, 64 This lack of effect could be due to the low level of 
remaining β cell function at the start of the study, suggesting that the therapeutic window 
for vitamin D supplementation is in the earliest phases of the disease. The study by Li 
et al. found that the protective effect is only visible when the disease duration was less 
than one year, supporting this hypothesis.62 In T1D the beneficial effects of 1,25(OH)
2
D
3
 
may lie more in the prevention of disease onset28, 29 than in treatment of disease, since the 
destruction of β cells cannot be reversed.
4.5 Systemic Lupus Erythematosus (SLE)
Vitamin D supplementation in SLE might even be more relevant than in the other 
autoimmune diseases, since 80% of the patients is sensitive for sunlight and therefore 
protect themselves against UV exposure.65 Two studies supplementing either 2,000 IU 
daily or 50,000 IU weekly demonstrate decreasing disease activity score, auto-antibody 
levels and fatigue.66, 67 Conversely, the type I interferon (IFN) signature was unchanged 
after 12 weeks of 2,000 or 4,000 IU cholecalciferol in another study.68 Since this study 
was performed in patients with inactive disease, had a short supplementation period and 
the signature was based on the expression of only three genes, it remains to be determined 
whether cholecalciferol supplementation truly does not affect the complete IFN signature 
in patients with active disease. 
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SLE is the only autoimmune disease is which a larger study was done, with 158 
cholecalciferol-treated patients and 89 placebo controls.66 The promising results in this 
clinical trial await further confirmation before vitamin D can be used therapeutically in 
these patients.
5 IMMUNE MODULATION BY VITAMIN D
In addition to exploring the potential of therapeutic vitamin D supplementation, there has 
been a great deal of research towards the working mechanisms of 1,25(OH)
2
D
3
 in cells 
of the immune system. Since autoimmune diseases are characterized by an over-active 
immune response, it seems logical that the beneficial effects of vitamin D on autoimmunity 
are due to effects on the immune system. Furthermore, virtually all immune cells express 
the VDR, making them susceptible to 1,25(OH)
2
D
3
-mediated modulation.11, 12, 69, 70 Various 
immune cells, including monocytes, dendritic cells, macrophages, B cells and T cells, 
also have the capability to convert 25(OH)D
3
 into 1,25(OH)
2
D
3
.71-78 This allows for local 
regulation of the concentration of 1,25(OH)
2
D
3 
at the site of inflammation and illustrates 
an important role for the cells of the immune system in the systemic effects of vitamin D.
Therefore, insight into how 1,25(OH)
2
D
3
 modulates the immune system could uncover 
new therapeutic targets in autoimmune diseases. Here we discuss the effects of vitamin 
D on various cell types involved in the immune response, the current knowledge about 
the underlying mechanisms and what this means for the therapeutic potential of vitamin 
D in autoimmunity (figure 2). 
5.1 Dendritic cells
Dendritic cells (DCs) are antigen-presenting cells (APCs), which means that their main 
function is to take up foreign antigens and present them as peptides to T cells on the human 
leukocyte antigen (HLA) molecules. DCs are predominantly found in an immature state 
in peripheral tissues such as the skin, gut and lungs, where they probe the surroundings 
for potential pathogens. Upon encountering a foreign antigen, they mature and migrate 
to the lymphoid tissues to stimulate antigen-specific T cells. Depending on the cytokines 
secreted by the DC, the T cell will differentiate into an effector cell with appropriate 
pro- or anti-inflammatory properties. Through these actions APCs are crucial in initiating 
effective adaptive immune responses against pathogens, but also for maintaining self-
tolerance and immune homeostasis. 
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Figure 2. The anti-inflammatory effects of 1,25(OH)
2
D
3
 on cells of the immune system. An overview of 
the anti-inflammatory effects of 1,25(OH)
2
D
3
 on the cells of the immune system in autoimmunity. Red dots 
represent pro-inflammatory cytokines, while green dots represent anti-inflammatory cytokines. Red arrows 
indicate decreased differentiation, green arrows indicate increased differentiation. References: CD8+ T cells 
201, 202, 204; ILC 203, 211-213, 220; Unconventional T cells 144, 161, 208; B cells 75, 133-136, 138, 139, 143; DC 85-87, 91, 93-95; Macrophages 
115, 125-128; CD4+ T cells 141, 150, 155, 159, 163-167, 177-182, 184, 194.
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The important role of DCs in autoimmune pathogenesis is illustrated in experimental 
autoimmune models, where deletion of specific DC subtypes ameliorates, or even prevents, 
disease onset.79-82 In addition, APCs, including DCs but also macrophages and B cells, 
are associated with human autoimmunity through the correlation between specific HLA 
alleles and the risk of developing an autoimmune disease. For example, HLA-DRB1*15:01 
is associated with an increased risk for MS.83 while HLA-DRB1*04:01 confers a greater 
susceptibility to RA.84 
DCs differentiated in vitro from monocytes or bone marrow cells in the presence of 
1,25(OH)
2
D
3
 will remain in an immature-like tolerogenic state. This is characterized by 
decreased production of pro-inflammatory factors like IL-12 and TNFα and increased 
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anti-inflammatory IL-10 production. These tolerogenic DCs are less capable of promoting 
proliferation and cytokine production of pro-inflammatory T cells, while they induce 
the differentiation of T regulatory (Treg) cells.85-87 Furthermore, they specifically induce 
apoptosis in autoreactive T cells, while not affecting proliferation of other T cells.88 Of 
note, 1,25(OH)
2
D
3
 can only induce this tolerogenic phenotype in DCs when it is added 
before their maturation. Once a maturation stimulus like lipopolysaccharide (LPS) is 
present or when the cells have already matured, the effects of 1,25(OH)
2
D
3
 on DCs are 
minimal.89 Aside from in vitro differentiated DCs, 1,25(OH)
2
D
3
 also induces a tolerogenic 
phenotype in dermal DCs, Langerhans cells and plasmacytoid DCs, even though there 
are subtle differences between the effects on these subsets.90-92
While the tolerizing effects of 1,25(OH)
2
D
3
 on DCs are well described, the underlying 
mechanisms are less clear. Recently, Ferreira et al. suggested that a metabolic switch 
towards glycolysis and activation of the PI3K-Akt-mTOR pathway are the first steps for 
the generation of tolerogenic DCs by 1,25(OH)
2
D
3
.93 Also the induction of indoleamine 
2,3-dioxygenase (IDO) on DCs has been reported to be essential for the induction of a 
tolerogenic DC (tDC) phenotype and thereby for the beneficial effect of 1,25(OH)
2
D
3
 on 
EAE.94 Although all tDCs promote regulatory T cells (Tregs), the mechanism by which 
they do this depends on the type of DC. While tDC derived in vitro from bone marrow 
cells promote Tregs via induction of herpesvirus entry mediator (HVEM), tolerized 
Langerhans cells use TGFβ for this.91, 95 Dermal DCs induce the differentiation of T 
regulatory 1 (Tr1) cells, another type of regulatory T cell, via IL-10.91 So in recent years 
advances have been made to fully understand how 1,25(OH)
2
D
3
 modulates DCs, but the 
picture is not yet complete.
Despite the incomplete understanding of the molecular mechanism behind the effects 
of 1,25(OH)
2
D
3
 on DCs, tDCs generated with 1,25(OH)
2
D
3
 alone or in combination with 
dexamethasone are considered for therapy in autoimmune diseases.96 Their persistent 
tolerogenic state and the possibility to pulse them with tissue-specific antigens has made 
them valuable candidates to treat various diseases, including autoimmune diseases.87, 
88, 97 This is illustrated in experimental disease models for T1D, MS and RA, where 
administered antigen-specific tDCs migrate to inflammatory sites and reduce disease 
activity upon administration.94, 98-100 Importantly, DCs with an increased activation status 
from patients with autoimmune diseases can become equally tolerogenic in response to 
1,25(OH)
2
D
3
 as healthy DCs.101-105 Because they can also be pulsed with auto-antigens and 
they can be generated under current Good Manufacturing Practice (cGMP) conditions, this 
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opens up the way for the use of autologous tDCs in the treatment of human autoimmune 
diseases.101, 106 Currently the use of tDCs generated with 1,25(OH)
2
D
3 
has not been 
clinically tested. However, tDCs generated using antisense oligonucleotides or Bay11-7082 
were found to be safe upon administration in patients with T1D or RA, respectively.107, 108 
It remains to be determined whether these tDCs also have effects on disease activity and 
whether tDCs generated using 1,25(OH)
2
D
3
 could also be used in this context. Increased 
understanding on how 1,25(OH)
2
D
3
, with or without dexamethasone, modulates the DCs 
can provide insights in how to further optimize the tolerogenic potential of the DCs.
5.2 Macrophages
Macrophages are known for their supreme phagocytic capacities, but they are also 
important APCs. In a normal immune response, an infection activates tissue-resident 
macrophages after which they produce inflammatory mediators and recruit other immune 
cells to eradicate the pathogen. Macrophages can roughly be divided in two categories: 
the M1 and M2 macrophages. M1 macrophages produce pro-inflammatory mediators like 
nitric oxide, TNFα, IL-23, IL-12 and IL-1β, whereby they kill pathogens and promote the 
polarization of T helper cells to Th1 and Th17 cells to assist in the immune response. On 
the other hand, M2 macrophages produce the anti-inflammatory cytokine IL-10 and are 
important in wound repair and restoring tissue homeostasis.109 
The role of macrophages in the pathogenesis in autoimmune diseases is illustrated by 
an increase in macrophages at inflammatory sites.110-113 In addition, macrophages are 
hyper-activated and produce more pro-inflammatory cytokines, suggesting a dysregulated 
balance between M1 and M2 cells.111, 114, 115 As a result of their hyper-inflammatory state, 
they are essential for the development and activation of β-cell specific cytotoxic T 
cells which leads to insulitis in NOD mice.116 Interestingly, the suppression of EAE by 
1,25(OH)
2
D
3
 is preceded by a rapid reduction of macrophages in the CNS. This suggests 
that macrophages are another important target for vitamin D in the suppression of 
autoimmunity.117
Notably, 1,25(OH)
2
D
3
 has dual roles in macrophage differentiation and activation. In 
the early stages of infection, 1,25(OH)
2
D
3
 stimulates differentiation of monocytes into 
macrophages.118 Furthermore, toll-like receptor (TLR) triggering or IFNγ-induced 
activation activates Cyp27B1 and thereby potentiates the conversion of 25(OH)D
3
 into 
1,25(OH)
2
D
3
.119, 120 1,25(OH)
2
D
3
 obtained via this pathway is then required for producing 
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cathelicidin and for the antimicrobial activity of human monocytes and macrophages.121, 
122 In addition, 1,25(OH)
2
D
3
 induces IL-1β, either directly or via upregulation of C/EBPβ 
or Erk1/2.123, 124 So initially, 1,25(OH)
2
D
3
 is essential for effective pathogen clearance. 
The hyper-responsiveness of VDR-/- mice to LPS stimulation indicates that in the later 
stages of infection, 1,25(OH)
2
D
3
 plays a role in the contraction of the immune response.125 
The anti-inflammatory effect of 1,25(OH)
2
D
3 
on macrophages is characterized by decreased 
production of pro-inflammatory factors like IL-1β, IL-6, TNFα, RANKL, COX-2 and 
nitric oxide and increased anti-inflammatory IL-10.115, 125-128 These changes suggest that 
1,25(OH)
2
D
3
 promotes the M2 phenotype while inhibiting the M1 phenotype, thereby 
restoring the balance between these subsets. Finally, 1,25(OH)
2
D
3
-treated macrophages 
have reduced T cell stimulatory capacity.128
In recent years some advances were made with unraveling the mechanism behind this anti-
inflammatory effect of 1,25(OH)
2
D
3
 on macrophages. An important target of 1,25(OH)
2
D
3
 
is thioesterase superfamily member 4 (THEM4), an inhibitor of the NFκB signaling 
pathway. THEM4 inhibits the direct binding of NFκB to the COX-2 locus and thereby 
prevents COX-2 transcription.126 Furthermore, THEM4 inhibits IL-6 and TNFα expression 
by preventing the signaling cascade in which NFκB induces miR-155 to suppress SOCS 
.125 Whether this THEM4-dependent pathway also inhibits the other pro-inflammatory 
mediators is not yet clear.115
The balancing effect of 1,25(OH)
2
D
3
 between the pro- and anti-inflammatory status of 
macrophages is of particular interest in the treatment of autoimmune diseases. Currently, 
many inflammatory mediators secreted by M1 macrophages, like IL-1β, COX-2, IL-6 
and especially TNFα, are already successful therapeutic targets in various autoimmune 
diseases. However, since current therapies result in systemic reduction of these mediators, 
patients may become prone to infections. Therefore it is of interest to understand the 
mechanism by which 1,25(OH)
2
D
3
 balances between pro- and anti-inflammatory actions. 
This may provide insights in how to suppress the pro-inflammatory cytokines only in 
case of hyper-activation, without affecting the normal immune response. 
5.3 B cells
B cells are mostly known for their crucial role in the immune response via the 
differentiation towards plasma cells and the production of antibodies. However, they 
also modulate the immune response via antigen presentation and cytokine secretion. In 
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the context of autoimmunity, B cells play a crucial role by the production of autoreactive 
antibodies. These auto-antibodies, like anti-nuclear antibodies (ANA) in SLE and anti-
citrullinated peptide antibodies (ACPA) in RA, can be found in >95% and 70% of patients, 
respectively.129, 130 
Interestingly, the VDR binds to the promoter region of genes involved in the immune 
system in lymphoblastoid B cell lines, suggesting a role for B cells in the effect of 
vitamin D on autoimmune diseases.131 Here we discuss what is known about the direct 
effects of 1,25(OH)
2
D
3
 on B cell differentiation and the three B cell functions of antibody 
production, cytokine secretion and antigen presentation.
Before B cells become plasma cells that secrete high-affinity antibodies, they have to 
go through various stages of differentiation, class-switch recombination and somatic 
hypermutation.132 Various reports indicate that 1,25(OH)
2
D
3
 reduces the proliferation 
of B cells, induces their apoptosis and inhibits immunoglobulin class switching.133-135 
This inhibition of differentiation may involve preventing nuclear translocation of NF-κB 
p65 and thereby inhibiting the signaling pathway downstream of CD40 costimulation.136 
On the other hand, 1,25(OH)
2
D
3
 stimulates plasma cell development when added to 
terminally differentiating B cells. Furthermore, it induces the chemokine receptor CCR10 
on these plasma cells, promoting their migration towards mucosal sites of inflammation.137 
Therefore, it appears that the effect of 1,25(OH)
2
D
3
 depends on the activation and 
differentiation status of the B cells. 
Independent of the effect of 1,25(OH)
2
D
3
 on B cell differentiation, there is ample evidence 
that it decreases the antibody production.133-135, 138, 139 Interestingly, the presence of ANA 
is correlated with a lower serum 25(OH)D
3
 level even in healthy people without SLE,140 
while cholecalciferol supplementation decreases auto-antibody titers.66, 141
Next to antibody production, B cells also secrete cytokines to influence the inflammatory 
milieu. Interestingly, VDR binds directly to the promoter region of IL-10 in B cells, 
thereby inducing the expression of IL-10.75 However, in a cohort of healthy controls and 
relapsing-remitting MS patients there was no correlation between IL-10 producing B cells 
and serum 25(OH)D
3
 levels.142 
There has been limited research towards the effect of 1,25(OH)
2
D
3
 on the APC function of 
B cells. However one study suggests that B cells primed with 1,25(OH)
2
D
3
 have decreased 
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CD86 surface expression. Thereby, these B cells are less potent stimulators of naïve T 
cell proliferation and cytokine production.143 
Altogether, the effect of 1,25(OH)
2
D
3
 on B cells is still not completely clear. Currently it is 
hypothesized that 1,25(OH)
2
D
3
 inhibits the pathogenic function of B cells in autoimmunity 
by preventing plasma cell differentiation and thereby auto-antibody production, by 
inducing IL-10 production and by inhibiting the antigen presentation capabilities. However, 
the limited amount of studies warrants further research to support this hypothesis and 
what role these effects play in the suppression of autoimmunity by 1,25(OH)
2
D
3
.
5.4 T cells
Historically, it was thought DCs were the main target of vitamin D and that effects 
observed on T cells were mediated via DCs. However, it has now become clear that upon 
activation various T cell populations express the VDR, including CD4+ T helper (Th) 
cells, CD8+ cytotoxic T cells and TCRγδ cells.12, 144, 145 This makes the T cell another direct 
immunological target for 1,25(OH)
2
D
3
. The effects of 1,25(OH)
2
D
3
 on T cells include 
modulation of cytokine secretion and differentiation, but VDR is also required for the 
activation of T cell by propagating TCR signaling.77 Since T cells are proposed to play 
an important role in the pathogenesis of autoimmunity, we will discuss the effects of 
1,25(OH)
2
D
3
 on the various T cell populations.
5.4.1 CD4+ T cells
CD4+ T cells are a heterogeneous group of cells, including T-helper 1 (Th1), Th2, Th17 
and Treg cells. In the normal immune response, Th1 cells are important for fighting 
intracellular pathogens, Th2 cells for helminth infections and Th17 cells for extracellular 
pathogens and fungi. On the other hand, Tregs mediate immunological tolerance against 
self-antigens and harmless foreign antigens such as food and intestinal microbiota. 
Furthermore, they control the immune response via various mechanisms, including 
the secretion of anti-inflammatory mediators such as IL-10 and TGF-β.146 However, 
in autoimmune diseases T cells mediate an immune response against the body itself, 
suggesting either hyper-activation of the pro-inflammatory T cells or insufficient control 
by Treg cells, or both. 
The importance of the T cells as a target of 1,25(OH)
2
D
3
 in experimental autoimmune 
diseases is illustrated by Mayne et al., who showed that 1,25(OH)
2
D
3
 is not able to suppress 
EAE when the VDR is absent in T cells.147 For these studies they used the CD4-Cre 
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system, resulting in VDR deficiency in both CD4+ and CD8+ T cells. However, in this 
disease model CD4+ are likely the prime 1,25(OH)
2
D
3
 target cells, since other studies show 
that in this model CD8+ T cells are dispensable for the effects of 1,25(OH)
2
D
3
.148 Further 
strengthening the hypothesis that the suppression of EAE by 1,25(OH)
2
D
3
 is driven by 
modulation of CD4+ T cells, is the finding that 1,25(OH)
2
D
3
 prevents CD4+ T helper 
cell migration into the CNS.149 Finally, VDR binding is enriched near SNPs associated 
with autoimmune diseases in human CD4+ T cells, suggesting that these cells are also 
important in the effects of 1,25(OH)
2
D
3
 in human autoimmunity.  
Because the effects of 1,25(OH)
2
D
3
 differ between the various CD4+ Th cell subsets,150 
we will give an overview of the current knowledge on how these individual subsets are 
modulated by 1,25(OH)
2
D
3
 to suppress the autoimmune response.
5.4.1.1 Th1 and Th2 cells
Classically, CD4+ T cells were subdivided into two classes: Th1 and Th2 cells. Th1 cells 
are characterized by the expression of IFNγ and T-bet, while Th2 cells produce IL-4, IL-5 
and IL-13 and express the transcription factor GATA3. In the context of autoimmunity it 
was long thought that Th1 cells mediate the disease pathogenesis, since mice lacking the 
transcription factor T-bet are protected against EAE.151 However, the discovery of Th17 
cells, which will be discussed in the next section, and the finding that IFNγ is not required 
for induction of autoimmunity have led to a debate as to whether Th1 cells are important 
for autoimmune pathogenesis.152, 153 However, since adoptive transfer of myelin-specific 
IFNγ+ cells induces EAE,154 Th1 cells may still play a role in the disease pathogenesis. 
Within Th1 cells, some studies suggest that 1,25(OH)
2
D
3
 inhibits IFNγ production when 
added at the first phases of differentiation.155, 156 On the other hand, another study found 
no effects on IFNγ.150 This contradiction could be explained by the addition of exogenous 
IL-2 in the first two studies. Since 1,25(OH)
2
D
3
 directly downregulates IL-2, exogenous 
IL-2 might be required for the inhibition of IFNγ by 1,25(OH)
2
D
3
.157, 158 Although these 
studies indicate that 1,25(OH)
2
D
3
 modulates Th1 cells under certain circumstances, given 
their relatively small role in autoimmune pathogenesis and the low expression of VDR 
compared to other CD4+ T cell subsets, it is unlikely that they play an important role in 
the suppression of autoimmunity by 1,25(OH)
2
D
3
.150, 159 
In contrast to Th1 cells, Th2 cells might be protective in Th17-driven autoimmune diseases 
even though they are pathogenic in the development of asthma and allergies. Studies 
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in experimental arthritis demonstrate that T cell specific overexpression of GATA3 is 
protective in autoimmunity due to suppression of Th17 responses.160 Interestingly, IL-4 is 
required for 1,25(OH)
2
D
3
 to inhibit EAE, suggesting an important role for this cytokine 
in the effect of 1,25(OH)
2
D
3
.161 In the same model, 1,25(OH)
2
D
3 
induces GATA3 and 
its regulator STAT6. The functional relevance of this upregulation is demonstrated in 
STAT6-KO mice, where 1,25(OH)
2
D
3
 is unable to inhibit EAE development.162 Altogether 
these studies suggest a role for Th2 induction in the immune suppression by 1,25(OH)
2
D
3
. 
However, the data on the effect of 1,25(OH)
2
D
3 
on Th2 cytokines like IL-4 seems 
contradictory. When naïve CD4+ T cells or the entire CD4+ T cell population are cultured 
without polarizing cytokines, 1,25(OH)
2
D
3
 induces IL-4 and GATA3.163, 164 Also, in PBMC 
of treatment-naïve early RA patients, where IL-4 production is diminished, 1,25(OH)
2
D
3
 
restores the IL-4 levels to the levels of healthy controls.165 However, when naïve CD4+ 
T cells, effector CD4+ T cells or total CD4+ T cells are cultured in the presence of IL-4 
to induce Th2 polarization, cellular IL-4 production is unaffected or even inhibited by 
1,25(OH)
2
D
3
.155, 156 Also when patients are supplemented with cholecalciferol, there is no 
increased IL-4 production by their T cells.141, 166, 167 Combining these data leads to the 
hypothesis that 1,25(OH)
2
D
3
 promotes Th2 differentiation and IL-4 production to assist in 
suppression of autoimmunity, but only when no sufficient IL-4 is present. The mechanism 
behind the precise regulation of IL-4 is of interest, not only for treatment of autoimmunity, 
but also of allergies and asthma where Th2 cytokines play an important pathogenic role.
5.4.1.2 Th17 cells
In most autoimmune diseases, Th17 cells are considered to be important drivers of disease 
pathogenesis. Th17 cells are characterized by production of cytokines such as IL-17A, 
IL-17F, TNFα and GM-CSF and the transcription factor RORC2 (RORγt in mice). They 
can also be distinguished based on the expression of the chemokine receptor CCR6, which 
directs migration towards the chemokine CCL20. Their differentiation can be driven by 
TGFβ, IL-6 and IL-1β, but they require IL-23 to become pathogenic Th17 cells.168 In 2003 
two hallmark studies showed that IL-23, and not IL-12, is required for the induction of 
EAE and CIA 169, 170, suggesting an important role for the IL-23/IL-17 immune pathway in 
the pathogenesis of autoimmune diseases. Indeed, local IL-17A overexpression in mouse 
knee joints induces an arthritis-like phenotype with inflammation, bone erosions and 
damaged cartilage.171 In EAE the pathogenic cells appear to be the ex-Th17 cells, which 
now express IFNγ and T-bet, indicating the importance of Th17 plasticity in autoimmune 
diseases.172 In human autoimmunity, for example in RA and SLE, levels of Th17 cells are 
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elevated in the peripheral blood and synovial fluid of patients and correlate with disease 
activity.173-175 Furthermore, specifically the CCR6+ memory Th cells, which include Th17 
cells, are potent activators of synovial fibroblasts.173 We have previously shown that this 
interaction leads to a pro-inflammatory feedback loop with increased production of IL-
17A, IL-6, IL-8 and tissue-destructive enzymes. Via this mechanism, Th17 cells may 
contribute to local joint inflammation in RA.173 Combining the important role of Th17 
cells in autoimmunity and the beneficial effect of 1,25(OH)
2
D
3
 on autoimmune diseases, 
it is hypothesized that 1,25(OH)
2
D
3
 suppresses autoimmunity at least partially via the 
inhibition of Th17 activity. 
In support of this hypothesis, the effect of 1,25(OH)
2
D
3
 on an experimental model for anti-
retinal autoimmunity depends on inhibiting Th17 activity.176 Also in vitro 1,25(OH)
2
D
3
 
decreases expression of pro-inflammatory cytokines like IL-17A, IL-17F and IL-22 in 
CD4+ T cells, CD4+ memory cells or CD4+CCR6+ memory cells.165, 177-179 Functionally, this 
decrease in Th17 activity diminishes activation of synovial fibroblasts, thereby inhibiting 
the pro-inflammatory loop between these cell types.179 Interestingly, 1,25(OH)
2
D
3
 also 
inhibits the secretion of IL-17A and other Th17 cytokines in the presence of Th17 
polarizing cytokines.178, 180 
1,25(OH)
2
D
3 
not only inhibits the activity of Th17 cells, but also Th17 differentiation. 
When naïve CD4+ T cells are differentiated towards the Th17 lineage in vitro, the presence 
of 1,25(OH)
2
D
3
 inhibits Th17-related cytokines and transcription factors such as IL-17A, 
IL-17F, RORC and CCR6.150, 159, 181 Functionally, MOG-specific Th17 cells differentiated in 
the presence of 1,25(OH)
2
D
3
 are less capable of inducing EAE upon adoptive transfer.178 
Aside from the decreased pathogenicity of the cells, this effect may also be due to a 
decrease in CCR6, the chemokine receptor required for migration to the CNS.182
Although the inhibitory effect on Th17 activity is well described, the mechanisms behind 
it are less clear. First of all, Joshi et al. showed that the regulation of IL-17A can be 
mediated via direct binding of the VDR to the IL-17A promoter. VDR-RXR complexes 
compete with NFAT for the binding sites in the promoter, after which they recruit RUNX1 
and HDAC (histone deacetylase) to inhibit IL-17A gene expression.178 This competition for 
the NFAT binding site also occurs at the promoter of IL-2, a known primary 1,25(OH)
2
D
3
 
target gene, suggesting that this may be a general mechanism that also applies to other 
NFAT-regulated genes.157 Recruitment of HDAC indicates that epigenetic regulation is 
also important in the inhibition of IL-17A by 1,25(OH)
2
D
3
, especially given the relative 
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epigenetic instability of the IL-17A gene locus.183 Aside from this direct regulation of 
IL-17A, other mechanisms have also been proposed. One study showed that CHOP is 
crucial for the inhibitory effect of 1,25(OH)
2
D
3
, while a second study indicated IRF8 to 
be important.159, 181 Yet another study indicated that VDR forms a complex with VDR, 
RXR, HDAC2 and Smad3 to inhibit Smad7 transcription, thereby preventing IL-17A 
production.184 Of note, TGFβ is the cytokine that induces Smad3 and Erk, leading to this 
inhibition of IL-17A, but it is also the cytokine responsible for inducing the VDR.180 How 
these mechanisms relate to each other remains to be investigated.
5.4.1.3 Th17.1 cells
Before the discovery of Th17 cells it was thought that Th1 cells, characterized by 
expression of IFNγ, T-bet and CXCR3, were the major drivers of the autoimmune response. 
The finding that IL-23, and not IL-12, was required for experimental autoimmunity, at 
first completely shifted the viewpoint towards Th17 cells as the pathogenic drivers of 
autoimmunity. However, lately more and more studies indicate that the subdivision into 
Th17 and Th1 is not as linear as previously assumed. Upon stimulation by IL-12 or TNFα 
Th17 cells can become double producers of IL-17A and IFNγ or even shift towards high 
IFNγ production with little or no IL-17A. Since these latter cells still express CCR6 and 
RORC, together with T-bet and CXCR3, they are called non-classic Th1 or Th17.1 cells.185 
Currently, it is hypothesized that the Th17.1 cells are more pathogenic than Th17 cells in 
autoimmune diseases, because they are enriched at the sites of inflammation in several 
diseases.186, 187 
Interestingly, we have shown that in CCR6+ cells, which includes Th17 and Th17.1 cells, 
1,25(OH)
2
D
3
 reduces the frequency of IFNγ+, IL-17A+ and IFNγ+IL-17A+ cells.179 This 
suggests that 1,25(OH)
2
D
3
 can inhibit T helper cell pathogenicity in autoimmunity via 
the inhibition of Th17 and Th17.1 cells. A similar effect was found in the CD4+ T cells 
of SLE patients supplemented with 10400 IU cholecalciferol for 6 months.188 Other 
supplementation studies have not addressed the combined or single expression of IFNγ 
and IL-17A, but the results on total IL-17A+ or total IFNγ+ cells are ambiguous.141, 166, 167
5.4.1.4 Regulatory T cells
In contrast to the pro-inflammatory T helper subsets mentioned above, regulatory T cells, 
or Tregs, suppress the immune response. Tregs express FoxP3, the anti-inflammatory 
cytokines IL-10 and TGFβ, the inhibitory co-receptor CTLA4 and a high level of CD25. 
They exert immunomodulatory effects on other immune cells such as macrophages, 
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dendritic cells, CD8+ T cells but also other CD4+ T cells, thereby maintaining immune 
homeostasis. Their essential role in preventing autoimmunity is demonstrated in patients 
with a mutation in FoxP3. These patients are suffering from the IPEX syndrome, which 
is characterized by massive autoimmunity.189 In the autoimmune diseases discussed here 
it is hypothesized that an imbalance between pro-inflammatory T cells, such as Th17 or 
Th17.1, and regulatory T cells underlies the immune pathogenesis. 1,25(OH)
2
D
3
 may act 
by restoring this balance and thereby restoring immune homeostasis.
Indeed, 1,25(OH)
2
D
3
 induces FoxP3+ Tregs in the spleen, lymph nodes and spinal cord of 
EAE mice.178, 184 Additionally, without IL-10 or IL-10-mediated signaling, 1,25(OH)
2
D
3
 
cannot inhibit EAE.190 In in vitro cultures of Tregs, either obtained via in vitro polarization 
or sorted from peripheral blood, 1,25(OH)
2
D
3 
induces the production of IL-10, but not 
FoxP3.164, 191, 192 Polarized Tregs express a higher level of Treg-associated markers such 
as CTLA4, PD1 and CD25 and their suppressive capacity is enhanced by 1,25(OH)
2
D
3
.192 
Also, the suppressive capacity of Tregs is positively correlated with the serum 25(OH)
D
3
 level in MS patients.193 However, when sorted Tregs are used, 1,25(OH)
2
D
3
 does not 
further enhance their suppressive capacity.164, 191 This suggests that 1,25(OH)
2
D
3
 optimizes 
Treg function in order to suppress autoimmunity. 
Interestingly, 1,25(OH)
2
D
3
 also induces IL-10 production when CD4+ cells are cultured 
under neutral conditions, and even further in the presence of Th17 polarizing cytokines. 
Furthermore, in these cultures 1,25(OH)
2
D
3
 also induces FoxP3 and CTLA4, while 
enhancing the suppressive capacity of the cells.163, 177, 178, 180, 181, 184, 194 Because 1,25(OH)
2
D
3
 
inhibits Th17 polarization while inducing IL-10 in these cultures, it was postulated that 
1,25(OH)
2
D
3
 may inhibit Th17 activity via IL-10 induction. However, IL-10 is dispensable 
for the inhibition of IL-17A, suggesting that Th17 inhibition and Treg induction are two 
independent mechanisms of 1,25(OH)
2
D
3
.150 
On a molecular level three mechanisms have been proposed by which 1,25(OH)
2
D
3
 can 
stimulate a Treg-like phenotype even under Th17 polarizing conditions. Firstly, the 
VDR can bind to three VDREs in the conserved non-coding sequence of the FoxP3 
promoter, thereby directly controlling FoxP3 transcription.178, 194 The second mechanism 
is by reversing the inhibitory effect of Th17 polarizing cytokines on CTLA4, leading to 
upregulation of CTLA4.180 Finally, 1,25(OH)
2
D
3
 induces the expression of IDO, which 
increases the number of Tregs.76 The latter finding is interesting, since IDO was also 
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reported to be important for the induction of tDCs (see section 5.1).94 suggesting it might 
be a general target of 1,25(OH)
2
D
3
 in the immune system.
Although the in vitro data demonstrate that 1,25(OH)
2
D
3
 induces Treg cells, not all 
cholecalciferol supplementation studies find an effect on Tregs. Several studies suggest 
an increase in the proportion or number of Treg cells based on surface marker expression 
141, 166, 195 or based on IL-10 production.52, 167 However, another study did not find this 
induction in Treg cells.61 and Treg suppressive function is unaffected by cholecalciferol 
supplementation.167 
Overall, in CD4+ T cells 1,25(OH)
2
D
3
 inhibits the pro-inflammatory Th cell functions 
while stimulating Treg activity. These effects are observed under both healthy and 
pathogenic conditions, such as in patients with autoimmune diseases.191 Therefore, 
restoring the disturbed balance between effector T cells and Treg cells may underlie the 
beneficial effects of 1,25(OH)
2
D
3
 on autoimmunity. 
5.4.2 CD8+ cytotoxic T cells
In addition to CD4+ T cells, cytotoxic CD8+ T cells comprise the second important class 
within the T cells. These cells contribute to the immune response by inducing apoptosis 
in abnormal cells, for example in case of infection or uncontrolled growth in cancer. In 
addition they modulate other immune cells by secreting cytokines.196 Although the role 
of CD8+ T cells in autoimmune diseases is not as well characterized as the role of CD4+ T 
cells, various studies indicate that they play a role in disease pathogenesis. For example, 
myelin-specific CD8+ T cells induce EAE in mice, with characteristics of human MS 
that are not conferred by myelin-specific CD4+ T cells.197, 198 Similarly, hsp60-specific 
CD8+ T cells induce autoimmune intestinal inflammation.199 More recently it was shown 
that IL-17A+CD8+ T cells are enriched in the synovial fluid of psoriatic arthritis patients. 
These cells do not express cytolytic markers, but their levels are positively correlated with 
markers of disease activity.200 Since CD8+ T cells have a higher expression of VDR than 
CD4+ T cells,145 CD8+ T cells may also be a target for 1,25(OH)
2
D
3
 in the suppression of 
autoimmunity.
Indeed, adoptive transfer of VDR-/- CD8+ T cells in Rag-deficient mice induces intestinal 
inflammation. When VDR-/-IL-10-/- CD8+ T cells are transferred the intestinal inflammation 
is even worse and leads to wasting disease.201 The increased proliferation of VDR-/- CD8+ 
T cells, even in the naive state, suggests that VDR-induced signaling is required for 
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maintaining quiescence of these cells. Thereby 1,25(OH)
2
D
3
 prevented hyper-activation of 
CD8+ T cells and subsequent autoimmune pathology in diseases such as Crohn’s disease.201 
In addition to maintaining quiescence, 1,25(OH)
2
D
3
 also inhibits the secretion of IFNγ and 
TNFα by activated CD8+ T cells.202 Finally, topical treatment with calcipotriol decreases 
the frequency of IL-17A+CD8+ cells in psoriatic lesions, which is interesting in light of the 
correlations between these cells and disease activity in psoriatic arthritis.200, 203 
Aside from modulating the activity of the classical CD8+ T cells to reduce autoimmunity, 
1,25(OH)
2
D
3
 is also important in the development of CD8αα+ T cells. CD8αα+ T cells are 
self-reactive cells that have a regulatory function by maintaining homeostasis in the gut. 
In VDR-/- mice the number of these cells is reduced, which may explain the susceptibility 
of these animals to intestinal inflammation.204
It is important to note that the effect of 1,25(OH)
2
D
3
 is not mediated via the CD8+ T cells 
in every autoimmune disease, since they were dispensable for the attenuation of EAE by 
1,25(OH)
2
D
3
.148 However, it seems that in IBD and psoriatic arthritis the CD8+ T cells are 
target for 1,25(OH)
2
D
3
. It will be of great interest to determine what the role of the CD8+ 
T cells is in the effect of 1,25(OH)
2
D
3
 on other autoimmune diseases. This will not only 
provide insight into the mechanisms behind the effect of vitamin D, but also about the 
differences in pathogenesis in the various autoimmune diseases.
5.4.3 Unconventional T cells
Next to the traditional CD4+ and CD8+ T cells, there are also cells expressing the TCR but 
lacking both CD4 and CD8. These so-called unconventional T cells have a less diverse 
TCR repertoire and they are not restricted to MHC class I or II. The unconventional T 
cells include mucosal associated invariant T (MAIT) cells, TCRγδ T cells and natural 
killer T (NKT) cells. 
Although MAIT cells have been implicated to be suppressive in autoimmunity, as reviewed 
by Godfrey et al.,205 there is currently no data available on the effect of 1,25(OH)
2
D
3
 on 
these cells.
TCRγδ T cells are rapid responders in the event of an infection with intracellular 
pathogens, due to their recognition of phospho-antigens. Interestingly, they are pathogenic 
in autoimmune models like EAE and CIA and they produce a wide range of pro-
inflammatory cytokines like IL-17A, IL-17F, GM-CSF, TNFα and IFNγ.206 There is only 
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one study that investigated the effect of 1,25(OH)
2
D
3
 on the pro-inflammatory activity of 
these cells. They demonstrated that TCRγδ T cells express the VDR upon activation. In 
response to 1,25(OH)
2
D
3
 the production of IFNγ and the proliferation of these cells was 
inhibited.144 Currently it is thought that the main pathogenic action of the TCRγδ T cells 
in autoimmunity is the secretion of IL-17A.206 Unfortunately, there is no data available 
yet that describes the effect of 1,25(OH)
2
D
3
 on this cytokine, or any of the other cytokines 
secreted by the TCRγδ T cells.
The last subset of unconventional T cells that will be discussed here are the NKT cells. 
They recognize glycolipid antigens and are thereby involved in the protection against a 
wide range of pathogens. Upon TCR stimulation, NKT cells can rapidly secrete various 
pro-inflammatory cytokines, including IL-4, IFNγ and IL-17A. NKT cells can be divided 
into type I and type II NKT cells. Type I NKT cells are also called invariant NKT 
(iNKT) cells due to their invariant TCR. Type II NKT cells have a variable TCR and are 
therefore called the variant NKT cells. The exact role of NKT cells in the pathogenesis 
of autoimmune disease is not yet completely clear. They are pathogenic in CIA, but they 
are protective in EAE, T1D and SLE.161, 207 
Interestingly, VDR is required in the thymus for the development of functionally mature 
iNKT cells. Furthermore, the iNKT cells in VDR-/- mice are hyporesponsive to TCR 
stimulation.208 In addition, the protective effect of 1,25(OH)
2
D
3
 in EAE is partially 
dependent on iNKT cells, possibly via inducing IL-4 in these cells.161 These data suggest 
that 1,25(OH)
2
D
3
 promotes a suppressive function of iNKT cells. However, given the 
two-sided effect of iNKT cells in the different autoimmune diseases, further research is 
needed to fully examine the effect of 1,25(OH)
2
D
3
 on iNKT cell activity and what this 
means for each individual disease.
5.5 Innate lymphoid cells
Recently a new group of cells became the center of attention in the field of immunology; 
the innate lymphoid cells (ILC). ILCs play an important role in tissue repair, tissue 
homeostasis and the immune response against bacteria, viruses and fungi. ILCs can be 
grouped into three classes; (i) the group 1 ILCs (ILC1) that secrete IFNγ and depend on 
T-bet expression, (ii) the group 2 ILCs (ILC2) that secrete type 2 cytokines such as IL-5 
and IL-13 and depend on GATA3 and (iii) the group 3 ILCs (ILC3) that secrete IL-17A 
and/or IL-22 and depend on RORC.209
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The ILC1s include natural killer cells, which have been known for a longer time and play 
a role in the clearance of viruses. Since viral triggers are thought to play a role in the 
initiation of some autoimmune diseases, the NK cells have been investigated for their 
role in this context. However, under some circumstances NK cells are protective, while 
in others they can be pathogenic as recently reviewed by Poggi and Zocchi.210 Also the 
data on the effect of 1,25(OH)
2
D
3
 on NK cells are somewhat contradictory. In an NK cell 
line, 1,25(OH)
2
D
3
 induces the cytolytic killing capacity of NK cells,211 but this effect has 
not been found in healthy control peripheral blood.212, 213 However, when 1,25(OH)
2
D
3
 
is added during the in vitro differentiation of NK cells from hematopoietic stem cells, 
the development of NK cells is impaired and their cytotoxicity and IFNγ production are 
reduced.212 Interestingly, 1,25(OH)
2
D
3
 specifically inhibits activation, cytotoxic capacity 
and pro-inflammatory cytokine production in over-activated NK cells in women with 
recurrent pregnancy losses.213 This supports a hypothesis in which 1,25(OH)
2
D
3
 is not a 
general inhibitor of the immune response, but rather a regulator of immune homeostasis. 
Therefore it is of interest whether this abnormal NK activation is also seen in autoimmune 
diseases and can be modulated by 1,25(OH)
2
D
3
.
Based on their cytokine signature, it can be hypothesized that in the context of 
autoimmunity ILC3 cells play a role in disease pathogenesis. Indeed, an increase in ILC3 
cells has been demonstrated in the lesional skin of psoriasis patient 214, 215, in the inflamed 
intestine of Crohn’s disease patients,216 in the peripheral blood of MS patients 217 and in 
the gut, peripheral blood, bone marrow and synovial fluid of patients with ankylosing 
spondylitis.218 Furthermore, ILC3 were shown to be responsible for experimental innate-
induced colitis.219 Interestingly, in VDR-KO mice, which are susceptible for colitis, the 
levels of ILC1 and ILC3 are increased.220 On the other hand, calcipotriol treatment did 
not affect the frequencies of ILC subsets in psoriatic skin lesions after two weeks.203 
Since the research into ILC has only started to expand in recent years, the effects of 
1,25(OH)
2
D
3
 on these cells have not been investigated extensively. Current data suggests 
that 1,25(OH)
2
D
3
 may also have anti-inflammatory effects on these cells, but more studies 
are required to distinguish the effects on the different subsets and its role in the protective 
effect of vitamin D in autoimmunity.
5.6 Indirect immunomodulatory effects
In the previous sections we discussed the direct modulatory effects of 1,25(OH)
2
D
3
 on 
various cells of the immune system. However, 1,25(OH)
2
D
3 
and the VDR also affect tissue 
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resident cells, such as hepatic and pancreatic stellate cells, and the inflammatory mediators 
that they secrete.221, 222 This indirect mechanism of immune modulation by 1,25(OH)
2
D
3
 
is also relevant in autoimmune diseases. For example, in RA the interaction between T 
cells and synovial fibroblasts contributes to disease pathogenesis.173 Therefore it is also 
of interest to study the effect of 1,25(OH)
2
D
3
 on the tissue-resident cells in the context 
of autoimmunity.
Similar to the tissue-resident tissue cells in liver and pancreas, 1,25(OH)
2
D
3 
also directly 
affects RA synovial fibroblasts. Not only is the IL-1β-induced production of tissue-
degrading matrix metalloprotease 1 (MMP1) inhibited, also the infiltration capacity of 
RA fibroblasts is reduced upon treatment with 1,25(OH)
2
D
3
.223 But this effect on tissue-
resident cells is not only found in the synovial cells. It was also shown that the VDR 
is required for intestinal homeostasis by limiting the production of IL-6 by epithelial 
cells through inhibition of the NFκB pathway.224 Finally, 1,25(OH)
2
D
3
 also affects brain 
pericytes, which may be relevant for MS. The pericytes line the epithelial cells of blood 
vessels and in the brain they are important for maintaining the blood-brain-barrier and 
neuron functioning. Brain pericytes cells produce less pro-inflammatory genes when 
exposed to 1,25(OH)
2
D
3
 while upregulating anti-inflammatory genes. Interestingly, brain 
pericytes express Cyp27B1 upon stimulation with TNFα and IFNγ. This indicates that 
an inflammatory environment promotes the conversion of 25(OH)D
3
 into 1,25(OH)
2
D
3
, 
which then can dampen the inflammation by modulating the pericytes.225
Overall, the indirect effects of vitamin D and the VDR on immune cells via tissue-resident 
cells have been underexposed in the past years. However, if we truly want to understand 
the molecular mechanisms by which 1,25(OH)
2
D
3
 acts in autoimmune diseases, these 
effects are very important for future studies.
6 FUTURE DIRECTIONS
In this review we have discussed the advancements that have been made regarding the 
clinical effects of vitamin D and the molecular mechanisms that underlie these effects. 
However, there is still a lot that is unclear at the moment which will be subject of 
investigation in the coming years.
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6.1 Vitamin D supplementation
Based on the current data on the effect of vitamin D supplementation it is still not possible 
to draw conclusions about the added value for the treatment of autoimmunity. This is due 
to the low number of trials, small patient numbers and heterogeneity in trial setup. In 
order to determine the therapeutic value of vitamin D supplementation, there are two big 
open questions that need to be addressed.
Firstly it is important to assess what serum 25(OH)D
3
 level is required for a beneficial 
effect of vitamin D in autoimmune diseases. Based on the requirements for calcium 
homeostasis, current guidelines indicate that a level below 50 nmol/L corresponds 
with deficiency, between 50 and 74 nmol/L as insufficiency and above 75 nmol/L as a 
sufficient 25(OH)D
3
 level.226, 227 However, in the context of autoimmunity it is not known 
whether it is enough to correct deficiency or whether we should strive for an even higher 
serum 25(OH)D
3
 level. Using 75 nmol/L as a cut-off point, Raftery et al. showed that 
CD patients with sufficient serum 25(OH)D
3
 have significantly higher quality of life and 
less severe disease as measured by intestinal permeability, LL-37 expression and CDAI.58 
Furthermore, in healthy individuals the serum 25(OH)D
3
 level is correlated with number 
of VDR binding sites in CD4+ T cells. When they have a level above 75 nmol/L, the VDR 
binding is enriched near genes associated with autoimmune diseases and regulatory T 
cells.  However, clinical trials, either with or without placebo controls, do not consistently 
find immune modulation regardless of the baseline and endpoint serum 25(OH)D
3
 level 
(table 2). It should be noted that these measurements have been done in the peripheral 
blood or in cells from the peripheral blood, which is not the site of inflammation and 
therefore may not be the most relevant place to look for immunological effects.
The second question that is still matter of debate is in what form and dosage vitamin D 
should be supplemented. In the experimental autoimmune models animals are mostly 
supplemented with a high dose of 1,25(OH)
2
D
3
, but in humans this strategy may lead 
to hypercalcemia. Therefore most clinical trials use cholecalciferol as the form of 
choice, although some use 1,25(OH)
2
D
3
 or less calcemic analogues like alfacalcidiol. 
Of note, a study comparing the effects of alfacalcidiol (analogue for 1,25(OH)
2
D
3
) with 
colecalciferol (analogue for cholecalciferol) indicates that in the short term alfacalcidiol 
might be more effective, but this effect disappears after 12 months.228 Analogues like 
calcipotriol that are used in the topical treatment of psoriasis have not been tested in 
the other autoimmune diseases that were discussed here. Other analogues have been 
developed, which show equal or better immunomodulatory potential and have been 
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successfully used in experimental autoimmune diseases.191, 229-233 The only analogue that 
was used in clinical trials was alfacalcidiol, mainly in type 1 diabetes patients (table 1). 
However, the effects of alfacalcidiol do not seem better than calcitriol, and at the same 
dosage there were no severe side effects from either alfacalcidiol or calcitriol.60, 63, 64 More 
research into the actual effects of vitamin D analogues on human autoimmune disease 
is required for establishing whether these analogues can be used safely and effectively. 
Furthermore, in the clinical trials performed so far there were no serious adverse events 
after cholecalciferol supplementation. Therefore it is important to establish the added 
value of the vitamin D analogues compared to cholecalciferol supplementation. Currently, 
cholecalciferol is the most used supplementation form in clinical practice. Vitamin D 
supplementation guidelines indicate a maximum safe dose of 4,000 IU cholecalciferol per 
day for healthy adults.226 However, no adverse effects were found with dosages of up to 
50,000 IU cholecalciferol weekly for 12 weeks, or 100,000 IU weekly for 1 month followed 
by 100,000 IU monthly for 5 months.54, 141, 167 Interestingly, the dose-escalation regime used 
by Burton et al. and 20,000 IU weekly by Smolders et al. did not elicit hypercalcemia 
despite reaching a serum 25(OH)D
3
 level of 400 and 380 nmol/L, respectively.49, 167
In considering the best strategy for cholecalciferol supplementation it should also not 
be forgotten that 1,25(OH)
2
D
3
 may have a synergistic effect with other treatments. For 
example, in vitro studies have shown that 1,25(OH)
2
D
3
 synergizes with retinoic acid (an 
active vitamin A metabolite) or dexamethason in the inhibition of Th17 pathogenicity.165, 234 
Also in monocytes the combination of dexamethasone and 1,25(OH)
2
D
3
 has added effects 
over the compounds separately, partially because 1,25(OH)
2
D
3
 enhances the effects of the 
glucocorticoid receptor.235, 236 Furthermore, we have previously shown that 1,25(OH)
2
D
3
 
has an added effect on TNFα blockade in inhibiting the pro-inflammatory loop between 
Th17 cells and RASF in RA, suggesting that vitamin D combined with anti-TNFα could 
yield a better treatment response in the treatment of RA patients.179 Finally, combining 
1,25(OH)
2
D
3
 with Lovastatin has an added therapeutic effect on EAE. This is due to 
the inhibition of RhoA-ROCK signaling in autoreactive T cells, leading to decreased 
expression of Cyp24A1 and thereby less inactivation of 1,25(OH)
2
D
3
.237 Altogether, these 
data indicate that it may be worthwhile to investigate the addition of cholecalciferol to 
current treatments like anti-TNFα, or to combine cholecalciferol with for example retinoic 
acid or statins. Due to the synergy between 1,25(OH)
2
D
3
 and these already approved 
drugs, a lower dose of cholecalciferol may be sufficient for achieving beneficial clinical 
effects.
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Currently several clinical trials are ongoing and recruiting patients in MS (clinicaltrials.gov 
identifier NCT01490502), RA (NCT02243800) and IBD (NCT02704624, NCT01046773, 
NCT02208310) for which the results are expected in the coming 3 to 5 years. Hopefully 
they can provide more insight into the answers on these remaining questions. However, 
to firmly establish the added value of cholecalciferol supplementation, large multi-center 
trials are required. Ideally, in these trials the patients should be randomized into different 
treat-to-target arms, in which every arm has a target 25(OH)D
3
 serum level, such as 75, 
100 and 150 nmol/L. Since the effect of cholecalciferol alone is probably not sufficient 
to control disease activity, patients should receive standard care following pre-defined, 
harmonized treatment protocols in addition to the cholecalciferol supplementation.
6.2 Molecular mechanisms underlying immunomodulation
In addition to the studies where cholecalciferol has been supplemented, attention has also 
focused on understanding the immunomodulatory effects of 1,25(OH)
2
D
3
 on a cellular 
level. Based on the current knowledge, 1,25(OH)
2
D
3
 reduced the pathogenicity of dendritic 
cells, macrophages, CD4+ T cells, CD8+ T cells and B cells. Similar effects have been 
observed in γδ T cells, iNKT cells and ILCs, but more research is necessary to confirm 
these data (see section 5). It should be noted that 1,25(OH)
2
D
3
 does not merely work as an 
anti-inflammatory agent. Instead, 1,25(OH)
2
D
3
 assists in maintaining the balance between 
a pro- and anti-inflammatory state and is thereby able to restore the disturbed balance 
that is associated with autoimmunity. 
This balancing effect of 1,25(OH)
2
D
3
 is best illustrated in monocytes and macrophages, 
where it has pro-inflammatory effects in the early stages of activation but later shifts to an 
anti-inflammatory state.238 Therefore it is interesting to study the effects of 1,25(OH)
2
D
3
 
in more detail in the various stages of differentiation and activation from monocyte to 
macrophage. The Carlberg lab has performed ChIP-seq experiments in the monocytic 
THP-1 cell line at early time points.  Detailed studies have revealed several primary target 
genes such as ASAP2 and THBD,239-241 but also identified Bcl6 as a primary target that 
mediates important secondary responses.242 Next to the primary target genes, combining 
the ChIP-seq dataset with publically available ChIA-PET and FAIRE-seq datasets has 
improved the knowledge on VDR binding kinetics.243, 244
This is just an example of how next generation sequencing techniques can be combined to 
yield more understanding of the molecular mechanisms behind the effects of 1,25(OH)
2
D
3
. 
Since it has already been shown that 1,25(OH)
2
D
3
 has different effects on every cell type, 
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even closely related cell types such as Th1 and Th17,150 it will be interesting to study 
VDR DNA binding and identify primary target genes in separate cell types. This will 
give insight into the similarities and differences between the effects of 1,25(OH)
2
D
3
 on 
each cell, and what will be important to balance the immune response in patients with 
autoimmune diseases.
7 CONCLUSION
Although various studies have shown a beneficial effect of cholecalciferol supplementation 
in autoimmune diseases, there are also studies that do not find any effect on disease 
parameters. This might be due to the supplementation strategy or the subjects included 
in the study, which are issues that should be addressed in properly designed multi-center 
clinical trials. 
However, it is also possible that systemic cholecalciferol supplementation is not sufficient 
to establish effects in every patient. Therefore, another way to use the immunomodulatory 
effects of vitamin D to the advantage of patients with autoimmune diseases, is to mimic 
the effects by targeting important pathways within immune cells. In order to do this, it 
is crucial to understand the working mechanisms of 1,25(OH)
2
D
3
. In the coming years 
attention should be paid towards unraveling these molecular mechanisms to optimize the 
therapeutic potential of vitamin D.
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ABSTRACT
Vitamin D and its active metabolite 1,25(OH)
2
D
3
 are associated with the incidence 
and severity of autoimmune diseases, such as rheumatoid arthritis (RA). Although the 
mechanisms behind the 1,25(OH)
2
D
3
-mediated suppression of RA are incompletely 
understood, inhibition of the pathogenicity of T-helper-17 (Th17) cells is considered to 
play an important role. Interestingly, 1,25(OH)
2
D
3
 also promotes the development of Th2 
and regulatory T (Treg) cells and induces production of cytokines such as IL-4 and IL-10. 
Since these cytokines can suppress Th17 differentiation, we here studied their contribution 
to the immunomodulatory effects of 1,25(OH)
2
D
3
 on Th17 cells.
First, we determined whether 1,25(OH)
2
D
3
 could induce IL-4 and IL-10 in splenic CD4+ 
T (Th) cells under Th17 polarizing culture conditions (TGFβ, IL-6, IL-23, anti-IL-4 and 
anti-IFNγ). In splenocyte cultures enriched for Th cells , 1,25(OH)
2
D
3
 inhibited pro-
inflammatory cytokines such as IL-17A and IL-17F, while inducing IL-4 and IL-10. The 
splenic Th cell population is comprised of CD62L- cells (effector and effector memory 
Th cells) and CD62L+ cells (mainly naïve Th cells). Therefore, we studied the effects of 
1,25(OH)
2
D
3
 and the contribution of IL-4 and IL-10 in CD62L+ and CD62L- (TEFF/EM) 
cells. Neutralizing IL-4, but not IL-10, diminished the 1,25(OH)
2
D
3
-mediated inhibition of 
Th17 polarization in the IL-4-rich TEFF/EM cells. In CD62L+ Th cells, which produce low 
levels of IL-4, IL-4 neutralization did not influence the effects of 1,25(OH)
2
D
3
. However, 
adding recombinant IL-4 improved the effects of 1,25(OH)
2
D
3
 on Th17 differentiation in 
CD62L+, but not TEFF/EM cells. Interestingly, IL-4 neutralization in TEFF/EM cells reduced 
expression of the vitamin D receptor (VDR), whereas recombinant IL-4 upregulated VDR 
in CD62L+ Th cells. This shows that IL-4 augments the effects of 1,25(OH)
2
D
3
 through 
upregulation of VDR.
Altogether, these data demonstrate a previously unknown function of IL-4 to sensitize 
Th17 cells for 1,25(OH)
2
D
3
-mediated modulation via VDR upregulation. Thereby IL-4 
contributes to 1,25(OH)
2
D
3
-mediated inhibition of Th17 differentiation and activation.
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INTRODUCTION
Vitamin D is a secosteroid hormone, synthesized in the skin in response to sunlight, 
that is mostly known for its role in calcium metabolism and skeletal health.1,2 However, 
in the past two decades it has become increasingly clear that vitamin D also has 
strong immunomodulatory properties. In that context, serum vitamin D levels and 
VDR polymorphisms have been shown to be correlated to the incidence and severity 
of several autoimmune diseases, such as rheumatoid arthritis (RA), multiple sclerosis 
(MS) and inflammatory bowel diseases (IBD).3 Interestingly, the active vitamin D 
metabolite 1,25(OH)
2
D
3
 can prevent disease in experimental autoimmune models for 
RA and MS, including collagen-induced arthritis (CIA) and experimental autoimmune 
encephalomyelitis (EAE).4,5 Furthermore, when applied therapeutically, 1,25(OH)
2
D
3
 
prevents disease progression in these models. However, treatment with a high dose of 
1,25(OH)
2
D
3
 cannot be directly translated into clinical practice due to the risk of severe 
side effects due to hypercalcemia. However, understanding the mechanisms by which 
1,25(OH)
2
D
3
 suppresses autoimmunity may provide alternative targets at which therapy 
can be directed without the hypercalcemic side effects.
Although 1,25(OH)
2
D
3
 affects most types of immune cells, studies in EAE demonstrated 
that CD4+ T cells are essential for the disease-suppressing properties of 1,25(OH)
2
D
3
.6,7 
CD4+ T cells comprise various subsets, including T-helper-17 (Th17) cells. These pro-
inflammatory cells are characterized by the production of IL-17A and IL-17F and the 
transcription factor RORγt, and they differentiate from naïve cells in vitro under the 
influence of TGFβ, IL-6 and IL-23. Th17 cells are considered to play an important role in 
disease pathogenesis, since IL-23 is required for the development and progression of the 
autoimmune phenotype in EAE and CIA.8,9 Furthermore, mice lacking IL-17 have reduced 
disease in CIA, whereas IL-17R-deficient mice are completely protected against arthritis in 
this model.10,11 Also in human RA, Th17 cells implicated in disease pathogenesis, possibly 
through activating synovial fibroblasts and promoting the development of pathogenic 
antibodies by plasma cells.12,13
Previously, we and others have shown that 1,25(OH)
2
D
3
 inhibits the pathogenicity of 
both human and mouse Th17 cells by inhibiting the production of pro-inflammatory 
cytokines such as IL-17A, IL-22 and IFNγ.14-17 Interestingly, 1,25(OH)
2
D
3
 has also been 
reported to induce cytokines that are protective in autoimmune diseases such as IL-4 and 
IL-10.14,18-21 However, the contribution of IL-4 and IL-10 to the immunomodulatory role 
of 1,25(OH)
2
D
3
 has not been elucidated. Here, we investigated whether IL-4 and IL-10 
3
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could contribute to the immunomodulatory effects of 1,25(OH)
2
D
3
 on Th17 cells in the 
context of CIA.
MATERIALS AND METHODS
Mice
DBA/1OlaHsd mice were purchased from Envigo (Horst, the Netherlands). Mice were 
given water and food ad libitum and were kept under specific pathogen-free conditions. 
Mice were 8-12 weeks old at the start of the experiments, which were approved by the 
Dutch Animal Ethics Committee.
Immunization
Bovine collagen type II (CII, Chondrex, Redmond, WA) was reconstituted with 0.1 M 
acetic acid and diluted to 2 mg/ml in saline, after which it was emulsified in an equal 
volume of Complete Freund’s Adjuvant (CFA, Difco, Detroit MI). 100 μg of CII (100 μl 
emulsion) was used to immunize mice intradermally at the tail base. Mice were sacrificed 
10 days after immunization.
Cell sorting
Splenocytes were isolated from spleens by gently pressing the spleens through nylon filters 
(pore size 100 μm) with Roswell Park Memorial Institute (RPMI)-1640 medium (Gibco, 
Waltham, MA, USA). Erythrocytes in the cell suspension were lysed using Gey’s solution. 
For magnetic activated cell sorting (MACS), splenocytes were stained with biotin-labeled 
antibodies against CD11b, GR-1, CD8, TER119, B220, NK1.1 and TCRγδ (BD Biosciences, 
San Diego, CA, USA) and subsequently incubated with streptavidin-coated magnetic 
beads (Miltenyi Biotec, Leiden, the Netherlands). Unstained cells, containing 70-90% 
CD4+ T cells, were isolated using autoMACS (Miltenyi Biotec).
For sorting TEFF/EM and CD62L+ CD4+ T cells, splenocytes were stained with antibodies 
against CD3 (BD Biosciences), CD4 and CD62L (BioLegend, San Diego, CA, USA) and 
pre-purified for CD4+ T cells by staining with CD4 microbeads (Miltenyi Biotec) and 
separation on autoMACS following manufacturer’s instructions. Dead cells were excluded 
using diamidino-2-pheylindole dilactate (DAPI) and then CD62L+ (CD3+CD4+CD62L+) 
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and TEFF/EM (CD3+CD4+CD62L-) cells were sorted with a FACSAriaII cell sorter (BD 
Biosciences).
Cell culture
Purified CD4+ T cells were cultured for 3 days under stimulation of 10 μg/ml plate-
bound anti-CD3 and 10 μg/ml plate-bound anti-CD28 (BD Biosciences) with 100 nM 
1,25(OH)
2
D
3
 (Leo Pharmaceutical Products, Ballerup, Denmark) dissolved in 100% 
ethanol or an equal volume of 100% ethanol (never exceeding 0,1% total concentration). 
Where indicated, the cells were restimulated using 5 ng/ml IL-2 and cultured for another 
4 days with fresh 1,25(OH)
2
D
3
. Th17 polarization was induced using 3 ng/ml TGFβ, 10 
ng/ml IL-6, 50 ng/ml IL-23, (R&D systems, Minneapolis, MN, USA) 10 μg/ml anti-
IFNγ and 10 μg/ml anti-IL4 where indicated. Reduced Th17 (redTh17) conditions do not 
contain anti-IL4. In some cultures, 10 μg/ml anti-IL-10 or 10 ng/ml recombinant IL-4 
(R&D systems) was added. All T cells were cultured in Iscove’s Modified Dulbecco’s 
Medium (IMDM) with 10% fetal calf serum (both from Gibco, Waltham, MA, USA), 2 
mM L-glutamine, 100 U/ml penicillin/streptomycin (Lonza, Verviers, Belgium) and 50 
μM β-mercaptoethanol (Sigma-Aldrich, St. Louis, MO, USA).
RT-PCR
RNA was isolated from cultured cells using the GenElute Mammalian Total RNA 
Miniprep Kit (Sigma-Aldrich, St. Louis, MA, USA) following manufacturer’s 
instructions. Purified RNA was treated with 0,1 U/µl DNAse (Invitrogen, 
Carlsbad, CA, USA) and reverse transcribed to cDNA using random hexamer 
primers and 10 U/µl Superscript II (Invitrogen). Primers and probes were chosen 
based on design by ProbeFinder Software (Roche Applied Science, Indianapolis, 
IN, USA) for 18s rRNA (forward primer 5’-GCAATTATTCCCCATGAACG-3’; 
reverse primer 5’-GGGACTTAATCAACGCAAGC-3’; probe 48) and VDR 
(forward primer 5’-CACCTGGCTGATCTTGTCAGT-3’; reverse primer 
5’-CTGGTCATCAGAGGTGAGGTC-3’; probe 89). Probes were selected from the 
Universal Probe Library (Roche Applied Science). Real-time PCR was performed with 
the Viia7 system and analyzed usingQuantStudio Real-time PCR Software version 1.3 
(Applied Biosystems, Waltham, MA, USA). Data were normalized against 18s ribosomal 
RNA (18s rRNA).
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ELISA
Levels of IL-17A, IL-17F, IL-22, IL-21 (R&D Systems, Minneapolis, MN, USA), IL-4, 
IL-10 (eBioscience, San Diego, CA, USA) and IFNγ (BD Biosciences and eBioscience) in 
culture supernatant were measured using ELISA following manufacturer’s instructions.
Flow cytometry
For intracellular flow cytometry, cultured cells were stimulated using 50 ng/ml phorbol 
12-myristate 13 acetate (PMA), 500 ng/ml ionomycin (Sigma-Aldrich) and Golgistop 
(BD Bioscience) as described by the manufacturer for 4 hours. Where indicated, 
restimulated cells were pre-stained for CD4 (BD Biosciences). Fixable Viability Dye 
eFluor506 (eBioscience) was used to exclude dead cells from the analysis. After fixation 
with 2% paraformaldehyde (PFA) and permeabilization using 0.5% saponin, cells were 
stained with antibodies against IL-17A, IL-4 (BioLegend), IL-17F, IL-10 (eBioscience) 
and IFNγ (BD Biosciences). For staining for FOXP3, RORγt and GATA3, the cells were 
fixated and permeabilized using the Intracellular Fixation & Permeabilization Buffer 
Set (eBioscience). Samples were acquired on the FACSCantoII flow cytometer (BD 
Biosciences).
Statistical analysis
The differences between two or more groups were tested using a Student’s T-test or 
ANOVA with Bonferroni post-tests, respectively. Calculations were made using GraphPad 
Prism version 6.01 (GraphPad Software, La Jolla, CA, USA).
RESULTS
1,25(OH)2D3 inhibits Th17 polarization and induces IL-4 and IL-10 production in 
splenic CD4+ T cells from CII-immunized mice
To investigate the effect of 1,25(OH)
2
D
3
 on Th17 differentiation in CIA, DBA/1 mice were 
immunized with type II collagen. Ten days after immunization their spleen was dissected, 
which at this stage contains increased proportions of activated CD4+ T cells. For the first 
screening to assess what happens to CD4+ T helper (Th) cells in pathogenic conditions, 
splenocytes enriched for CD4+ Th cells (70-90%) using MACS were cultured for 7 days 
with or without 1,25(OH)
2
D
3
 under Th17 polarizing conditions (TGFβ, IL-6, IL-23, anti-
IL-4 and anti-IFNγ). Compared to naïve mice (DBA/1), the splenic CD4+ T cells from 
CII-immunized mice (CII-DBA/1) expressed higher levels of IL-17A, IL-17F and IL-22, 
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but not IFNγ and IL-21 (figure 1A-C). 1,25(OH)
2
D
3
 treatment inhibited this increased 
Th17 differentiation. This effect was also observed for RORγt, the master transcription 
factor for Th17 cells (figure 1D).
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Figure 1. 1,25(OH)
2
D
3
 inhibit Th17-specific markers in CD4+ T cells. Splenocytes from non-immunized 
(DBA/1) or CII-immunized (CII-DBA/1) mice were enriched for CD4+ T cells using MACS and cultured for 
7 days with or without 100 nM 1,25(OH)
2
D
3
 under Th17 polarizing conditions (TGFβ, IL-6, IL-23, anti-IFNγ 
and anti-IL-4). (A) Representative flow cytometry staining for IL-17A and IFNγ, gated on CD4+ cells. (B) 
Quantification of (A). (C) Protein production as measured in culture supernatant using ELISA. (D) Repre-
sentative flow cytometry plot of RORγt staining. Data are shown as mean with SEM for n = 4 mice per group, 
representative of 2 independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Figure 2. Inhibition of Th17 differentiation by 1,25(OH)
2
D
3
 is accompanied by induction of IL-4 and IL-10. 
Cells were isolated and cultured as in figure 1. (A) Flow cytometry plot representing IL-17A, IL-4 and IL-10 
staining in 4 mice per group, gated on CD4+ cells. (B) Data quantification for figure (A). (C) Expression (as 
mean fluorescent intensity, MFI) of FOXP3 and GATA3 as measured by intracellular flow cytometry. Mean 
and SEM are shown for n = 4 mice per group, representing 2 independent experiments. *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001.
Previously it has been shown that 1,25(OH)
2
D
3
 promotes Th2 cells and Treg cells, but it 
is unknown whether this also occurs under Th17 polarizing conditions. Therefore, we 
investigated whether the inhibition of Th17 differentiation is accompanied by induction of 
Th2 or Treg signatures in splenocytes enriched for CD4+ T cells. The proportion of IL-4- 
and IL-10-producing cells did not differ between cells from DBA/1 or CII-DBA/1 mice, 
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but in both cultures 1,25(OH)
2
D
3
 induced IL-4 and IL-10 expression despite the presence 
of Th17 polarizing cytokines (figure 2A, B). To determine whether the 1,25(OH)
2
D
3
-
treated cells adopt a Th2- or Treg-like phenotype, the expression of GATA3 and FOXP3 
was next analyzed. Although FOXP3 was slightly increased in the 1,25(OH)
2
D
3
-treated 
cells from CII-DBA/1 mice compared to those from DBA/1 mice, there was no effect of 
1,25(OH)
2
D
3
 when comparing the treated with the untreated cells (figure 2C). GATA3 was 
only induced by 1,25(OH)
2
D
3
 in the cells from CII-DBA/1 mice, which could indicate that 
these overly activated cells have an altered response to 1,25(OH)
2
D
3
. However, these data 
do not support a model in which 1,25(OH)
2
D
3
 mediates a shift towards Th2 or Treg cells. 
Overall, these data demonstrate that 1,25(OH)
2
D
3
 inhibits Th17 differentiation while 
inducing IL-4 and IL-10, but differentiation was not skewed towards genuine Th2 or 
Treg cells under Th17 polarizing conditions.
IL-4, but not IL-10, is required for optimal 1,25(OH)2D3-mediated suppression of 
Th17 polarisation of TEFF/EM cells
Since IL-4 and IL-10 are known suppressors of Th17 differentiation, they could play a role 
in the suppressive effects of 1,25(OH)
2
D
3
 on Th17 cells in the context of CIA. To study 
the role of IL-4 and IL-10 in the direct effects of 1,25(OH)
2
D
3
 on Th17 polarization, we 
sorted the effector and effector memory CD4+CD62L- (TEFF/EM) cells from spleens of CII-
DBA/1 mice. TEFF/EM cells will predominantly migrate towards affected tissue and thereby 
contribute to synovial inflammation. When these cells were cultured under reduced Th17 
polarizing conditions (redTh17; as before but without anti-IL-4), 1,25(OH)
2
D
3
 inhibited 
IL-17A and IL-17F, but not IFNγ, similar to the previous data (figure 3A, C). Upon IL-4 
and IL-10 blockade, the expression of IL-17A and IL-17F was higher under control 
conditions, as would be expected given the Th17-suppressive effect of IL-4 (figure 3A).22,23 
Interestingly, when IL-4 was blocked the effect of 1,25(OH)
2
D
3
 on IL-17A and IL-17F 
was less strong, whereas blocking IL-10 had no effect. Also, the combination of blocking 
IL-4 and IL-10 showed no additive effect compared to blocking only IL-4 (figure 3A, C). 
Similar results were obtained via protein detection in the supernatant (data not shown). 
In contrast to the findings in CD4-enriched splenocytes, 1,25(OH)
2
D
3
 does not upregulate 
IL-4 in the TEFF/EM cultures and IL-10 was induced only when both IL-4 and IL-10 were 
blocked (figure 3B, C). These data indicate that IL-4, but not IL-10, is required for an 
optimal effect of 1,25(OH)
2
D
3
 suppressing Th17 polarization in TEFF/EM cells.
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Figure 3. 1,25(OH)
2
D
3
-mediated inhibition of Th17 polarization in TEFF/EM partially depends on IL-4, but 
not IL-10. TEFF/EM cells were sorted from splenocytes of CII-immunized DBA/1 mice and cultured for 3 days 
with or without 1,25(OH)
2
D
3
. Cultures were exposed to reduced Th17 (redTh17) conditions, with or without 
anti-IL-4 and anti-IL-10. (A,B) Representative flow cytometric plots, gated on living lymphocytes. (C) Quan-
tification of data shown in figure (A), depicted as the fold change (1,25(OH)
2
D
3
/Control). Below the dotted 
line is inhibition in response to 1,25(OH)
2
D
3
, above the dotted line is upregulation. Results represent at least 
2 independent experiments and are depicted as mean with SEM for n = 6 mice. *p < 0.05, **p < 0.01, ***p < 
0.001, ****p < 0.0001.
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1,25(OH)2D3 inhibits Th17 differentiation in CD62L+ Th cells independent of IL-4 
or IL-10
The finding that 1,25(OH)
2
D
3
did not induce IL-4 directly in the TEFF/EM cells leads to the 
question whether IL-4 and IL-10 were induced in the CD62L+ Th cells, which contain the 
naïve but also central memory Th cells that mostly remain inside the secondary lymphoid 
organs. Furthermore, we asked whether IL-4 and IL-10 were required for the effects of 
1,25(OH)
2
D
3
 on Th17 polarization in CD62L+ Th cells. Therefore, splenic CD62L+ Th 
cells were isolated from CII-immunized mice and cultured with or without 1,25(OH)
2
D
3
 
under reduced Th17 conditions. In these cells, 1,25(OH)
2
D
3
 reduced IL-17A and IL-17F 
but still could not induce IL-4 or IL-10 (figure 4A, S1). However, in contrast to TEFF/EM 
cells, neither blocking IL-4 nor IL-10 affected the modulation by 1,25(OH)
2
D
3
 in CD62L+ 
cells. Interestingly, the CD62L+ Th cells produced lower levels of IL-4 than TEFF/EM as 
measured both by flow cytometry and ELISA (figure 4B), which could explain this lack 
of effect of IL-4 blockade on CD62L+ cells.
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Figure 4. Effects of 1,25(OH)
2
D
3
 on Th17-polarized CD62L+ Th cells are not affected by IL-4 blockade. (A) 
CD62L+ Th cells sorted from spleens of CII-immunized DBA/1 mice, were cultured as in figure 3. Percentage 
of cytokine expressing cells were measured using flow cytometry and shown here as fold change (1,25(OH)
2
D
3
/
Control) as in figure 3B. (B) IL-4 production as percentage of IL-4-producing cells within cultured CD62L+ 
Th or TEFF/EM cells cells (upper panel) or as measured in the supernatant these cultures using ELISA (lower 
panel). Data depict mean with SEM for n = 6 mice representing at least 2 independent experiments. *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001.
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Figure 5. IL-4 augments effects of 1,25(OH)
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3
 by upregulating VDR. CD62L+ and TEFF/EM cells were simul-
taneously sorted from the spleens of CII-immunized mice and cultured for 3 days with or without 1,25(OH)
2
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under redTh17 conditions. Anti-IL4 (aIL-4) and recombinant IL-4 (rIL-4) were added as indicated. (A) Cyto-
kine expression was measured in culture supernatant using ELISA and calculated to fold change (1,25(OH)
2
D
3
/
Control). Data are shown for CD62L+ (upper panels) and TEFF/EM (lower panels) cells. (B) VDR expression 
after indicated cultures as measured by RT-PCR, for CD62L+ (upper figure) and TEFF/EM (lower figure) cells. 
Results are shown for n = 6 mice as mean with SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
 
IL-4 augments the effects of 1,25(OH)2D3 via upregulating VDR
The previous data showed that IL-4 was able to enhance the immunomodulatory effects 
of 1,25(OH)
2
D
3
. To test this, splenic TEFF/EM and CD62L+ cells were sorted from CII-
immunized mice and cultured under reduced Th17 conditions with either anti-IL4 or 
recombinant IL-4. In CD62L+ cells, adding IL-4 further suppressed production of IL-17A 
and IL-17F (figure 5A). However, in the TEFF/EM cells there was no additional effect of 
adding IL-4, suggesting that there is a maximum to the effects that IL-4 can accomplish. 
Previously, it has been shown that the effects of 1,25(OH)
2
D
3
 on Th17 cells depend on the 
vitamin D receptor (VDR).15 Therefore, we hypothesized that the beneficial effects of IL-4 
might be due to upregulation of the VDR. Interestingly, in the CD62L+ cells there was 
a striking increase in the levels of VDR upon stimulation with recombinant IL-4 (figure 
5B). In TEFF/EM, the levels of VDR under redTh17 conditions were higher than in CD62L+ 
cells and were decreased upon IL-4 blockade. Adding recombinant IL-4 did not affect 
VDR levels in the TEFF/EM cells, which corresponds with the lack of effect of recombinant 
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IL-4 on the 1,25(OH)
2
D
3
-mediated Th17 differentiation. Notably, the expression of VDR 
was decreased in all cultures upon 1,25(OH)
2
D
3
 stimulation. This has been previously 
described after 72 hours of culture24, suggesting a regulatory feedback mechanism that 
regulates the sensitivity of the cell to 1,25(OH)
2
D
3
. Altogether, these data show that 
IL-4 enhances the effect of 1,25(OH)
2
D
3
 through induction of VDR, but this process is 
regulated to prevent excessive 1,25(OH)
2
D
3
-mediated modulation.
DISCUSSION
Previously, it has been demonstrated that 1,25(OH)
2
D
3
 inhibits Th17 differentiation, which 
may contribute to its inhibitory effects on autoimmune diseases. Next to 1,25(OH)
2
D
3
, 
also the cytokines IL-4 and IL-10 are known to inhibit Th17 polarization. Here we found 
that 1,25(OH)
2
D
3
 induced the production of IL-4 and IL-10 in CD4+ T cells under Th17 
polarizing conditions. Whereas IL-10 did not play a role in the suppression of Th17-related 
cytokines by 1,25(OH)
2
D
3
, IL-4 upregulated VDR and thereby enhanced the 1,25(OH)
2
D
3
-
mediated effects on Th17 polarization.
The induction of IL-4 in T cells by 1,25(OH)
2
D
3
 has been reported, but appears to be 
context dependent. Without polarizing cytokines, 1,25(OH)
2
D
3 
induces IL-4 in both 
naïve and the full CD4+ T cell population.18,25 IL-4 can also be upregulated in PBMC of 
treatment-naïve early RA patients, which have diminished IL-4 levels compared to healthy 
controls.14 However, under Th2 polarizing conditions IL-4 production is unaffected 
or inhibited.26,27 In the present study we found IL-4 induction in CD4+ T cells from 
splenocyte cultures highly enriched for CD4+ T cells, but not in sorted TEFF/EM or CD62L+ 
T cells. This illustrates that to fully understand the suppression of autoimmunity by 
1,25(OH)
2
D
3
, research should focus on multiple types of immune cells. 
Although the specific mechanisms behind IL-4 upregulation by 1,25(OH)
2
D
3
 have not been 
elucidated in this study, the observation that IL-4 can assist 1,25(OH)
2
D
3
 by upregulating 
VDR in Th17 cells suggests an important role for this cytokine in the immunomodulatory 
capacities of 1,25(OH)
2
D
3
. Interestingly, Lu et al. showed that VDR, induced by a synthetic 
agonist, interacts with GATA3 and thereby prevents IL-4 transcription in Th2 cells.28 This 
could indicate that IL-4 upregulates VDR as part of an autocrine regulatory feedback loop 
to prevent further induction of IL-4. Such a mechanism would also explain why adding 
more IL-4 has no additional effect as shown for the TEFF/EM cells in this study. 
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IL-4
VDR
IL-17A
1,25(OH)2D3
?
Figure 6. Proposed molecular mechanism underlying the role of IL-4 in 1,25(OH)
2
D
3
-mediated inhibition 
of Th17 differentiation. The feedback mechanism by which IL-4 is prevented from further inducing VDR is 
currently unknown (dashed line). 1,25(OH)
2
D
3
 binds to the VDR (black line). Green arrow indicate upregula-
tion, red arrows indicate inhibition.
However, these data seem to be contrasting another study which shows decreased IL-4 
production in VDR-knockout mice.29 These differences could be due to the strong T cell 
stimulation in the study by Lu et al., but also compensatory mechanisms may play a role 
in the VDR-knockout model. Overall it seems that there is a delicately regulated balance 
between 1,25(OH)
2
D
3
, VDR and IL-4 (figure 6). Further understanding this balance 
will provide more insight into the immunomodulatory effects of 1,25(OH)
2
D
3
 and could 
perhaps explain some of the controversies on the effects of 1,25(OH)
2
D
3
 on IL-4.
It should be noted that it is possible that aside from the classical T-helper cells, also 
natural killer T cells (NKT) were present in the cultures. Although they only make up 
about 2% of the lymphocytes in CIA spleen30, their production of IL-4 in response to TCR 
stimulation and 1,25(OH)
2
D
3
 treatment may affect the 1,25(OH)
2
D
3
-VDR-IL-4 balance 
that is observed in this present study.31 Further research is thus required to examine this 
balance and whether it is specific for CD4+ T cells or also occurs in other IL-4 producing 
cells such as NKT cells.
Surprisingly, although Th17 cells in this study produced higher levels of IL-17A upon 
IL-10 blockade, IL-10 did not play a role in the 1,25(OH)
2
D
3
-mediated inhibition of 
Th17 polarization. However, IL-10 signaling is required for the suppression of EAE by 
1,25(OH)
2
D
3
, indicating that it does play a role in the immunomodulatory effects of 
vitamin D.32 This suggests that 1,25(OH)
2
D
3
-induced IL-10 has mostly effects on other 
immune cells, monocytes for example, and on tissue-specific cells such as synovial 
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fibroblasts in which IL-10 reduces their invasive properties.33 Another possibility is that 
there is a limit to the amount of IL-17A reduction that IL-10 can exert, and that this level 
is already reached by 1,25(OH)
2
D
3
 via direct mechanisms. Future research is required to 
unravel the exact role of 1,25(OH)
2
D
3
 induced IL-10 in autoimmune arthritis.
Although this study revealed a role for IL-4 in the effects of 1,25(OH)
2
D
3
, IL-17A and 
IL-17F could still be inhibited by 1,25(OH)
2
D
3
 upon IL-4 blockade, probably because 
CD4+ T cells already express VDR upon TCR stimulation.34,35 Furthermore, our data 
still do not reveal the mechanisms that are activated in Th17 cells upon treatment with 
1,25(OH)
2
D
3
 that lead to inhibition of the Th17 phenotype. Various mechanisms have 
been described, as previously reviewed3, but further studies are still required to fully 
understand 1,25(OH)
2
D
3
-mediated immune regulation.
In conclusion, we revealed a previously unknown function for IL-4 to induce VDR in 
Th17 cells, sensitizing them for regulation by 1,25(OH)
2
D
3
. This process is regulated to 
prevent excessive 1,25(OH)
2
D
3
-mediated modulation and contributes to the inhibition of 
Th17 differentiation and activation by IL-4.
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Figure S1. Flow cytometric representation of the effects of anti-IL-4 and anti-IL-10 in CD62L+ Th cells. Cells 
were sorted and cultured as described for figure 4. Plots are representative of n=6 mice.
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ABSTRACT
Background
Understanding the underlying inflammatory processes could improve the treatment in 
patients with rheumatoid arthritis (RA). CCR6+ memory T-helper (memTh) activate 
RA synovial fibroblasts (RASF) and could therefore play a role in disease pathogenesis. 
However, CCR6+ memTh cells comprise multiple subpopulations, including Th17 
and Th17.1 cells, and it is unknown which of these are important in RA pathogenesis. 
Therefore, RASF activation by four CCR6+ memTh subpopulations was studied, including 
modulation of this process by cytokine directed therapy and 1,25(OH)
2
D
3
.
Methods
Th17 (CXCR3-CCR4+), Th17.1 (CXCR3+CCR4-), DP (CXCR3+CCR4+) and DN (CXCR3-
CCR4-) CCR6+ memTh cells sorted from PBMC of healthy donors or treatment-naïve 
early RA patients were co-cultured with RASF with or without anti-IL17A, anti-IFNγ or 
the active vitamin D metabolite 1,25(OH)
2
D
3
. Cultures were analyzed by RT-PCR, ELISA 
or flow cytometry.
Results
Both ex vivo and after three days of culture Th17, Th17.1, DP and DN cells equally express 
RORC. However, they differ in production of T-bet and cytokines like IL-17A and IFNγ. 
Despite these differences, RASF were more activated by the different CCR6+ memTh 
subpopulations than by Th1 cells, either from healthy individuals or RA patients. RASF 
activation was partially inhibited by blocking IL-17A, but not by neutralizing IFNγ or 
T-bet. 1,25(OH)
2
D
3
 inhibited pathogenicity of all subpopulations and suppressed RASF 
activation.
Conclusion
Th17, Th17.1, DP and DN CCR6+ memTh cells express equal levels of RORC and all 
activate RASF. This interaction can be suppressed by 1,25(OH)
2
D
3
, but not by neutralizing 
IFNγ or T-bet. Therefore, new therapeutic strategies for RA should focus on targeting all 
these CCR6+ memTh subpopulations
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INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disease, in which the immune system is 
aberrantly activated and creates a chronic inflammation in the synovial joints. This results 
in pain, fatigue and functional disability, which cannot be sufficiently suppressed in a 
large group of patients due to ineffective treatment response or treatment resistance.1-3 In 
order to further improve the quality of life of RA patients, it is important to understand the 
underlying pathogenesis and which cells play a role in driving the chronic inflammation.
Previously, we and others have shown that CCR6+ memory T-helper (memTh) cells are 
elevated in the blood of treatment-naïve early RA patients and are present in the synovial 
fluid.4,5 These cells express the transcription factor RORC and pro-inflammatory cytokines 
such as interleukin (IL)-17A, tumor necrosis factor alpha (TNFα) and interferon-gamma 
(IFNγ).6 Functionally, they contribute to synovial inflammation by activating synovial 
fibroblasts from RA patients (RASF), which in turn further activate the CCR6+ memTh 
cells to create a pro-inflammatory loop. This loop also leads to the induction of IL-8 to 
attract more immune cells, of prostaglandin-E2 (PGE2), IL-6 and IL-1β to activate other 
immune cells and of matrix metalloproteases (MMPs) that contribute to the tissue damage 
in RA.4
CCR6+ memTh cells are a heterogeneous group of cells, containing multiple subpopulations 
of which Th17 cells are the most intensively studied.6 Th17 cells became the center of 
attention in RA research when IL-23, one of the cytokines that guides Th17 differentiation, 
was found to be essential for the development of experimental arthritis.7 Furthermore, 
in the same collagen-induced arthritis model, IL-17A-deficient mice develop less severe 
arthritis8, while mice without IL-17R are completely protected from arthritis development.9 
In recent years, also Th17.1, or non-classical Th1, cells have been identified as cells which 
co-express RORC and T-bet, but also high levels of IFNγ and low amounts of IL-17A. 
Th17.1 cells are specifically elevated at the inflammatory sites in autoimmune diseases 
such as sarcoidosis, Crohn’s disease and juvenile idiopathic arthritis.10 
Th17 and Th17.1 cells can be distinguished within the CCR6+ memTh cells as being 
CCR4+CXCR3- or CCR4-CXCR3+, respectively. Interestingly, there are also 
subpopulations within CCR6+ memTh cells that are less well described. They express 
either both CCR4 and CXCR3 (double-positive cells, DP) or neither receptors (double-
negative cells, DN).6 
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The functional role of the individual CCR6+ memTh subpopulations is currently under 
debate. Whereas Th17 cells were classically thought to be the main drivers of autoimmune 
inflammation, Th17.1 cells are now considered to be more pathogenic in for example 
Crohn’s disease and multiple sclerosis.11,12 The DP cells, together with the Th17.1 cells, are 
elevated in ACPA positive RA patients compared to ACPA negative patients, suggesting 
a distinct role for these cells in different RA subtypes.13 
Therefore, in this study we aim to further elucidate the functional role that the individual 
CCR6+ memTh subpopulations could play in RA pathogenesis by investigating their 
capacity to activate RASF. Furthermore, the possibilities to suppress this activation are 
studied.
MATERIALS AND METHODS
Subjects
Peripheral blood mononuclear cells (PBMC) from healthy individuals were isolated from 
buffycoats (Sanquin Bloodbank, Rotterdam, the Netherlands). RA PBMC were isolated 
from treatment-naïve early RA patients embedded in the Treatment in the Rotterdam Early 
Arthritic Cohort (tREACH), which all fulfilled the American College of Rheumatology 
2010 classification criteria for RA. The study was approved by the Medical Ethics Review 
Board of Erasmus MC Rotterdam. Relevant clinical characteristics are shown in table 
S1. Synovial fibroblasts were isolated from established RA patients undergoing joint 
replacement surgery. Informed consent was obtained from all individuals.
Cell sorting
PBMC were isolated from peripheral blood or buffycoats through a ficoll gradienst and 
stored in liquid nitrogen until use. For sorting, isolated PBMC were first pre-purified for 
CD4 using magnetic beads (Miltenyi Biotech) and then sorted using monoclonal antibodies 
against CD4, CD25, CXCR3, CCR4 (BioLegend, San Diego, CA, USA), CD45RO and 
CCR6 (BD Biosciences, San Diego, CA, USA). All cells were CD4+CD45RO+CD25low/int, 
and then further sorted on CCR6-CCR4-CXCR3+ (Th1), CCR6+CCR4+CXCR3- (Th17), 
CCR6+CCR4-CXCR3+ (Th17.1), CCR6+CCR4+CXCR3+ (DP) or CCR6+CCR4-CXCR3- 
(DN).
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Cell culture
RASF were grown out of small biopsies from synovial tissue after joint replacement 
surgery. The cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM), 
supplemented with 10% fetal calf serum (FCS, Gibco, Waltham, MA, USA)) and 100 
U/ml penicillin/streptomycin (pen/strep, Lonza, Verviers, Belgium) and used between 
passage 3 and 8. 
Sorted CCR6+ memTh subpopulations were cultured at a density of 2.5x104 cells/ml in 
Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 10% FCS, 2 mM 
L-glutamine (Lonza), 100 U/ml pen/strep and 50 μM β-mercaptoethanol (Sigma-Aldrich, 
St. Louis, MO, USA). Where indicated, the CCR6+ Th memory subpopulations were 
co-cultured with 1.0x104 RA synovial fibroblasts (RASF), which were seeded in flat-
bottom 96-well plates 24 hours earlier. T cells were stimulated with 300 ng/ml soluble 
anti-CD3 and 400 ng/ml soluble anti-CD28 (Sanquin, Amsterdam, the Netherlands). For 
some experiments, the cells were cultured with 100 nM 1,25(OH)
2
D
3
 dissolved in 100% 
ethanol (Leo Pharmaceutical Products, Ballerup, Denmark), 100 μg/ml secukinumab (anti-
IL-17A, Novartis, Basel, Switzerland) or 10 μg/ml anti-IFNγ (R&D Systems, Minneapolis, 
MN, USA). Controls were an equal volume of 100% ethanol (with a maximum final ethanol 
concentration of 0,1%) or equal concentrations of corresponding isotype control antibodies, 
respectively.
Lentiviral vectors and T cell transduction
LVRU6MP plasmids containing scrambled shRNA or four different TBX21-targeting 
shRNAs were obtained from GeneCopoeia (Rockville, MD, USA). They were amplified in 
GCI-5α competent cells (GeneCopoeia) and extracted using the PureYield Plasmid Midiprep 
System (Promega Benelux, Leiden, the Netherlands), both following manufacturer’s 
protocol. LVRU6MP plasmids and the Lenti-PAC HIV Expression Packaging Kit 
(GeneCopoeia) were used to generate replication-deficient lentiviral vectors in 293T 
cells (GeneCopoeia) as described in manufacturer’s protocol. 293T culture supernatant 
containing lentiviral vectors was filtered through 0.45 μm polyethersulfone filters and 
stored at -80°C until use.
For transduction of T cells, CCR6+ Th memory cells (CD4+CD45RO+CCR6+CD25lo/int) 
were sorted and activated with 300 ng/ml soluble anti-CD3 and 400 ng/ml soluble anti-
CD28 for two days. Then medium was replaced with either 50% 293T culture supernatant 
containing relevant lentiviral vectors with 50% normal T cells medium, or 100% T cell 
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medium for mock conditions, both supplemented with 8ng/ml polybrene (Sigma-Aldrich). 
T cells were then transduced by centrifuging cells at 1000xg and 32°C for 90 minutes, 
followed by 4 hours incubation at 37°C and 5% CO2. Then transduction medium was 
removed and cells were further cultured in normal T cell medium at a density of  ̴ 0,1x10^4 
cells/ml together with 0,5x10^5 autologous irradiated PBMC (50 Gy, using RS320, X-strahl, 
Surrey, UK) and 50 ng/ml phytohaemaglutinin (PHA). After six days of culture, cells 
were restimulated with 5 ng/ml IL-2 and cultured for another six days. Then the stably 
transduced cells were sorted based on MFP expression and cultured with RASF as 
described in the cell culture section.
Flow cytometry
For intracellular cytokine detection by flow cytometry, cultured cells were restimulated 
for 4 hours using 50 ng/ml phorbol 12-myristate 13 acetate (PMA) (Sigma-Aldrich), 500 
ng/ml ionomycin (Sigma-Aldrich) and Golgistop (BD Biosciences). Restimulated cells 
were stained with Fixable Viability Dye eFluor506 (eBioscience, San Diego, CA, USA) 
following manufacturer’s instructions. For intracellular staining, the cells were fixed with 
2% paraformaldehyde in PBS and permeabilized using 0,5% saponin in FACS buffer 
(PBS with 0,5% BSA and 0,05% NaN3). Monoclonal antibodies against IL-17A, IL-22 
(eBioscience) and IFNγ (BioLegend) were then used for staining in permeabilization buffer. 
Samples were measured on a FACSCantoII Flow Cytometer (BD Biosciences).
ELISA
Concentration of IL-17A, IL-17F, IL-22, IFNγ, GM-CSF, IL-6, IL-8 (all eBioscience), 
MMP1 and MMP3 (both R&D systems) were measured in culture supernatant using 
ELISA following manufacturer’s protocols.
RT-PCR
RNA was isolated with the GenElute Mammalian Total RNA Miniprep Kit (Sigma-
Aldrich), treated with 0.1 U/µl DNAse (Invitrogen) and reverse transcribed into cDNA 
using 10 U/µl Superscript II (Invitrogen) and random hexamer primers. Primers and probes 
were designed and chosen using ProbeFinder Software and the Universal Probe library 
(Roche Applied Science, Indianapolis, IN, USA) and are listed in table S2. Hypoxanthine 
phosphoribosyltransferase (HPRT) was used to normalize gene expression. RT-PCR 
was performed with the Viia7 System and analyzed using QuantStudio Real-Time PCR 
Software version 1.3 (Applied Biosystems, Waltham, MA, USA).
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Statistical analysis
To test differences between two or more groups, Student’s T-test or ANOVA with a 
Bonferroni post-test were used, respectively. Statistical analyses were done using Prism 
software version 6.01 (GraphPad Software, La Jolla, CA, USA).
RESULTS
CCR6+ memTh subpopulations differ in cytokine production, but not in expression 
of RORC, in healthy donors and treatment-naïve RA patients
For studying the role and properties of CCR6+ memTh subpopulations, Th17, Th17.1, 
double positive (DP) and double negative (DN) cells were sorted from healthy PBMC 
based on the chemokine receptors CXCR3 and CCR4 (figure 1A). Directly after sorting, the 
populations differed in their expression of IL-17A, IL-22, IFNγ and GM-CSF. Th17 cells 
were the strongest producers of IL-17A, IL-22 and GM-CSF, whereas Th17.1 and DP cells 
produced the highest levels of IFNγ (figure 1B, upper panel). On the level of transcription 
factors, TBX21 followed the same pattern as IFNγ. Interestingly, RORC was equal in 
all subpopulations despite the differences in IL-17A expression (figure 1B, upper panel).
Since the phenotype stability of the subpopulations is currently unknown, the cells were 
cultured for three days under stimulation of anti-CD3 and anti-CD28 and examined for 
cytokine and transcription factor expression. After three days, the DN cells produced equal 
levels of IL-17A and IL-22 as Th17 cells while they had a lower expression ex vivo (figure 
1B, lower panel). Also Th17.1 and DP cells produced more IL-22. Whereas the expression 
pattern of IFNγ did not change within the subsets, the expression of GM-CSF was highest 
in Th17.1 and DN cells after culture while it was highest in Th17 cells ex vivo. RORC and 
TBX21 showed similar expression profiles in ex vivo and after culture analyses (figure 
1B, lower panel). Similar results were found on the protein level, both in the percentage 
of cytokine-expressing cells (figure 1C) and cytokine levels in the culture supernatant 
(figure 1D). Interestingly, in contrast to the gene expression data, GM-CSF protein levels 
were equal between all subsets.
Although these data provide information on the healthy properties of the subpopulations, 
they do not necessarily represent the same phenotype as the subpopulations in an 
autoimmune disease such as RA where the T cells are abnormally activated. Therefore, 
the Th17, Th17.1, DP and DN cells from treatment-naïve RA patients were also studied. 
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Figure 1. CCR6+ Th memory subpopulations differ in cytokine production, but not in RORC expression. (A) 
Gating strategy for the four subpopulations. (B) Gene expression directly ex vivo (upper panel) or after three 
days of stimulation with anti-CD3 and anti-CD28 (lower panel) is determined using RT-PCR. (C) Representa-
tive flow cytometry plot of IL-17A, IL-22 and IFNγ expression after three days of stimulation from one healthy 
donor. (D) Production of IL-17A, IL-22, IFNγ and GM-CSF after three days of stimulation as measured by 
ELISA. Data represent mean ± SEM of n=3-8 healthy controls of at least 2 independent experiments.
Similar to healthy donors, all four subpopulations were present in the PBMC of RA 
patients, with the majority being Th17 cells (figure 2A). Importantly, the subpopulations 
could also all be distinguished within the synovial fluid mononuclear cells (SFMC) and 
PBMC of established RA patients (figure 2B). Similar to the findings in healthy cells, all 
CCR6+ memTh subpopulations expressed equal levels of RORC, whereas IL-17A was 
predominantly produced by Th17 cells. Also the expression patterns for IFNγ and TBX21 
were similar to the healthy situation, with the highest levels in Th17.1 cells and the lowest 
in Th17 cells. These data demonstrate that although all CCR6+ memTh subpopulations 
express equal levels of RORC, they differ in other parameters such as IL-17A and IFNγ. 
These properties are similar between healthy donors and treatment-naïve early RA patients.
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Figure 2. CCR6+ memTh subpopulations from treatment-naïve RA patients have similar properties as those 
from healthy controls. (A) Percentage of Th17, Th17.1, DP and DN cells in 32 treatment-naïve early RA patients. 
(B) Representative flow cytometric plot of CCR6+ memTh subpopulations in paired PBMC and SFMC from 
an established RA patient. (C) Gene expression after three days of culture upon stimulation of anti-CD3 and 
anti-CD28 as measured by RT-PCR, representing n=4-9 treatment-naïve early RA patients (mean ± SEM). 
All CCR6+ subpopulations can activate RA synovial fibroblasts to create a pro-
inflammatory feedback loop
To determine whether the differences in pro-inflammatory cytokines secreted by the 
individual CCR6+ memTh subpopulations resulted in different pathogenic potential, 
the ability of the subpopulations to activate RASF was investigated. CCR6+ memTh 
subpopulations, but also Th1 cells (CCR6- CXCR3+ CCR4-) as a negative control, were 
sorted from healthy donors as in figure 1A and subsequently co-cultured with RASF for 
three days. When compared to Th1 cells, all CCR6+ subpopulations activated RASF 
as measured by increased IL-6 and IL-8 production (figure 3A). However, there were 
differences in the extent of activation, with Th17 cells being the most potent inducers of 
IL-6 and IL-8. Interestingly, Th17 cells were less potent inducers of MMP1 than Th17.1 
and DP cells, whereas DN cells appear to be the predominant population to induce MMP3 
(figure 3A). The properties of the CCR6+ memTh populations in terms of IL-17A and IFNγ 
expression did not differ in the coculture with RASF compared to the T cell only cultures 
in figure 1D, although the overall levels were slightly elevated due to the interaction with 
RASF.
Similar to the CCR6+ memTh subpopulations from healthy individuals, those from 
treatment-naïve early RA patients also all activated RASF upon coculture as demonstrated 
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by the increased levels of IL-6 and IL-8 (figure 3B). Interestingly, in contrast to the ‘healthy 
cells’, the subpopulations from RA patients did not differ in their capacity to induce IL-6 
and IL-8. Furthermore, where in the healthy situation mainly Th17.1 and DP cells induce 
MMP1, using the cells from RA patients demonstrated a predominance of Th17 cells in the 
induction of MMP1. Th17 cells from RA patients were also more potent in the activation 
of MMP3 than those from healthy individuals. However, similar to healthy individuals, 
the properties of the subsets in terms of IL-17A and IFNγ expression did not drastically 
change upon coculture with RASF (figure 2 and 3B).
Altogether, these data indicate that all CCR6+ memTh subpopulations from both healthy 
individuals and RA patients can activate RASF. However, there are subtle differences 
between the healthy and RA cells in terms of which pro-inflammatory factors they 
predominantly activate in RASF.
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Figure 3. All CCR6+ subpopulation from healthy controls and RA patients activate RASF. Sorted CCR6+ 
subpopulations were sorted from healthy donors (A) or treatment-naïve early RA patients (B) and cultured for 
three days together with RASF upon stimulation with anti-CD3 and anti-CD28. Cytokines were measured in the 
culture supernatant on day 3 using ELISA. Data are shown as mean ±SEM of n=6 healthy controls or n=5 RA pa-
tients and representative of at least 2 independent experiments. *p<0,05, **p<0,01, ***p<0,001, ****p<0,0001.
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All CCR6+ subpopulations use IL-17A to induce IL-6 production by RASF
In order to understand why there are differences in RASF activation between CCR6+ 
memTh subpopulations from healthy individuals and RA patients, it is important to 
know which factors play a role in this pro-inflammatory feedback loop. Previously, we 
have shown that induction of the pro-inflammatory loop by CCR6+ Th memory cells is 
dependent on IL-17A.4 However, not all CCR6+ subpopulations express equal amounts of 
IL-17A. Therefore, we next investigated whether IL-17A was important for RASF activation 
in the individual CCR6+ subpopulations. Given the similar properties of subpopulations 
from healthy donors and RA patients and the limited availability of cells from RA patients, 
these functional studies were conducted with healthy donor T cells and RASF. Upon 
treatment with anti-IL-17A the induction of IL-6 by all subpopulations decreased (figure 
4A). IL-8, MMP1 and MMP3 also appeared to decrease upon IL-17A neutralization, 
although this only reached significance for IL-8 by Th17 and MMP1 by Th17.1 cells. The 
RASF activation by DP cells was hardly affected by IL-17A neutralization, suggesting that 
these cells work via a different mechanism.
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Figure 4. IL-17A plays a role in RASF activation, but not in induction of a pro-inflammatory loop. The CCR6+ 
subpopulations were sorted from healthy controls as in figure 1A and cultured as in figure 2, with the addition 
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One of the features of the pro-inflammatory loop between RASF and CCR6+ memTh is that 
increased activation of the RASF leads to increased activation of the Th cells. Interestingly, 
despite the reduced RASF activation upon IL-17A blockade, the T cell derived cytokines 
IL-17A, IL-22, IFNγ and GM-CSF were not affected by anti-IL-17A treatment (figure 4B). 
Since IL-17A induction by RASF depends on PGE214, this lack of effect could be due to 
irresponsiveness of PGE2 on the anti-IL-17A treatment. However, PGE2 was inhibited by 
anti-IL17A in all subpopulations except Th17.1 cells. From these data we conclude that 
IL-17A blockade reduces RASF activation, but that these RASF are still capable of further 
activating the Th cells. This suggests that a mechanism that does not include PGE2 or IL-6 
is responsible for the Th cell activation in the RASF-Th cell cocultures.
Activation of RASF by CCR6+ subpopulations is independent of IFNγ and T-bet
Since IL-17A was mainly responsible for the induction of IL-6 by RASF, other cytokines 
may also play a role in the pro-inflammatory loop between CCR6+ subpopulations and 
RASF. Therefore, first the role of IFNγ was studied. In contrast to IL-17A blockade, 
neutralizing IFNγ had no effect on the production of IL-6, IL-8, MMP1 and MMP3 (figure 
5A). Even though less IFNγ was detected in the culture supernatant, there was no effect 
on the other T-cell derived cytokines (figure 5B).
Next to IFNγ, also TBX21 showed a distinct pattern of expression between the subsets. 
Therefore, T-bet, the protein encoded by TBX21, was knocked down using lentiviral 
shRNA. Due to the low cell numbers that can be obtained for the individual subpopulations, 
we used the entire CCR6+ Th memory pool for these experiments. In the transduced 
CCR6+ Th memory cells T-bet expression was decreased by 70% (figure 5C). Importantly, 
this repression did not induce EOMES, a transcription factor known to take over the role 
of T-bet (figure 5C). When the T-bet-deficient CCR6+ Th memory cells were cultured 
together with RASF, there was no difference in fibroblast activation as demonstrated by 
IL-6, IL-8, MMP1 and MMP3 expression, despite a reduction in IFNγ and a slight increase 
in IL-17A (figure 5D). Altogether, these data indicate that the activation of RASF and 
induction of the pro-inflammatory loop between RASF and CCR6+ Th memory cells are 
independent of IFNγ and T-bet.
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Figure 5. RASF activation is independent of IFNγ and TBX21. (A and B) CCR6+ subpopulations were cultured 
and analyzed as in figure 4, but with 10μg/ml neutralizing IFNγ antibody or isotype control. (C) Total CCR6+ 
Th memory cells were not transduced (mock) or transduced with a scrambled shRNA (sh-scr) or two different 
TBX21 shRNA (sh1-TBX21 and sh2-TBX21). Stably transduced CCR6+ Th memory cells were cultured for 
three days with RASF under stimulation of anti-CD3 and anti-CD28. Expression of TBX21 and EOMES was 
measured using RT-PCR on day 3. (D) Cytokine expression in culture supernatant from (C) was determined 
after three days using ELISA. Data represent mean ±SEM from n=6 healthy controls, pooled from 2 independent 
experiments. **p<0,01, ***p<0,001, ****p<0,0001. In figures C and D, *, ** and *** represent differences 
compared with scrambled shRNA.
Both RASF activation and the pro-inflammatory loop between CCR6+ 
subpopulations and RASF can be inhibited by 1,25(OH)2D3
Previously, we have shown that blocking IL-22 does not affect the pro-inflammatory loop 
between CCR6+ memTh cells and RASF15, and here we found that IFNγ neutralization 
has no effect, while IL-17A is partially responsible for RASF activation. However, the 
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Figure 6. 1,25(OH)
2
D
3
 can reduce RASF activation and the pro-inflammatory loop. CCR6+ subpopulations 
were cultured with RASF for three days with stimulation from anti-CD3 and anti-CD28 in the presence of 100 
nM 1,25(OH)
2
D
3
. (A-B) Representative flow cytometry plots and quantification of 6 healthy donors displaying 
IL-17A, IL-22 and IFNγ-producing cells after three days of culture. (C-D) Expression levels of cytokines, 
MMPs and PGE2 in culture supernatant on day 3. Data show mean ±SEM from n=6 healthy controls, repre-
sentative of at least 3 independent experiments. **p<0,01, ***p<0,001, ****p<0,0001.
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combined blockade of all pro-inflammatory cytokines may have additional benefits. We 
and others have shown that Th17 cells are highly susceptible to modulation by the active 
vitamin D metabolite 1,25(OH)
2
D
3
16-18, leading to decreased production of IL-17A, IL-22 
and IFNγ. Therefore, this may be a valuable manner to block these cytokines together and 
evaluate the effects on RASF activation.
Since it is unknown whether all CCR6+ memTh subpopulations are susceptible to 
1,25(OH)
2
D
3
-mediated modulation, we first studied its effects in T cell only cultures. In 
line with the known effects in total CCR6+ Th cells, the percentage of cytokine-producing 
cells was decreased in all individual CCR6+ subpopulations in response to 1,25(OH)
2
D
3
 
(figure 6A-B). Since this suggests that all subpopulations were affected by 1,25(OH)
2
D
3
, 
the compound was added to cocultures of RASF and CCR6+ memTh subpopulations. In 
these cultures, 1,25(OH)
2
D
3
 inhibited RASF activation by all CCR6+ subpopulations, as 
demonstrated by a decrease in IL-6, IL-8, PGE2 and MMP1 (figure 6C). 1,25(OH)
2
D
3
 
also decreased the production of IL-17A, IL-22 and IFNγ, but not GM-CSF. Since RASF 
activation was inhibited by 1,25(OH)
2
D
3
, this could indicate that GM-CSF is not important 
for RASF activation (figure 6D). Therefore, we concluded that 1,25(OH)
2
D
3
 inhibits the 
full pro-inflammatory loop in CCR6+ memTh-RASF co-cultures.
DISCUSSION
In this study we demonstrated that Th17, Th17.1, DP and DN CCR6+ memTh cells are all 
capable of activating RASF and establishing a pro-inflammatory loop which may underlie 
chronic synovial inflammation. RASF activation can be suppressed by blocking IL-17A, 
but not IFNγ or T-bet. Both RASF activation and the pro-inflammatory loop are inhibited 
upon treatment with 1,25(OH)
2
D
3
.
Of the four CCR6+ memTh subpopulations that were studied here, most knowledge is 
available on Th17 and Th17.1 cells. Both can be derived directly in vitro through priming 
them using autologous monocytes pulsed with Staphylococcus Aureus or Candida 
Albicans, respectively.19 However, Th17.1 cells can also arise when Th17 cells are stimulated 
with IL-12 and upon exposure to synovial fluid from juvenile idiopathic arthritis (JIA) 
patients.10,20,21 For DP and DN cells, this ontogeny is less clearly defined. Since the current 
study shows that based on cytokine and transcription factor expression DN and DP have 
characteristics in between those of Th17 and Th17.1 cells, it is possible that they represent 
intermediate cell types that are influenced by local inflammatory conditions. To further 
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characterize these differences and determine whether DN and DP are indeed intermediate 
cell types or are distinct from Th17 and Th17.1 cells, full transcriptomic and proteomic 
analysis are required.
In various autoimmune diseases, such as multiple sclerosis, sarcoidosis and Crohn’s 
disease, Th17.1 cells are thought to be especially pathogenic due to their high numbers 
at the site of inflammation, specific recruitment to the brain or drug resistance.11,22,23 
Also in juvenile idiopathic arthritis (JIA) these cells are increased in the synovial fluid 
compared to the peripheral blood.10,21 However, the present study did not imply a particular 
pathogenic role of Th17.1 cells when it comes to RASF activation when using cells from 
either healthy individuals or treatment naïve early RA patients. In contrast, our data suggest 
that all CCR6+ memTh subpopulations can activate RASF. Although there are differences 
between the subpopulations and between healthy individuals and RA patients, since all 
subpopulations are present in the synovial fluid of RA patients they can all contribute to 
synovial inflammation. Therefore, targeting all subpopulations may be more relevant in 
RA treatment than solely focusing on Th17.1 cells.
This study has also explored potential methods to suppress RASF activation and RASF-
CCR6+ interaction. Interestingly, IL-17A blockade only inhibited RASF activation but 
could not prevent the stimulation of the CCR6+ memTh cells by RASF despite reduction 
of PGE2. Overall, these data suggest that IL-17A blockade alone may not be sufficient to 
inhibit the synovial inflammation in RA patients, which is in line with the relatively low 
effects of IL-17A blockade in RA patients.24,25 
Whereas IL-17A blockade at least affected RASF activation, IFNγ neutralization had no 
effect at all on the interaction between RASF and CCR6+ memTh subpopulations, which 
supports the hypothesis that Th17.1 cells are not specifically pathogenic in terms of RASF 
activation. Although the role of GM-CSF was not investigated in the present study, the 
finding that it was not inhibited by 1,25(OH)
2
D
3
 whereas all other inflammatory mediators 
were inhibited suggests that it does not play a role in RASF activation. This does not mean 
that IFNγ and GM-CSF do not play a role in synovial inflammation, because they could 
still for example activate monocytes to perpetuate inflammation.26,27
Since IL-17A, and also TNFα17,  is only partially responsible for the pro-inflammatory 
loop between RASF and CCR6+ memTh populations, there must be another mechanism 
through which RASF activate T cells aside from soluble factors. Th17 cells are known 
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to adhere to collagen via CD49b and thereby stimulate joint damage28,29, suggesting that 
adhesive properties of these cells may be important for their pathogenic functions. Indeed, 
it has been demonstrated that cell-cell contact is also required for the pro-inflammatory 
interaction between RASF and T cells, probably via VCAM-1 and ICAM-1.30 Further 
research should study the importance of adhesion molecules in the pro-inflammatory 
feedback loop and identify which molecules are crucial in the interaction. This could 
provide clues on how to fully suppress RASF activation and the subsequent synovial 
inflammation.
Another therapeutic option would be to utilize the immunomodulatory effects of 
1,25(OH)
2
D
3
. This active vitamin D metabolite has been shown to suppress Th17 
pathogenicity17,18, and here we have shown that all CCR6+ memTh subpopulations are 
susceptible for modulation. Furthermore, 1,25(OH)
2
D
3
 inhibits activation of both RASF and 
CCR6+ memTh subpopulations in coculture. There are several hypotheses that can explain 
the higher efficacy of 1,25(OH)
2
D
3
 compared to blockade of IL-17A, IL-22 or IFNγ. First 
of all, blocking each cytokine separately may result in other cytokines taking over. Since 
1,25(OH)
2
D
3
 blocks all pro-inflammatory cytokines at once, this is no longer possible. 
Another possibility is that 1,25(OH)
2
D
3
 not only affects the pro-inflammatory cytokines, 
but also the cell-cell interaction. For example, it has been shown that 1,25(OH)
2
D
3
 inhibits 
VCAM-1 in endothelial cells and VLA-4 in various cell lines.31,32 Finally, it is also possible 
that 1,25(OH)
2
D
3 
modulates RASF directly.33 However, in our hands the direct effect of 
1,25(OH)
2
D
3
 on RASF is always minimal compared to the effects seen in the RASF-Th 
cocultures (data not shown), suggesting that the main mode of action of 1,25(OH)
2
D
3
 is 
through T cell modulation. Since 1,25(OH)
2
D
3
 is not a clinically applicable therapeutic 
due to severe side effects, the molecular mechanism underlying these changes should be 
investigated to find new therapeutic targets.
Finally, since all CCR6+ memTh express RORC, their pathogenicity may also be reduced 
by inhibiting this transcription factor. In rat models for RA pharmacological inhibition of 
RORC indeed reduced joint inflammation, suggesting it could be effective in the treatment 
of human RA.34 However, therapeutic safety and efficacy still needs to be investigated.
In conclusion, we demonstrated that all CCR6+ memTh subpopulations activate RASF and 
that this is partially dependent on IL-17A, but independent of IFNγ and T-bet. Therefore, 
it is important to further investigate the mechanisms behind RASF-memTh interaction 
and develop new therapies that target this interaction.
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SUPPLEMENTARY MATERIAL
Parameters Treatment-naïve early RA patients (n=10)
Age (years) 47.3 (14.3)
DAS, median (IQR) 3.0 (2.7-3.4)
VAS global 49.2 (28.8)
ESR 20.56 (12.25)
CRP, median (IQR) 6.5 (4.5-9.5)
TJC28 9.5 (6.1)
SJC28 6.6 (3.4)
Duration of complaints (days) 184.8 (86.7)
Table S1. Characteristics of patients used in this study. Data are reported as mean (SD) unless otherwise 
indicated. Abbreviations: DAS, disease activity score; IQR, inter quartile range; VAS, visual analogue scale; 
ESR, erythrocyte sedimentation rate; CRP, c-reactive protein; TJC, tender joint count; SJC, swollen joint count.
Gene Forward primer Reverse primer Probe 
HPRT 5’-TGACCTTGATTTATTTTGCATACC-3’ 5’-CGAGCAAGACGTTCAGTCCT-3’ 73
IL17A 5’-TGGGAAGACCTCATTGGTGT-3’ 5’-GGATTTCGTGGGATTGTGAT-3’ 8
IL22 5’-CAACAGGCTAAGCACATGTCA-3’ 5’-ACTGTGTCCTTCAGCTTTTGC-3’ 6
IFNG 5’-GGCATTTTGAAGAATTGGAAAG-3’ 5’-TTTGGATGCTCTGGTCATCTT-3’ 21
GMCSF 5’-TCTCAGAAATGTTTGACCTCCA-3’ 5’-GCCCTTGAGCTTGGTGAG-3’ 1
RORC 5’-CAGCGCTCCAACATCTTCT-3’ 5’-CCACATCTCCCACATGGACT-3’ 69
TBX21 5’-TGTGGTCCAAGTTTAATCAGCA-3’ 5’-TGACAGGAATGGGAACATCC-3’ 9
EOMES 5’-CTTCTACCCGCTGGAGAGTG-3’ 5’-TGTCTAAGTCCAACTTCTGAGGAGA-3’ 10
Table S2. Primers and probes used for RT-PCR
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ABSTRACT
Autoimmune diseases are characterized by an aberrantly activated immune system, 
resulting in tissue damage and functional disability in patients. An important therapeutic 
goal is to restore the deregulated immunological balance between pro- and anti-
inflammatory T cells. This imbalance is illustrated by elevated levels and activity of 
memory Th17 cell populations, such as Th17, Th1/Th17 and Th17.1 cells, in various 
autoimmune diseases. These cells are characterized by the chemokine receptor CCR6, 
RORC expression and production of IL-17A, IFNγ and TNFα. Using rheumatoid arthritis 
(RA) as a model autoimmune disease, we here demonstrate that pro-inflammatory 
memory CCR6+ Th cells can switch into anti-inflammatory cells with regulatory capacity 
using the active vitamin D metabolite 1,25(OH)
2
D
3
. Memory CCR6+ Th cells, excluding 
Tregs, were sorted from healthy controls or treatment-naïve patients with early rheumatoid 
arthritis (RA) and cultured with or without 1,25(OH)
2
D
3
. Treatment with 1,25(OH)
2
D
3
 
inhibited pro-inflammatory cytokines such as IL-17A, IL-17F, IL-22 and IFNγ in memory 
CCR6+ Th cells from both healthy controls and RA patients. This was accompanied by 
induction of anti-inflammatory factors, including IL-10 and CTLA4. Interestingly, these 
formerly pathogenic cells suppressed proliferation of autologous CD3+ T cells similar to 
classical Tregs. Importantly, the modulated memory cells still migrated towards the site of 
inflammation, modelled by RA synovial fluid, and retained their suppressive capacity in 
this environment. These data show the potential to reset the pathogenic profile of human 
memory Th cells into non-pathogenic cells with regulatory capacity.
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INTRODUCTION
Autoimmune diseases are an increasing health problem in the Western industrialized 
countries.1 Even though treatment has improved in the last decades with the introduction 
of so-called ‘biologicals’, many patients do not respond to or become resistant to treatment. 
Also, we are still not able to cure these disabling diseases.2 In order to achieve better 
treatment of the patients, it is crucial to understand the pathogenesis of autoimmune 
diseases and how the important players in this pathogenesis can be modulated.
Autoimmune diseases are characterized by an aberrant activation of the immune system, 
where the immune reaction is directed against the body itself and the inflammation is 
not appropriately inhibited. T-helper-17 (Th17) cell populations, which include Th17, 
Th1/Th17 and Th17.1 cells, are a group of pro-inflammatory cells which are thought to 
play an important role in the development of various autoimmune diseases.3 They are 
characterized by the transcription factor RORC, produce pro-inflammatory cytokine such 
as IL-17A, IFNγ and TNFα and can be distinguished based on the chemokine receptor 
CCR6. Th17 cells and IL-17-mediated signalling are required for the development of 
experimental autoimmune diseases such as collagen-induced arthritis and experimental 
autoimmune encephalomyelitis.4-6 Furthermore, Th17 cell populations are elevated and 
more active in various autoimmune diseases including RA, systemic lupus erythematosus 
and inflammatory bowel diseases.7-10 
During a normal immune response, pro-inflammatory T cells are balanced by regulatory 
T cells, such as classical regulatory T cells (Tregs), characterized by FOXP3, and type 
1 regulatory (Tr1) cells which do not express FOXP3 but produce high levels of IL-10. 
Treg-depleted mice develop more severe disease in various experimental autoimmune 
models, demonstrating the importance of these cells in limiting inflammation.11,12 
Interestingly, the Th17/Treg ratio is increased in patients with autoimmune diseases, 
suggesting a dysregulated balance between these pro- and anti-inflammatory T cells which 
may underlie the aberrant immune activation in autoimmune diseases.13-15 Therefore, 
normalizing this balance to suppress the autoimmune response is an important therapeutic 
goal in RA.16
It has been shown in mice that IL-17A-producing cells acquire a regulatory phenotype 
similar to Tr1 cells during normal resolution of inflammation, indicating the potential 
of pro-inflammatory cells to switch to a regulatory phenotype.17 In line with these 
findings, we hypothesized that also human IL-17A-producing cells, characterized by 
5
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CCR6 expression, can be turned into anti-inflammatory cells under the right conditions. 
Interestingly, the active vitamin D metabolite inhibits the pro-inflammatory cytokine 
production from these CCR6+ Th memory cells.18 Therefore, we investigated whether 
it is possible to induce a regulatory phenotype in pro-inflammatory IL-17A-producing 
human memory CCR6+ Th cells through exposure to 1,25(OH)
2
D
3
.
MATERIALS AND METHODS
Subjects
Healthy control peripheral blood mononuclear cells (PBMC) were used in most 
experiments and isolated from buffy coats were obtained from Sanquin Blood Bank 
(Rotterdam, the Netherlands). RA PBMC, used for microarray gene expression profiles, 
were isolated from treatment-naïve early RA patients included in the Rotterdam Early 
Arthritis Cohort Study. This study was approved by the medical ethics committee of the 
Erasmus MC Rotterdam. RA synovial fluid was isolated from swollen knee joints of RA 
patients as part of usual care and informed consent was given by all patients. Relevant 
clinical and pharmaceutical patient information shown in table S1. 
Cell sorting 
PBMC were isolated using a Ficoll-gradient and stored in liquid nitrogen until use. Frozen 
PBMC were thawed and stained with monoclonal antibodies against CD45RO, CD4, 
CD127, CCR6 (BD Biosciences, San Diego, CA, USA), CD4, CD3, CCR6 and CD25 
(Biolegend, San Diego, CA, USA) as appropriate in 0,5% BSA + 2mM EDTA in PBS. Dead 
cells were excluded from analysis by 4’6-Diamidino-2-Phenylindole Dilactate (DAPI). 
For sorting CCR6+ Th memory cells and Tregs, PBMC were pre-purified via automated 
magnetic-activated cell sorting (autoMACS; Miltenyi Biotec, Leiden, The Netherlands) 
using CD4 microbeads (Miltenyi Biotec) following manufacturer’s instructions. Target 
cells were sorted on the FACSARIA III flow cytometer (BD Biosciences) (figure S1). 
Cell culture
Memory CCR6+ Th cells, excluding Tregs, (CD4+CD45RO+CCR6+CD25low/int, figure 
S1) were cultured at a density of 1,25-2,5x104 cells/ml in Iscove’s Modified Dulbecco’s 
Medium (IMDM) supplemented with 10% fetal calf serum (FCS; Gibco, Waltham, 
MA, USA), 100 U/ml penicillin/streptomycin, 2 mM L-glutamine (all Lonza, Verviers, 
Belgium), and 50 μM β-mercaptoethanol (Sigma-Aldrich, St. Louis, MO, USA). Cells were 
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stimulated with soluble 0.3 μg/ml αCD3 and 0.4 μg/ml αCD28 (Sanquin, Amsterdam, 
The Netherlands) and cultured with 100 nM 1,25(OH)
2
D
3
 dissolved in 100% ethanol (Leo 
Pharmaceutical Products, Ballerup, Denmark) or with an equal volume of 100% ethanol 
(control treatment). Final ethanol concentration in medium was 0,1%.
Suppression assay
CD3+ cells (CD3+CD25low/intCD127+, figure S1) were sorted as responder cells 
and stained with 20 µM Cell Proliferation Dye eFluor450 following manufacturer’s 
protocol (CPD; eBioscience Inc., San Diego, CA, USA). Autologous Tregs 
(CD4+CD45RO+CD25hiCD127-, figure S1) or cultured memory CCR6+ Th cells (see 
Cell culture) were used as putative suppressors and stained with 5 μM carboxyfluorescein 
succinimidyl ester (CFSE; LifeTechnologies, Eugene, OR, USA) as described by others 
19. In 96-well plates 2,5x104 responder cells were co-cultured with 2,5x104 suppressor 
cells per well, under stimulation of 2,5x104 irradiated autologous PBMC (40 Gy, RS320, 
X-strahl, Surrey, UK) and 10 μg/ml phytohemagglutinin P (PHA-P, Sigma-Aldrich). 
Where indicated, 20% cell-free synovial fluid diluted in culture medium was added. 
Proliferation was measured on the FACSCantoII Flow Cytometer (BD Biosciences, San 
Diego, CA, USA) after 6 days.
Chemotaxis assay
4-5x104 cultured memory CCR6+ Th cells were seeded into the upper chamber of 96-well 
transwell plates with a 3.0 μm pore polycarbonate membrane (Corning, New York, NY, 
USA) in migration medium (T cell culture medium supplemented with 0,5% BSA instead 
of 10% FCS). Migration medium with or without 20% cell-free synovial fluid, 150 ng/
ml CCL2, 1000 ng/ml CCL20 or 150 ng/ml CXCL10 (all R&D Sytems, Minneapolis, 
MN, USA) was added to the lower chamber. Each condition was run in duplicate or 
triplicate. After 3 hours incubation at 37°C and 5% CO
2
, migrated cells were counted 
using CountBright beads (Invitrogen, Waltham, MA, USA) on a FACSCantoII Flow 
Cytometer. The migration index was calculated by the number of cells that migrated in 
response to chemokines or synovial fluid divided by the number of cells that migrated 
to migration medium.
Flow cytometry
For flow cytometry after culture, cells were stained in FACS buffer (0,5% BSA + 0,05% 
NaN3 in PBS) with monoclonal antibodies against CD4, CCR3, CXCR3, CCR2, CXCR4 
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(BioLegend), CCR6 (R&D Systems), CD45RO, CCR6, CCR7 (BD Biosciences) and 
CXCR5 (eBioscience). Samples were measured on a FACSCantoII Flow Cytometer.
Microarray
RNA was isolated from cells using the GenElute Mammalian Total RNA Miniprep Kit 
(Sigma-Aldrich) following manufacturer’s instructions. RNA purity was measured using 
the 2100 Bioanalyzer Instrument (Agilent, Santa Clara, CA, USA). For each sample 150 ng 
total RNA was amplified using the Illumina TotalPrep RNA Amplification Kit (Ambion, 
Invitrogen). 750 ng of amplified RNA was hybridized following the Illumina protocol. 
Gene expression profiles were generated using HumanHT-12 v4 BeadChip human whole-
genome expression arrays, which were scanned using iScan (all Illumina, San Diego, CA, 
USA). Raw data were background subtracted using Illumina GenomeStudio (V2010.1, 
Illumina) and used for further analysis. The probe numbers of genes discussed in this 
paper are listed in table S2.
ELISA
Concentrations of IL-17A, IL-17F, IL-22, IFNγ and IL-10 were measured in culture 
supernatant using Ready-SET-Go! ELISA (eBioscience) according to manufacturer’s 
instructions.
RT-PCR
RNA was isolated using the GenElute Mammalian Total RNA Miniprep Kit (Sigma-
Aldrich) following manufacturer’s instructions. Isolated RNA was treated with 0.1 U/
μl DNAse (Invitrogen) and reverse transcribed into cDNA using 10 U/μl Superscript II 
(Invitrogen) and random hexamer primers. Primers were designed using ProbeFinder 
Software and probes were selected from the Universal Probe Library (Roche Applied 
Science, Indianapolis, IN, USA) (table S3). Real-time PCR was performed using the 
Viia7 system (Applied Biosystems, Waltham, MA, USA) and data were analyzed using 
QuantStudio Real-Time PCR Software version 1.3 (Applied Biosystems). Gene expression 
was normalized against hypoxanthine phosphoribosyltransferase (HPRT).
Statistical analysis
Student’s T-test or ANOVA with a Bonferroni post-test were used to test differences 
between two or more groups, respectively. The analysis was performed using Prism 
software version 6.01 (GraphPad Software, La Jolla, CA, USA).
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RESULTS
1,25(OH)2D3 inhibits the Th17 phenotype while inducing a regulatory gene 
signature in memory CCR6+ Th cells
To study the potential conversion from a pro- to an anti-inflammatory phenotype in 
memory CCR6+ Th cells, we first studied their cytokine expression profiles after in vitro 
1,25(OH)
2
D
3
 treatment. Memory CCR6+ Th cells, specifically excluding Tregs since they 
can also express CCR620, were sorted from healthy controls and cultured with or without 
1,25(OH)
2
D
3
 for three days. In line with previous data18, we found that 1,25(OH)
2
D
3
 
inhibited the pro-inflammatory cytokines IL-17A, IL-22 and IFNγ. Interestingly, the anti-
inflammatory cytokine IL-10 was upregulated (figure 1A). This potential induction of an 
anti-inflammatory phenotype was further studied via gene expression analyses for factors 
important for the Th17 phenotype and pathogenicity (RORC, IL23R), transcription factors 
characterizing Treg or Tr1 cells (FOXP3, ITGA2, CD226, LAG3)21,22, genes required for 
Tr1 development and IL-10 production (PRDM1, AHR, MAF)23-25 and factors important 
for the suppressive function of Tregs and Tr1 cells (CTLA4, PDCD1, IL10RA, IL10RB).26-
28 Although RORC and IL23R were not significantly modulated in the memory CCR6+ 
Th cells from healthy controls, regulatory genes such as FoxP3 and CTLA4 were induced 
in response to 1,25(OH)
2
D
3 
(figure 1B). While MAF showed a trend towards induction 
by 1,25(OH)
2
D
3
, it was only expressed in two out of seven donors (data not shown). Of 
the other investigated genes only IL10RB, PRDM1 and AHR were not modulated by 
1,25(OH)
2
D
3
, whereas PDCD1, encoding for the inhibitory co-receptor PD1, was inhibited 
(figure 1B).
These data show that 1,25(OH)
2
D
3
 induces an anti-inflammatory signature in CCR6+ cells 
from healthy controls, but this effect may not be similar in the more activated cells from 
patients with an autoimmune disease such as rheumatoid arthritis (RA).8,29 Therefore, 
memory CCR6+ Th cells from treatment-naïve early RA patients were treated with or 
without 1,25(OH)
2
D
3
 and used to generate microarray-based gene expression profiles. 
Similar to our findings in healthy cells, 1,25(OH)
2
D
3
 inhibited pro-inflammatory genes 
in the memory CCR6+ Th cells from RA patients, except that in RA cells also RORC 
and IL23R are inhibited (figure 1C, normal font). Interestingly, also in the RA cells the 
anti-inflammatory genes were upregulated, again with the exception of PDCD1 (figure 1C, 
bold font). Altogether, these data suggest that 1,25(OH)
2
D
3
 inhibits the pro-inflammatory 
phenotype of pathogenic memory CCR6+ Th cells, while inducing an anti-inflammatory 
phenotype in these cells.
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Figure 1. 1,25(OH)
2
D
3
 treatment reduces pro-inflammatory gene expression in memory CCR6+ Th cells, while 
inducing an anti-inflammatory expression profile. Memory CCR6+ Th cells were sorted from healthy controls 
(A, B) or treatment-naïve early RA patients (C) and cultured for three days with or without 1,25(OH)
2
D
3
. 
Cytokine expression was measured using ELISA (A) and gene expression via RT-PCR (B) or microarray-
based gene-expression profiles (C). In figure C, fold change is calculated by dividing the expression level 
after 1,25(OH)
2
D
3
 treatment by the level after control treatment. Pro-inflammatory genes are in normal font, 
anti-inflammatory genes in bold font. FOXP3 and IL-17A were investigated but could not be detected by the 
probes on the microarray. Numbers behind genes indicate different probes that were used to measure gene 
expression. Mean and SEM are given for 3 patients (C) or 7-8 healthy controls pooled from 2 independent 
experiments (figures A and B). *p<0.05, **p<0.01.
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1,25(OH)2D3-treated memory CCR6+ Th cells suppress proliferation of CD3+ 
T cells
The induction of genes such as IL-10 and CTLA4, which are required for the suppressive 
function of regulatory T cells, suggests that 1,25(OH)
2
D
3
-treated memory CCR6+ Th cells 
could also have suppressive properties. Therefore, their capacity to suppress proliferation 
of autologous CD3+ T cells (excluding Tregs) was compared with the suppressive potential 
of classical Tregs. In these suppression assays, control-treated memory CCR6+ Th cells 
already slightly suppressed proliferation of CD3+ T cells (figure 2), a phenomenon 
that has been described before when untreated cultured T cells are used as suppressor 
cells.30 Importantly, 1,25(OH)
2
D
3
-treated memory CCR6+ Th cells were equally potent 
suppressors of CD3+ T cell proliferation as Tregs (figure 2). This was similar for the CD4+ 
cells and the CD4- cells within the CD3+ T cells, demonstrating that both Th cells and 
cytotoxic T cells, which are the main CD3+CD4- population, can be suppressed by treated 
CCR6+ T helper memory cells (figure S2). These data show that the pro-inflammatory 
memory CCR6+ Th cells acquire regulatory properties upon treatment with 1,25(OH)
2
D
3
.
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Figure 2. Memory CCR6+ Th cells acquire regulatory capacities after treatment with 1,25(OH)
2
D
3
. Memory 
CCR6+ Th cells (without regulatory T cells) were sorted from healthy controls and cultured for three days 
with or without 1,25(OH)
2
D
3
. Then they were co-cultured for 6 days with CPD-stained CD3+ T cells to assess 
their suppressive potential. Target cell proliferation was assessed using flow cytometry, and sorted Treg cells 
were used as a positive control for suppression of proliferation. (A) Representative plot of proliferation data. 
(B) Pooled proliferation data for 3 healthy donors. No suppr; no suppressors. Control-CCR6+; control-treated 
memory CCR6+ Th cells. 1,25-CCR6+; 1,25(OH)
2
D
3
-treated memory CCR6+ Th cells. Mean and SEM are 
given and are representative of 4 independent experiments. **p<0.01, ***p<0.001, ****p<0.0001.
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1,25(OH)2D3-treated memory CCR6+ Th cells still migrate towards the site of 
inflammation
We next asked whether the 1,25(OH)
2
D
3
-treated memory CCR6+ Th cells could contribute 
to the suppression of synovial inflammation, for which the cells need to be able to migrate 
towards inflammation. Therefore, the effect of 1,25(OH)
2
D
3
 on the chemokine receptors 
expressed in treatment-naïve early RA patients was first investigated using the microarray-
based gene expression profiles. The 1,25(OH)
2
D
3
-exposed memory CCR6+ Th cells 
showed a shift in the chemokine receptor profile, where some receptors are upregulated 
while others are downregulated (figure 3A). Importantly, the signature chemokine receptor 
CCR6 is inhibited by 1,25(OH)
2
D
3
, while other receptors such as CXCR3 and CCR2 are 
upregulated. These data were verified on protein level using healthy memory CCR6+ Th 
cells, where 1,25(OH)
2
D
3
 similarly modulates the expression of all chemokine receptors 
except CCR4 (figures 3B and S3). To investigate what these changes mean for the actual 
migration of memory CCR6+ Th cells, both untreated and 1,25(OH)
2
D
3
-treated memory 
CCR6+ Th cells were tested for their migration towards towards CCL20, CXCL10 and 
CCL2. These chemokines were selected because they are the ligands for CCR6, CXCR3 
and CCR2, respectively, which were the most up- or downregulated chemokine receptors 
in both healthy and RA cells. In a transwell chemotaxis assay, migration of memory 
CCR6+ Th cells towards CCL20, the ligand for CCR6, was significantly decreased after 
treatment with 1,25(OH)
2
D
3
 (figure 4A). On the other hand, there was no difference in 
the migratory capacity of the cells towards ligands for CXCR3 and CCR2, CXCL10 and 
CCL2 respectively (figure 4A). Since single chemokines may not accurately represent 
the site of inflammation, the migratory potential towards synovial fluid obtained from 
RA patients was assessed as an example of an inflammatory environment. 20% synovial 
fluid from these patients, all with a high disease activity (table S1), induced migration 
of both control-treated and 1,25(OH)
2
D
3
-treated cells, although the latter migrated less 
efficiently in two out of three patients (figure 4B). This indicates 1,25(OH)
2
D
3
-treated 
memory CCR6+ Th cells can still migrate towards synovial fluid, although their migratory 
capacities may be slightly altered.
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Figure 3. The chemokine receptor profile in memory CCR6+ Th shifts upon treatment with 1,25(OH)
2
D
3
. 
(A) Memory CCR6+ Th cells were sorted from treatment-naïve early RA patients and cultured for three 
days with or without 1,25(OH)
2
D
3
. RNA was isolated and used for microarray analysis. Log2 of fold change 
induced by 1,25(OH)
2
D
3
 treatment is shown for all chemokine receptors that were detected in the microarray 
data. (B) Changes in the chemokine receptor profile were verified using flow cytometry on memory CCR6+ 
Th cells sorted from healthy controls which were cultured for three days with or without 1,25(OH)
2
D
3
. Mean 
and SEM are given for 3 patients (figure A) or 5 healthy controls (figure B). MFI; mean fluorescent intensity. 
*p<0.05, **p<0.01, ***p<0.001.
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Figure 4. 1,25(OH)
2
D
3
-treated memory CCR6+ Th cells still migrate towards an inflammatory environment. 
Memory CCR6+ Th cells were sorted from healthy controls and cultured for three days with or without 
1,25(OH)
2
D
3
. Their migratory capacity towards CCL20, CXCL10, CCL2 (A) or 20% synovial fluid from RA 
patients (B) was assessed using a 3-μm pore transwell system. Mean and SEM are shown for 5 healthy controls 
from 2 independent experiments. *p<0.05, ***p<0.001.
1,25(OH)2D3-treated memory CCR6+ Th cells retain their suppressive capacity in 
synovial fluid 
Although memory CCR6+ Th cells acquire a functional regulatory phenotype and migrate 
towards sites of inflammation upon exposure, they can only contribute to inhibiting 
synovial inflammation if the local pro-inflammatory conditions do not reverse the 
1,25(OH)
2
D
3
-induced changes. Therefore, the suppressive capacity of 1,25(OH)
2
D
3
-
modulated memory CCR6+ Th cells was assessed in the presence of 20% RA synovial 
fluid using a similar assay as for figure 2. Although T cell proliferation was lower in 
synovial fluid than in medium (see also figure 2), 1,25(OH)
2
D
3
-treated memory CCR6+ 
Th cells still suppressed T cell proliferation similar to Tregs under these inflammatory 
conditions (figure 5). 
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Figure 5. The suppressive capacity of 1,25(OH)
2
D
3
-treated memory CCR6+ Th cells is retained in the pres-
ence of RA synovial fluid. Memory CCR6+ Th cells were sorted from healthy controls and cultured for three 
days with or without 1,25(OH)
2
D
3
. They were then used in the same suppression assay as for figure 3, but in 
the presence of 20% synovial fluid. Proliferation for CD3+ T cells of six healthy donors (each depicted by 
its own symbol) is shown with or without suppressor cells, in the presence of three different synovial fluid 
samples (upper panel). Overall proliferation in synovial fluid is calculated from the average proliferation of 
T cells from each healthy donor in three different synovial fluids (lower panel). No suppr; no suppressors. 
Ctr-CCR6+; control-treated memory CCR6+ Th cells. 1,25-CCR6+; 1,25(OH)
2
D
3
-treated memory CCR6+ Th 
cells. Mean and SEM are shown for 6 healthy controls from 2 independent experiments. **p<0.01, ***p<0.001.
DISCUSSION
In this study, we demonstrated that human pro-inflammatory IL-17A-producing memory 
CCR6+ Th cells acquire an anti-inflammatory gene expression profile and regulatory 
properties upon exposure to 1,25(OH)
2
D
3
. Importantly, these modulated cells can still 
migrate towards synovial fluid and maintain their suppressive capacity in this pro-
inflammatory environment. 
The 1,25(OH)
2
D
3
-mediated inhibition of the pro-inflammatory gene signature in memory 
CCR6+ Th cells is accompanied by induction of an anti-inflammatory gene signature in 
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both healthy controls and treatment-naïve early RA patients. An exception to this pattern 
was the inhibition of the suppressive co-receptor PD-1 by 1,25(OH)
2
D
3
. Although not 
much research has been performed into the role of PD-1 in RA, one case report suggests 
that PD-1 may be less important in suppressing the autoimmune response than CTLA4. In 
this case, an RA patient suffering from metastatic melanoma experienced RA flares when 
treated with anti-CTLA4, but not when treated with anti-PD-1 31. Therefore, the inhibition 
of PD-1 by 1,25(OH)
2
D
3
 may also not be important for the regulatory characteristics of 
modulated CCR6+ Th cells. 
Although the pattern of gene modulation by 1,25(OH)
2
D
3
 was largely similar between 
healthy controls and RA patients, there were a few notable exceptions. Firstly, RORC and 
IL23R were inhibited by 1,25(OH)
2
D
3
 in the cells from RA patients, but not from healthy 
controls. Also, MAF was expressed in cells from treatment-naïve early RA patients, but 
was hardly detectable in healthy control cells. These differences could be due to the higher 
activation state of the memory CCR6+ Th cells from RA patients.8,29 Furthermore, since 
vitamin D is considered to be immunomodulatory rather than immunosuppressive32, its 
effects on highly activated RA cells may be stronger than on healthy cells. The exact 
mechanism underlying the difference in modulation between healthy cells and cells from 
RA and other autoimmune diseases is of great interest for future research and could 
provide insight into disease-specific pathogenesis.
In line with the expression of anti-inflammatory genes, 1,25(OH)
2
D
3
-treated memory 
CCR6+ Th cells suppress proliferation of autologous T cells. This data corresponds with 
the murine immune system, where IL-17A-producing cells acquire Tr1-like properties 
during resolution of inflammation.17 In human cells, an analogue of 1,25(OH)
2
D
3
 induces a 
regulatory phenotype in the total CD4+ population (Tregs excluded).33 Also, 1,25(OH)
2
D
3
 
in combination with IL-2 can promote this phenotypical change.30 However, both studies 
still include naïve T cells, in which IL-10 production is also induced upon 1,25(OH)
2
D
3
 
treatment.34 Our study is the first to demonstrate that regulatory properties can be induced 
in a population of highly purified human pro-inflammatory memory Th cells. 
For the conversion from a pro-inflammatory IL-17A-producing memory CCR6+ Th cell 
to a regulating cell to be functional in suppressing autoimmune diseases, the cells should 
migrate towards the site of inflammation. 1,25(OH)
2
D
3
 treatment modulates the chemokine 
receptor profile of memory CCR6+ Th cells, which alters their migration towards CCL20 
but not CXCL10 and CCL2. This is in line with previous studies, which reported altered T 
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cell migration towards various chemokines after 1,25(OH)
2
D
3
 treatment.33,35 The migration 
capacity of 1,25(OH)
2
D
3
-treated memory CCR6+ Th cells towards RA synovial fluid was 
unaffected or partially reduced, in a patient-dependent manner. The differences between 
patients observed in our study could be treatment-related, since for example CCL2 is 
inhibited by TNFα treatment36,37, and CXCL9 and CXCL10 decrease during treatment 
response.38 Furthermore, the synovial fluid and memory CCR6+ Th cells were isolated 
from allogeneic donors, which may play a role in our chemotaxis assays. However, since 
the modulated memory CCR6+ Th cells still migrated faster towards synovial fluid than 
to medium alone, we concluded they still migrate towards the site of inflammation.
The modulated cells cannot only migrate to RA synovial fluid, they also still suppress 
autologous T cell proliferation in this environment. Notably, the baseline proliferation 
of T cells was already inhibited in the presence of synovial fluid. This might be due to 
the viscosity of the synovial fluid, which complicates the cell-cell interaction that is 
required for stimulation by irradiated PBMC. Inhibition of T cell proliferation has been 
shown before, but only when more than 50% of the medium consisted of synovial fluid 
and under stimulation that is not dependent on cell-cell interaction.39 Nonetheless, the 
novel finding in this study that 1,25(OH)
2
D
3
-treated memory CCR6+ Th cells retain their 
suppressive capacity in synovial fluid suggests that these cells may have therapeutic value 
in autoimmune diseases such as RA. 
It is tempting to consider transfer of autologous 1,25(OH)
2
D
3
-treated memory CCR6+ 
Th cells to promote tolerance, similar to the 1,25(OH)
2
D
3
-treated dendritic cells that are 
currently under clinical investigation.40 This could be beneficial not only for RA, but 
also other Th17-driven autoimmune diseases. For such a treatment to be effective, the 
cells require a stable anti-inflammatory phenotype and migratory capacity towards the 
site of inflammation. Importantly, the finding that modulated memory CCR6+ Th cells 
suppress T cell proliferation not only upon restimulation with irradiated PBMC and PHA, 
an inevitable consequence of the experimental setup, but also in the presence of synovial 
fluid, indicates that the anti-inflammatory phenotype might be stable. On the other hand, 
RORC is still expressed in 1,25(OH)
2
D
3
-treated memory CCR6+ Th cells in both healthy 
controls and RA patients, suggesting that the cells did not completely transdifferentiate 
into a classical Treg. Therefore, the extent of the phenotype stability after 1,25(OH)
2
D
3
 
exposure is of great clinical interest for various autoimmune diseases. Both migration 
capacity and therapeutic efficacy of 1,25(OH)
2
D
3
-treated memory CCR6+ Th cells should 
be further determined using transfer experiments in autoimmune models.
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Another important direction for future research is the molecular mechanism underlying the 
shift in phenotype upon exposure to 1,25(OH)
2
D
3
. Since direct supplementation of active 
1,25(OH)
2
D
3
 is not possible due to the possibility of severe side effects, understanding the 
mechanism may provide us with new therapeutic targets. As a first step to understanding 
the mechanism, the various subpopulations within the memory CCR6+ Th cells should be 
investigated. memory CCR6+ Th cells are a heterogeneous mixture of pro-inflammatory 
cells, such as Th17, Th1/Th17 and Th17.1 cells, but also unclassified cells that do not seem 
to belong to either of these populations. All CCR6+ subpopulations express RORC and 
varying levels of IL-17A, but they differ in chemokine receptor expression, production 
of other cytokines such as IFNγ and GM-CSF and transcription factor expression (e.g. 
Tbx21).41 It is of great interest to investigate which of these subpopulations is more prone 
to switch to an anti-inflammatory cell with regulatory capacity, so certain cell types can 
be more specifically targeted.
In this study it was demonstrated that committed pro-inflammatory IL-17A-producing 
memory CCR6+ Th cells acquire regulatory properties upon treatment with 1,25(OH)
2
D
3
. 
This process could normalize the balance between pro- and anti-inflammatory mediators 
in autoimmune diseases. These data provide a basis to further explore the mechanisms to 
reset the pathogenic profile of memory T cells during autoimmune inflammatory diseases. 
This may lead to new developments to activate resolution of inflammation in RA and 
other autoimmune diseases.
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Figure S1. Typical sorting strategy from frozen PBMC. (A) Backbone gating, with lymphocyte selection, 
doublet exclusion and dead cell exclusion. (B) Proceeding from (A), to sort CCR6+ Th memory cells. Examples 
are given before sort (top panels) and after sort (bottom panels) to check for purity and exclusion of Tregs. (C) 
Proceeding from (A) to sort Tregs. (D) Proceeding from (A) to sort responder cells for suppression assays; 
CD3+ T cells excluding Tregs.
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Figure S2. 1,25(OH)
2
D
3
-treated CCR6+ Th memory cells equally suppress proliferation in CD4+ and CD4- 
cells. Suppression assay is set-up as in figure 2, but during analysis of proliferation, responder cells are dis-
tinguished based on CD4 expression. Mean and SEM represent 3 healthy donors. Data are representative of 4 
independent experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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Figure S3. 1,25(OH)
2
D
3
-treated CCR6+ Th memory cell express a different chemokine receptor profile com-
pared to untreated cells. Cells were sorted and cultured as in figure 3. Chemokine receptor expression was quan-
tified using flow cytometry. Mean and SEM are given for 6 healthy donors. *p<0.05, **p<0.01, ***p<0.001.
Parameters Treatment-naïve early RA 
patients (PBMC)
Mean ± SEM (n=3)
Established RA patients (synovial 
fluid)
Mean ± SEM (n=6)
Age 42.06 ± 8.00 58.17 ± 2.14
DAS28 2.59 ± 0.15 4.57 ± 0.29
VAS 42.33 ± 5.89 81.50 ± 8.32
ESR 30.00 ± 2.62 26.40 ± 8.57
CRP 12.33 ± 8.03 19.00 ± 2.87
TJC28 2.33 ± 0.72 3.33 ± 0.51
SJC28 3.67 ± 0.98 1.83 ± 0.44
Disease duration (days) 99.00 ± 28.58 N/A
Medication None Methotrexate (5/6)
Vitamin D (800 IU/day, 4/6)
Tocilizumab (1/6)
Adalimumab (2/6)
Conventional DMARDs (1/6)
Table S1. Characteristics of patients used in this study. PBMC of treatment-naïve early RA patients were 
used for microarray gene expression profiles
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Gene Probe ID Gene Probe ID
AHR (1) ILMN_1812640 CXCR5 ILMN_2337928
AHR (2) ILMN_2162799 CXCR6 ILMN_1674640
CCR1 ILMN_1678833 CXCR7 (1) ILMN_1798360
CCR10 ILMN_1666493 CXCR7 (2) ILMN_2371458
CCR2 (1) ILMN_1774761 FOXP3 ILMN_1768049
CCR2 (2) ILMN_2276996 IFNG ILMN_2207291
CCR2 (3) ILMN_1777461 IL10 ILMN_2073307
CCR2 (4) ILMN_1669062 IL10RA ILMN_1652825
CCR2 (5) ILMN_1769895 IL10RB (1) ILMN_1767360
CCR4 ILMN_2086143 IL10RB (2) ILMN_2230892
CCR6 (1) ILMN_1690907 IL17A ILMN_1774983
CCR6 (1) ILMN_2387696 IL17F ILMN_2188247
CCR6 (2) ILMN_2387696 IL22 (1) ILMN_1735208
CCR6 (2) ILMN_1690907 IL22 (2) ILMN_2100046
CCR7 ILMN_1715131 IL23R (1) ILMN_1734937
CCR8 ILMN_1739421 IL23R (2) ILMN_2223663
CCR9 ILMN_1664316 IL26 ILMN_2123182
CCRL1 ILMN_1773992 ITGA2 ILMN_1665792
CCRL2 ILMN_3190833 LAG3 ILMN_1813338
CD226 ILMN_1687825 MAF (1) ILMN_1722206
CSF2 ILMN_1661861 MAF (2) ILMN_1719543
CTLA4 (1) ILMN_2261627 PDCD1 ILMN_1806725
CTLA4 (2) ILMN_2348905 PRDM1 (1) ILMN_2414165
CTLA4 (3) ILMN_1763487 PRDM1 (2) ILMN_2298159
CXCR3 ILMN_1797975 PRDM1 (3) ILMN_1655077
CXCR4 (1) ILMN_2320888 RORC (1) ILMN_1734366
CXCR4 (2) ILMN_2246410 RORC (2) ILMN_1771126
CXCR4 (3) ILMN_1801584 XCR1 ILMN_1764034
Table S2. Illumina probe ID and the corresponding gene code as used in this report.
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Gene Forward primer Reverse primer Probe
HPRT 5’-TGACCTTGATTTATTTTG-
CATACC-3’
5’-CGAGCAAGACGTTCAGTCCT-3’ 73
FOXP3 5’-ACCTACGCCACGCTCATC-3’ 5’-TCATTAAGTGTCCGCTGCT-3’ 50
CTLA4 5’-TCACAGCTGTTTCTTTGAG-
CA-3’
5’-AGGCTGAAATTGCTTTTCACA-3’ 21
CD49B 5’-TCGTGCACAGTTTTGAA-
GATG-3’
5’-TGGAACACTTCCTGTTGTTACC-3’ 7
LAG3 5’-CAAGAACGCTTTGTGTGGAG-3’ 5’-CCAGCCAAGGTCCTGAGA-3’ 82
IL10RA 5’-CCGAAAGAAGC-
TACCCAGTG-3’
5’-GGACGCTGGCTGATGAAG-3’ 23
IL10RB 5’-GGTCGTGTGCTTGGAGGA-3’ 5’-GGTACCATTCCCAATGCTGA-3’ 20
CD226 5’-CGTGATGAGATTGACTG-
TAGCC-3’
5’-AACAAACAACAACAATAAAACT-
GTCC-3’
5
PRDM1 5’-ACGTGTGGGTACGACCTTG-3’ 5’-CTGCCAATCCCTGAAACCT-3’ 67
PDCD1 5’-AGAAGGCGGCACTCTGGT-3’ 5’-GGCCTGTCTGGGGAGTCTA-3’ 32
AHR 5’-AGCCGGTGCAGAAAACAGT-3’ 5’-CTATGCCGCTTGGAAGGAT-3’ 33
RORC 5’-CAGCGCTCCAACATCTTCT-3’ 5’-CCACATCTCCCACATGGACT-3’ 69
IL23R 5’-CCTGGCTCTGAAGTGGAAT-
TA-3’
5’-GGCTATTACTGCATCCCATTG-3’ 38
Table S3. Primers and probes used for RT-PCR
5
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ABSTRACT
Background
IL-17A-producing memory T-helper (memTh) cells expressing the chemokine receptor CCR6 
are thought to be pathogenic in autoimmune diseases such as rheumatoid arthritis (RA) 
and multiple sclerosis. Interestingly, the active vitamin D metabolite 1,25(OH)
2
D
3
 inhibits 
CCR6+ memTh cell pathogenicity and induces an anti-inflammatory phenotype with 
regulatory capacity. Since this regulatory capacity was retained in an inflammatory 
environment, we here investigated the stability of 1,25(OH)
2
D
3
-mediated suppression of 
pro-inflammatory cytokines in CCR6+ memTh cells.
Methods
CCR6+ memTh cells were sorted from healthy controls and cultured with or without 
1,25(OH)
2
D
3
 for three days. After that, cells were restimulated under various conditions 
while 1,25(OH)
2
D
3
 treatment was continued or stopped. The histone deacetylase inhibitor 
valproic acid (VPA) was used to study the role of histone acetylation in the effects of 
1,25(OH)
2
D
3
. Cytokine production was assessed on day 6 using flow cytometry and ELISA. 
Results
1,25(OH)
2
D
3
 reduces production of the pro-inflammatory cytokines IL-17A, IL-22 and 
IFNγ in CCR6+ memTh cells and thereby their capacity to activate RA synovial fibroblasts. 
The reduction in IL-17A, IL-22 and IFNγ upon 1,25(OH)
2
D
3
 exposure was sustained upon 
removal of the compound, independent of TCR restimulation or presence of RA synovial 
fluid or the Th17 polarizing cytokines IL-23 and IL-1β. Finally, IL-17A, IL-22 and IFNγ 
were not reduced when CCR6+ memTh were exposed to VPA together with 1,25(OH)
2
D
3
. 
Conclusion
1,25(OH)
2
D
3
 induces a long-term suppression of pro-inflammatory cytokines in CCR6+ 
memTh cells, possibly through recruitment of histone deacetylases. This provides a 
potential basis for future therapeutic strategies in autoimmune diseases such as RA.
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INTRODUCTION
Vitamin D is a secosteroid hor mone which is synthesized in the skin in response to UV-
light and is then metabolized in the liver and kidneys to the active metabolite 1,25(OH)
2
D
3
. 
Aside from its well-known role in calcium homeostasis, vitamin D also has a broad 
immunomodulatory capacity.1 This insight has fueled a vast amount of research into the 
effects of vitamin D in autoimmune diseases such as rheumatoid arthritis (RA), multiple 
sclerosis (MS) and type 1 diabetes (T1D). In most of these diseases there is a correlation 
between the serum vitamin D levels and disease severity and/or incidence.2 Furthermore, 
supplementation of high doses 1,25(OH)
2
D
3
 can prevent or reduce experimental 
autoimmune diseases such as collagen-induced arthritis (CIA) and experimental 
autoimmune encephalomyelitis (EAE), modeling RA and MS, respectively.3-5 However, 
therapeutic application of high doses 1,25(OH)
2
D
3
 is limited in clinical practice due to the 
risk of hypercalcemia. Instead, the immunomodulatory potential of 1,25(OH)
2
D
3 
could be 
exploited by understanding and targeting the underlying mechanisms. 
Considering that autoimmune diseases are mediated by an aberrantly activated immune 
system and that virtually all immune cells express the vitamin D receptor (VDR), it is 
likely that many of the effects of 1,25(OH)
2
D
3
 in autoimmune diseases result from immune 
cell modulation.2 Since the VDR is required in total T cells, but not CD8+ T cells for the 
suppression of EAE, it is thought that CD4+ T-helper (Th) cells are important targets for 
1,25(OH)
2
D
3
 in the suppression of autoimmunity.6,7
Th cells can be divided into several subsets, such as Th1, Th2 and Th17 cells. Classically 
Th1 cells were thought to be the important subset in autoimmune pathogenesis. However, 
Th17 cells have become the center of attention when it was shown that IL-23, required for 
development of pathogenic Th17 cells, is indispensable for experimental autoimmunity.8,9 
Th17 cells are characterized by IL-17A production and expression of the transcription factor 
RORC. In peripheral blood, IL-17A+ RORC+ Th memory cells can be distinguished based 
on the chemokine receptor CCR6.10 CCR6+ memory Th (memTh) cells also produce other 
pro-inflammatory cytokines, such as IL-17F, IL-22, TNFα and IFNγ and are elevated in 
the blood and synovial fluid of treatment-naïve RA patients.11,12 
Interestingly, we have previously shown that 1,25(OH)
2
D
3
 decreases the pathogenicity of 
these cells and can even induce a functional regulatory phenotype that is maintained in the 
presence of synovial fluid from RA patients (chapter 5 of this thesis). This suggests that 
1,25(OH)
2
D
3
 could stably modulate CCR6+ memTh cells and thereby provides interesting 
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therapeutic opportunities to explore. However, currently there is insufficient knowledge on 
the stability of the suppressive effects of 1,25(OH)
2
D
3
 on the pro-inflammatory cytokines. 
Therefore, we here investigated whether the inhibition of IL-17A, IL-22 and IFNγ by 
1,25(OH)
2
D
3
 is stable and which mechanisms are responsible for this stability. 
MATERIALS AND METHODS
Subjects
Peripheral blood mononuclear cells (PBMC) were isolated from buffycoats (Sanquin 
Blood Bank, Rotterdam, the Netherlands). Synovial fluid was obtained from RA patients 
who presented at the rheumatology clinic with a swollen knee. Synovial fibroblasts from 
RA patients (RASF) were isolated from synovial explants after joint replacement surgery. 
Informed consent was obtained from all participating individuals. Relevant clinical and 
pharmaceutical information is shown in table S1.
Cell sorting
CCR6+ memTh cells (CD4+ CD45RO+ CCR6+ CD25low/int) were sorted from PBMC by 
first pre-purifying the cells using CD4 microbeads and magnetic activated cell sorting 
(MACS, Miltenyi Biotec, Bergisch Gladbach, Germany), followed by fluorescent activated 
cell sorting to get the purified population. Cells were stained using monoclonal antibodies 
against CD4, CCR6, CD25 (BioLegend, San Diego, USA) and CD45RO (BD Biosciences, 
San Diego, USA). Dead cells were excluded by 4’6’-diamidino-2-phenylindole dilactate 
(DAPI). Cells were sorted on a FACSARIA III cell sorter (BD Biosciences).
Cell culture
Sorted CCR6+ memTh cells were cultured in Iscove’s Modified Dulbecco’s Medium 
(IMDM), supplemented with 10% fetal calf serum (FCS; Gibco, Waltham, USA), 100 U/
ml penicillin/streptomycin, 2 mM L-glutamine (Lonza, Verviers, Belgium) and 50 µM 
β-mercaptoethanol (Sigma-Aldrich, St. Louis, USA) at a starting density of 1,25x105 cells/
ml. RASF were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% FCS and 100 U/ml penicillin/streptomycin.
For withdrawal experiments, sorted CCR6+ memTh cells were stimulated with 300 
ng/ml soluble anti-CD3 and 400 ng/ml soluble anti-CD28 (Sanquin, Amsterdam, the 
Netherlands) for three days with 100 nM 1,25(OH)
2
D
3
 (Leo Pharmaceutical Products, 
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Ballerup, Denmark) dissolved in 100% ethanol or an equal volume of 100% ethanol 
(control). The final concentration of ethanol in the culture was 0,1%. After three days, 
the cultured cells were washed with PBS and restimulated for another three days with 5 
ng/ml IL-2 (R&D systems, Minneapolis, USA), with or without 10 ng/ml IL-23, 10 ng/
ml IL-1β or 20% RA synovial fluid. Alternatively, cells were restimulated with 300 ng/
ml soluble anti-CD3 and 400 ng/ml soluble anti-CD28 or 75 ng/ml anti-CD3 and 100 ng/
ml anti-CD28 (1/4 anti-CD3 + ¼ anti-CD28 condition) instead of IL-2. Where indicated, 
the cultured cells were placed on 1x104 RASF, which were seeded 24 hours prior, during 
this three-day restimulation period. 
For experiments with histone deacetylase inhibitors, sorted cells were first stimulated 
with 300 ng/ml soluble anti-CD3 and 400 ng/ml soluble anti-CD28 for 24 hours. Then 
100 nM 1,25(OH)
2
D
3
 or 100% ethanol was added, together with indicated concentrations 
of valproic acid (VPA) or trichostatin A (TsA). DMSO was used as a vehicle control for 
TsA. After 24 hours, the cells were washed with PBS and restimulated with 300 ng/ml 
soluble anti-CD3 and 400 ng/ml soluble anti-CD28 with or without 100 nM 1,25(OH)
2
D
3
 
for three days.
Intracellular flow cytometry
Cultured cells were stimulated with 50 ng/ml phorbol 12-myristate 13 acetate (PMA) 
and ionomycin (Sigma-Aldrich) in the presence of GolgiStop (BD Biosciences) and 
stained with Fixable Viability Dye eFluor506 (eBioscience, San Diego, CA, USA). 
Subsequently, cells were fixated and permeabilized with 2% paraformaldehyde and 
0.5% saponin, respectively, before staining with monoclonal antibodies against IL-17A, 
IL-22 (eBioscience) and IFNγ (BioLegend). Flow cytometry was performed using a 
FACSCantoII flow cytometer (BD Biosciences). Data was analysed using FlowJo v7.6.5 
(Flowjo LLC, Ashland, OR, USA).
ELISA
Concentration of IL-17A, IL-22, IFNγ, IL-6 and IL-8 in culture supernatant was measured 
using the Ready-Set-Go! ELISA (eBioscience). MMP1 and MMP3 concentration was 
measured using the DuoSet ELISA (R&D systems). All ELISAs were performed following 
manufacturer’s instructions.
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Statistical analysis
Differences between two or more treatment groups were tested using a Student’s t-test 
or ANOVA with Bonferroni post-tests, respectively. Statistical analysis was performed 
using Prism software version 6.01 (GraphPad Software, La Jolla, USA).
RESULTS
The inhibitory effect of 1,25(OH)2D3 on CCR6+ memTh cells is sustained upon 
1,25(OH)2D3 withdrawal
In order to assess the stability of the effects of 1,25(OH)
2
D
3
, CCR6+ memTh cells were 
sorted from healthy individuals and first cultured with or without 1,25(OH)
2
D
3
 for three 
days. In line with previous results, treatment with 1,25(OH)
2
D
3
 reduced the production 
of IL-17A, IL-22 and IFNγ by CCR6+ memTh cells (figure 1A). Next, the medium was 
washed away and cultured cells received fresh control medium or medium containing 
1,25(OH)
2
D
3
. The cells were restimulated with IL-2 to support cell proliferation and 
cultured for another three days. After six days of culture, this resulted in three distinct 
conditions; (1) control, where cells received control medium for the entire six days, 
(2) 1,25(OH)
2
D
3
, where the cells were treated with 1,25(OH)
2
D
3
 for all six days and 
(3) withdrawal, where the cells were treated with 1,25(OH)
2
D
3
 for three days and then 
three days with control medium. As expected, the 1,25(OH)
2
D
3
-treated cells also had 
reduced IL-17A, IL-22 and IFNγ production on day 6 compared to the control-treated 
cells (figure 1B). Interestingly, the cells from which 1,25(OH)
2
D
3
 was removed after three 
days (withdrawal) produced equal amounts of cytokines as the 1,25(OH)
2
D
3
-treated cells, 
suggesting a stable effect of 1,25(OH)
2
D
3
 on the pro-inflammatory cytokine production.
However, the overall level of cytokine production during the last three days was around 
5- to 10-fold lower for IL-17A and IFNγ than in the first three days (figure 1A-B). To rule 
out that this meant that the cells are not capable of producing high levels of cytokines 
anymore due to the long-term in vitro culture or the addition of IL-2, we investigated 
the potential of these cells to produce cytokines using flow cytometry. After six days of 
culture and subsequent restimulation with PMA and ionomycin to detect intracellular 
cytokines, 27%, 40% and 60% of the cells produced IL-17A, IL-22 and IFNγ, respectively 
(figure 1C). In comparison, after three days these percentages were respectively around 
7%, 9% and 35% (data not shown), suggesting an enrichment of cytokine-producing cells 
rather than a reduction. Importantly, both 1,25(OH)
2
D
3
-treated and withdrawal-treated 
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CCR6+ memTh had less cytokine-producing cells than the control-treated cells, although 
in the withdrawal condition the production of cytokines was slightly higher than after 
full 1,25(OH)
2
D
3
 treatment. 
Altogether, these data suggest that the reduced cytokine production is not merely an effect 
of prolonged culture or IL-2 exposure and thus that inhibitory effect of 1,25(OH)
2
D
3
 on the 
pro-inflammatory cytokine profile of CCR6+ memTh cells is sustained upon withdrawal
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Figure 1. The anti-inflammatory effect of 1,25(OH)
2
D
3
 on CCR6+ memTh cells is maintained after withdrawal. (A) 
CCR6+ memTh cells were sorted and cultured for three days with 100 nM 1,25(OH)
2
D
3
 or ethanol (control) under 
stimulation of anti-CD3 and anti-CD28. Cytokine expression was measured using ELISA. (B-D) After the three 
days culture in A, the cells were washed, restimulated with IL-2 and cultured for another three days with 100 nM 
1,25(OH)
2
D
3
 or ethanol. Control (black bars) indicates cells that were never treated with 1,25(OH)
2
D
3
; 1,25(OH)
2
D
3
 
(white bars) cells that were always treated with 1,25(OH)
2
D
3
 and withdrawal (gray bars) cells that were treated 
with 1,25(OH)
2
D
3
 during the first three days and with ethanol during the second three days. Cytokine expression 
is measured at day six by ELISA (B) or flow cytometry (C-D). (C) shows a representative flow cytometry plot, 
(D) a quantification of 5 healthy donors. Data shown are mean ± SEM of n=10 (A,B) or n=5 (D) healthy donors, 
representative of at least three independent experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.. 
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1,25(OH)2D3-pretreated cells have reduced capacities to activate synovial 
fibroblasts from RA patients
One of the proposed pathogenic functions of CCR6+ memTh cells is the activation of 
synovial fibroblasts, which results in a pro-inflammatory feedback loop with increased 
production of IL-17A, IL-6, IL-8 and the tissue-destructive enzymes MMP1 and MMP3.11 
Since we have previously shown that 1,25(OH)
2
D
3
-treated CCR6+ memTh cells retain 
the capacity to migrate towards synovial inflammation (chapter 5 of this thesis), we next 
investigated if these cells could still activate synovial fibroblasts to sustain the local 
inflammatory milieu. Therefore, we harvested CCR6+ memTh cells which were activated 
and cultured for three days with or without 1,25(OH)
2
D
3
 and added them to RA synovial 
fibroblasts (RASF). The cells were cocultured for three days under restimulation with 
IL-2, after which the RASF activation was measured by the production of IL-6, IL-8, 
MMP1 and MMP3. Corresponding to the reduced pro-inflammatory phenotype in 
1,25(OH)
2
D
3
-pretreated cells, these cells were less capable of activating RASF than the 
control-pretreated cells (figure 2). Furthermore, the levels of IL-17A, IL-22 and IFNγ 
were also slightly decreased in the co-cultures with 1,25(OH)
2
D
3
-treated cells compared 
to control-treated cells. From this, we conclude that 1,25(OH)
2
D
3
-treated cells not only 
produce less pro-inflammatory cytokines, but that they are also less capable of activating 
synovial fibroblasts and thereby contribute less to synovial inflammation.
1,25(OH)2D3-mediated inhibition of IL-17A, IL-22 and IFNγ is stable upon TCR 
stimulation or pro-inflammatory cytokines
Although we found that effect of 1,25(OH)
2
D
3
 is stable upon removal of the compound, 
this does not necessarily mean that the cells stay in a stable non-inflammatory state once 
they are exposed to the immune-stimulating environment of an inflammation. Therefore, 
we studied the extent of phenotype stability using various types of restimulation. We 
used CCR6+ memTh cells that had already been activated and treated with control or 
1,25(OH)
2
D
3
 for three days and then restimulated them with IL-2 as before, or with two 
different dosages of T cell receptor (TCR) stimulation; full dose of anti-CD3 and anti-
CD28, which is the same as the initial stimulation, or a quarter of that normal dose. As 
shown in figure 3A, this restimulation through the TCR did not influence the stability of 
the 1,25(OH)
2
D
3
-induced phenotype. Notably, stimulating with a full dose of anti-CD3 
and anti-CD28, but not the quarter dose, restored the capacity of the CCR6+ Th cells to 
activate synovial fibroblasts (data not shown).
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Figure 2. 1,25(OH)
2
D
3
-pretreated CCR6+ memTh cells less capable of activating RA synovial fibroblasts. 
CCR6+ memTh cells were sorted and cultured as in figure 1A. Then the cells were washed and added to RA 
synovial fibroblasts, restimulated with IL-2 and cultured for another three days. No 1,25(OH)
2
D
3
 was added to 
these co-cultures. Cytokine production was measured using ELISA. Data represent mean ± SEM of n=5 healthy 
donors, representative of three independent experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
An inflammatory site does not only provide TCR stimulation, but also cytokines which 
can polarize T cells. Therefore, we restimulated the control- and 1,25(OH)
2
D
3
-treated cells 
with IL-2 together with IL-23, IL-1β or both, since these two cytokines are known to be 
involved in driving the pathogenicity of Th17 cells. Under IL-23 treatment, the cytokine 
production after 1,25(OH)
2
D
3
 withdrawal was still equal to the complete 1,25(OH)
2
D
3
 
treatment and lower than the control-treatment (figure 3A). However, upon IL-1β or IL-1β 
and IL-23 treatment the suppressive effect of 1,25(OH)
2
D
3
 on the levels of IL-17A, but 
not IL-22, was lost. IFNγ also appeared to be upregulated upon exposure to IL-1β or IL-
1β+IL-23, but it was still significantly lower than the control-condition and not different 
from the 1,25(OH)
2
D
3
-treated cells (figure 3A). 
Since we found in figure 1 that even with 1,25(OH)
2
D
3
 there are still cells that produce 
IL-17A, it could be that IL-1β increases IL-17A production from those cells rather than the 
ones that lost their IL-17A-producing capacity after 1,25(OH)
2
D
3
 treatment. Therefore, we 
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Figure 3. The effect of 1,25(OH)
2
D
3
 is stable upon restimulation with pro-inflammatory cytokines. CCR6+ 
memTh were sorted and cultured as in figure 1A. After these cultures, cells were washed and restimulated 
using various type of T cell stimulation and exogenous cytokines. The cells were cultured for another three 
days with or without 1,25(OH)
2
D
3
 to get the control, 1,25(OH)
2
D
3
 and withdrawal conditions as described 
for figure 1B-D. Cytokine expression was measured using ELISA (A) or flow cytometry (representative plot 
in (B) and summary of multiple donors in (C)). Data is depicted as mean ± SEM of n=6 healthy donors. Data 
are representative for at least two independent experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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investigated the stability of the 1,25(OH)
2
D
3
-induced phenotype under stimulation with 
IL-23, IL-1β or both using flow cytometry. Interestingly, neither IL-1β nor IL-23 affected 
the percentage of IL-17A-producing cells (figure 3B-C).
Since the total production of IL-17A was increased by IL-1β in the withdrawal condition, 
but the percentage of IL-17A-producing cells is the same, this indicates that the IL-17A+ 
cells that were still present after 1,25(OH)
2
D
3
-treatment were responsible for the increased 
production of IL-17A. As a result, the data suggest that the 1,25(OH)
2
D
3
-treated CCR6+ 
memTh cells that lost their production of IL-17A, IL-22 and IFNγ cannot be stimulated 
by IL-1β or IL-23 to restore their cytokine production. 
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Figure 4. RA synovial fluid does not influence the stable effects of 1,25(OH)
2
D
3
. CCR6+ memTh cells were 
sorted and cultured as described in figure 1. During the restimulation phase with IL-2, the cells were exposed 
to 20% synovial fluid from three independent RA patients. (A) A representative flow cytometry plot at day 
6. (B) Quantification of cytokine-producing cells from multiple donors using flow cytometry. (C) Cytokine 
production as measured by ELISA. The data shown indicate mean ± SEM of n=6 healthy donors and represent 
three independent experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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RA synovial fluid cannot reverse the changes induced by 1,25(OH)2D3 
Although cytokine exposure can provide information on how cells would respond in an 
inflammatory environment, it does not reflect the in vivo inflammatory site where multiple 
types of cytokines are present. Therefore, we next investigated whether the effect of 
1,25(OH)
2
D
3
 is sustained after withdrawal if the cells are restimulated in the presence of 
synovial fluid from RA patients. Flow cytometric analysis of these cultures showed that 
the inhibition of IL-17A, IL-22 and IFNγ was stable upon exposure to RA synovial fluid 
(figure 4A-B). Furthermore, a similar pattern was observed when studying the percentage 
of cytokine-producing cells using flow cytometry, although the inhibitory effect on IL-17A 
was non-significantly lost in synovial fluid number 3 (figure 4C). Interestingly, this was 
similar to the restimulation with IL-1β, where the percentage of IL-17A-producing cells 
was stable whereas the IL-17A production in the culture supernatant increased. Therefore, 
IL-1β levels were measured in the RA synovial fluids. Synovial fluids number 1, 2 and 3 
contained 4.3, 2.1 and 3.1 pg/ml IL-1β, respectively. Although this seems extremely low, it 
has been reported that 10 pg/ml can already increase IL-17A production 2-fold. Therefore, 
the partial restoring of IL-17A production might be due to the IL-1β in the synovial fluid, 
which is line with the previously obtained data and suggest an induction of IL-17A in the 
cells that still produce the cytokine rather than a reversal of the effect of 1,25(OH)
2
D
3
 in 
the cells that lost IL-17A expression.
Overall, the data shown here indicate that RA synovial fluid cannot restore the production 
of pro-inflammatory cytokines in cells that were affected by 1,25(OH)
2
D
3
.
The inhibition of CCR6+ Th pathogenicity by 1,25(OH)2D3 depends on histone 
deacetylation
The phenotype of T cells is at least partially determined by the epigenetic histone 
modifications, which dictate which parts of the genome are available for transcription. 
Therefore, changes in this histone code may underlie the stable effects of 1,25(OH)
2
D
3
. 
Previously it has been shown that 1,25(OH)
2
D
3
 recruit histone deactylases (HDAC) to 
the promoter of IL-17A to inhibit gene transcription.13 However, it is unknown whether 
1,25(OH)
2
D
3
 also regulates other cytokines through this mechanism. Therefore, we used 
the HDAC inhibitor valproic acid (VPA), to study the role of HDACs in the effect of 
1,25(OH)
2
D
3
 on IL-17A, IL-22 and IFNγ production by CCR6+ memTh cells. Due to the 
toxic effects of long-term HDAC inhibition and HDAC inhibition during cell activation, 
the culture protocol was adjusted compared to the previous experiments. First, CCR6+ 
memTh cells were activated with anti-CD3 and anti-CD28 for 24 hours. The activated 
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cells were then exposed to 1,25(OH)
2
D
3
 with or without VPA for another 24 hours. 
Subsequently, the medium was refreshed, new anti-CD3 and anti-CD28 was added and 
the cells were cultured for 72 hours with or without 1,25(OH)
2
D
3
. Using this protocol, we 
still found a stable reduction of IL-17A, IL-22 and IFNγ when no VPA was present (figure 
5). This shows that even 24 hours of 1,25(OH)
2
D
3 
exposure is enough to stably modulate 
the CCR6+ memTh cells. 
When VPA was added, 1,25(OH)
2
D
3
 treatment during the entire culture period reduced 
the production of IL-17A and IL-22 compared to the control conditions. However, in the 
withdrawal condition, the reduction of IL-17A and IL-22 was lost upon exposure to VPA 
in a dose-dependent manner (figure 5). IFNγ appeared to be similarly influenced by VPA 
treatment, although it did not reach statistical significance. A similar pattern for IL-17A, 
IL-22 and IFNγ was observed when trichostatin A, another HDAC inhibitor, was used 
(figure S1).
The data indicate that blocking HDAC recruitment during 1,25(OH)
2
D
3
 exposure inhibits 
its immunomodulatory effects. This mechanism may result in a stable inhibition of these 
cytokines and hence a stable change in phenotype.
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Figure 5. Histone deacetylation is required for the anti-inflammatory effect of 1,25(OH)
2
D
3
 on CCR6+ memTh 
cells. CCR6+ memTh cells were sorted and stimulated with anti-CD3 and anti-CD28 for 24 hours. Then 
1,25(OH)
2
D
3
 or ethanol (control treatment) was added, with or without the HDAC inhibitor VPA. After 24 
hours, the cells were washed, restimulated with anti-CD3 and anti-CD28, with or without 1,25(OH)
2
D
3
. Here 
the control-treated cells never received 1,25(OH)
2
D
3
, the 1,25(OH)
2
D
3
-treated cells got 1,25(OH)
2
D
3
 during 
HDACi treatment and during the last three days of culture and the withdrawal-cells were only exposed to 
1,25(OH)
2
D
3
 together with the HDACi. After the final culture, cytokine expression was measured using ELISA. 
Data show the mean ± SEM of n=6 healthy donors, representative of two independent experiments. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001.
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DISCUSSION
Recently, we have shown that 1,25(OH)
2
D
3
 induces an anti-inflammatory phenotype in the 
pro-inflammatory CCR6+ memTh cells, with regulatory capacities that are sustained in 
the presence of RA synovial fluid (chapter 5 of this thesis). Here we demonstrated that also 
the 1,25(OH)
2
D
3
-mediated inhibition of IL-17A, IL-22 and IFNγ is sustained upon removal 
of the compound. As a result, the treated CCR6+ memTh are less capable of activating 
RA synovial fibroblasts. Furthermore, TCR restimulation and exposure to IL-23, IL-1β 
or RA synovial fluid cannot reverse the 1,25(OH)
2
D
3
-induced changes. Finally, we found 
that histone deacetylases are required for the effects of 1,25(OH)
2
D
3
and could explain the 
stable change in CCR6+ memTh cells.
In line with the previously reported data that the suppressive capacity of 1,25(OH)
2
D
3
-
treated CCR6+ memTh cells is stable, we found that the production of pro-inflammatory 
cytokines remains low after 1,25(OH)
2
D
3
 is removed from the culture. Although it may 
seem that restimulation with IL-2, a known inhibitor of Th17 differentiation14, biases the 
results, in our experiments IL-2 has no inhibitory effect on cytokine production in CCR6+ 
memTh cells. Furthermore, 1,25(OH)
2
D
3
-mediated inhibition of IL-17A, IL-22 and IFNγ 
is stable even under restimulation with anti-CD3 and anti-CD28. Importantly, whereas the 
strength of stimulation plays a role in initial Th17 differentiation15, it does not affect the 
stability of the effects of 1,25(OH)
2
D
3
, since there was no difference between the full and 
¼ dose of anti-CD3 and anti-CD28. Taken together, these data indicate that the inhibition 
of IL-17A, IL-22 and IFNγ by 1,25(OH)
2
D
3
 is not dependent on the type of restimulation.
Surprisingly, also IL-23 and IL-1β could not reverse the inhibition of IL-17A, IL-22 and 
IFNγ by 1,25(OH)
2
D
3
. However, IL-1β did increase the levels of IL-17A produced in all 
conditions, which may be due to the IL-17A-producing cells that are left in the culture 
after 1,25(OH)
2
D
3
 treatment. Interestingly, IL-23 alone did not affect the stability of 
the 1,25(OH)
2
D
3
 effect, whereas it enhanced the cytokine-promoting effects of IL-1β 
when used in combination. This could be due to an increase of the IL-23 receptor in 
response to IL-1β stimulation16, increased IL1R1 in response to IL-2317, or both. Similar 
to these cytokines, also IL-6 and TNFα could not reverse the effects of 1,25(OH)
2
D
3
 (data 
not shown), suggesting that the cells are resistant to the stimulation with multiple pro-
inflammatory cytokines. In line with these data, we also found that synovial fluid from 
some RA patients could overrule the effects of 1,25(OH)
2
D
3
 on the cytokine levels, but not 
on the percentage of cytokine-producing cells. This might be due to IL-1β is the synovial 
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fluid, although it should be further studied whether the low levels that were detected are 
enough to stimulate IL-17A production.
Finally, we demonstrated that histone modifications are required for the effects of 
1,25(OH)
2
D
3
, since the addition of two different HDAC inhibitors dose-dependently 
prevented the anti-inflammatory effect of 1,25(OH)
2
D
3
 on the CCR6+ memTh cells. It 
is already known that histone acetylation on the promoter regions of IL-17A and IL-17F 
increases during Th17 differentiation.18 1,25(OH)
2
D
3 
recruits HDACs to the IL-17A locus, 
which can undo this acetylation and thereby inhibit transcription of IL-17A.13 Our results 
are consistent with these findings, but they also show that this mechanism may also apply 
to other gene loci since the effects of 1,25(OH)
2
D
3
 on IL-22 and IFNγ were also affected by 
HDAC inhibition. Although further research is required to find if other vitamin D-target 
genes are also regulated via HDACs, the data provided in this study suggest a general 
mechanism by which 1,25(OH)
2
D
3
 exerts its immunomodulatory effects.
However, our data do not definitively prove that the stability of the effect of 1,25(OH)
2
D
3
 
is due to changes in histone acetylation. It has been demonstrated previously that the 
epigenetic marks in Th1 and Th17 cells are relatively stable19, which provides a basis to 
believe that the modifications made by 1,25(OH)
2
D
3
 could also be stable and therefore 
mediate the stable effects of 1,25(OH)
2
D
3
. ChIP-seq experiments for specific histone 
modifications could provide more insight into this issue.
Functionally, the results from this study further elucidate how 1,25(OH)
2
D
3
 can modulate 
the immune system to suppress autoimmune responses. Since 1,25(OH)
2
D
3
-pretreated 
CCR6+ memTh cells are less capable of activation RASF, this could be one of the 
mechanisms through which 1,25(OH)
2
D
3
 exerts it anti-inflammatory effects. However, 
stimulation of both the control-treated and 1,25(OH)
2
D
3
-treated CCR6+ memTh cells with 
a full dose of anti-CD3 and anti-CD28 results in activation of RASF. How this strong 
stimulation relates to the stimulation-strength that is found at the site of inflammation and 
thus how well the model system reflects the in vivo situation remains to be investigated. 
Another pathway that could be affected by this stable suppression of pro-inflammatory 
cytokines is the activation of B cells to produce pathogenic autoantibodies. Recently, it 
has been shown that Th17 cells support this process through the cytokine IL-2220, which 
is stably modified by 1,25(OH)
2
D
3
 in this study.
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Interestingly, the finding that 1,25(OH)
2
D
3
 can stably modulate immune cells is not limited 
to T cells. Also dendritic cells have been found to acquire an irreversible regulatory 
phenotype change upon treatment with 1,25(OH)
2
D
3
.21 Because of this, these vD-DCs 
are being considered in cell-based therapies for autoimmune diseases such as type 1 
diabetes and RA.22,23 It is tempting to consider a similar opportunity for the therapeutic 
transfer of antigen-specific 1,25(OH)
2
D
3
-treated CCR6+ memTh cells, given their stable 
regulatory-like phenotype and their capacity to migrate towards the site of inflammation 
(chapter 5 of this thesis). However, in vivo experiments are required to test whether these in 
vitro findings also hold true in the complicated situation of an experimental autoimmune 
disease.
In conclusion, we have found that treatment with 1,25(OH)
2
D
3
 induces a stable reduction 
of the pro-inflammatory cytokines IL-17A, IL-22 and IFNγ, which is accompanied by 
modulation of epigenetic histone marks. This knowledge on the effects and working 
mechanisms of 1,25(OH)
2
D
3
 can be utilized to inhibit the pathogenicity of specific cell 
types in the context of autoimmune diseases such as RA.
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Figure S1. Trichostatin A prevents the reduction of pro-inflammatory cytokines by 1,25(OH)
2
D
3
. CCR6+ 
memTh cells were sorted and cultured as described for figure 5. Instead of VPA, indicated concentrations of 
TsA were used. Data are shown as mean ± SEM of n=6 healthy donors, representative of two independent 
experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
Parameters Patient #1 Patient #2 Patient #3
Age 50 57 58
DAS28 4.59 4.33 4.69
VAS 100 100 88
ESR N/A 11 66
CRP 24 25 22
TJC28 2 3 3
SJC28 1 1 2
Medication MTX
csDMARDs
Vitamin D (800 IU/day)
Prednisolone
Vitamin D (800 IU/day)
Prednisolone
MTX
Table S1. Characteristics of patients used in this study for synovial fluid. Abbreviations: DAS28, disease 
activity score for 28 joints; VAS, visual analogue scale; ESR, erythrocyte sedimentation rate; CRP, c-reactive 
protein; TJC28, tender joint count within 28 joints; SJC28, swollen joint count within 28 joints; MTX, metho-
trexate; csDMARDs, conventional synthetic disease modifying antirheumatic drugs; IU, international units.
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ABSTRACT 
Background
Despite recent improvements in treatment of rheumatoid arthritis (RA), insufficient 
treatment response and development of treatment resistance in many patients illustrate the 
need for new therapeutic strategies. Chronic synovial inflammation could be suppressed 
by targeting RA synovial fibroblasts (RASF) activation by for example IL-17A-producing 
CCR6+ T helper memory (memTh) cells. Here we modulated this interaction by combining 
the active vitamin D metabolite 1,25(OH)
2
D
3
 with dexamethasone (DEX) and explored 
potential therapeutic applications.
Methods 
CCR6+ memTh cells from PBMC of healthy donors or treatment-naïve early RA patients 
were cultured alone or with RASF from established RA patients for three days and treated 
with or without 1,25(OH)
2
D
3
, DEX or etanercept. Treatment effects were assessed using 
ELISA and flow cytometry. 
Results 
1,25(OH)
2
D
3
, and to  lesser extent DEX, reduces production of the pro-inflammatory 
cytokines IL-17A, IL-22 and IFNγ in CCR6+ memTh cells. TNFα was only inhibited by 
the combination of 1,25(OH)
2
D
3
 and DEX. In contrast, DEX was the strongest inhibitor 
of IL-6, IL-8 and tissue-destructive enzymes in RASF. As a result, 1,25(OH)
2
D
3
 and 
DEX additively inhibited inflammatory mediators in CCR6+ memTh-RASF co-cultures. 
Interestingly, low doses of mainly DEX, but also 1,25(OH)
2
D
3
, combined with etanercept 
better suppressed synovial inflammation in this co-culture model compared to etanercept 
alone.
Conclusion 
This study suggests that 1,25(OH)
2
D
3
 and DEX additively inhibit synovial inflammation 
through targeting predominantly CCR6+ memTh cells and RASF, respectively. 
Furthermore, low doses of DEX and 1,25(OH)
2
D
3
 enhance the effect of TNFα blockade 
in inhibiting RASF activation, providing a basis to improve RA treatment.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease, characterized 
by inflamed synovial joints resulting in pain, fatigue and disability in patients. Although 
treatment has improved over the last decades, many patients do not reach clinical remission, 
show progressive joint damage or become resistant to their treatment.1 Furthermore, the 
current therapies include the use of expensive biological disease modifying anti-rheumatic 
drugs (DMARDs), which pose a burden on the health care budget. Therefore, there is 
still a need to find new therapeutic options and to improve currently available treatments.
The main therapeutic goal in RA is to stop the chronic synovial inflammation and 
thereby prevent the subsequent cartilage and bone damage in the affected joint. Synovial 
fibroblasts play an important role in this process, since they can secrete pro-inflammatory 
cytokines that attract and activate immune cells, produce tissue-destructive enzymes and 
invade cartilage.2,3 How these RA synovial fibroblasts (RASF) are activated is currently 
unknown, although one of the hypotheses is that they are activated by infiltrating immune 
cells. Previously we have shown that specifically CCR6+, but not CCR6-, memory T helper 
(memTh) cells can activate RASF.4
CCR6+ memTh cells are characterized by IL-17A production and RORC expression. 
This subset contains the classical Th17 cells, but also for example Th17.1 cells which 
produce high levels of IFNγ.5 Other evidence that suggests a role for these IL-17A 
producing memTh cells is that Th17 cells and IL-17-mediated signalling are required for 
the development of murine autoimmune arthritis.6,7 Furthermore, CCR6+ memTh cells 
are more activated and more prevalent in the blood of treatment-naïve early RA patients 
and are also found in the synovial fluid of RA patients.4,8
Upon interaction with CCR6+ memTh cells, RASF secrete pro-inflammatory mediators 
such as IL-6, matrix metalloproteases (MMPs) and prostaglandin E2 (PGE2) via IL-17A 
and TNFα. In turn, these molecules, especially PGE2, further activate the CCR6+ 
memTh cells to produce more IL-17A, thereby creating a pro-inflammatory feedback 
loop that could drive the chronic synovial inflammation.4,9 Therefore, inhibiting this pro-
inflammatory loop may be beneficial in the treatment of RA. 
We have previously shown that combining the active vitamin D metabolite 1,25(OH)
2
D
3
 
with TNFα blockade, a commonly used therapy in RA, additively suppresses the pro-
inflammatory loop between CCR6+ memTh and RASF.10 However, clinical translation 
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of these findings is challenging as high concentrations of 1,25(OH)
2
D
3
 were used. 
Interestingly, the effects of 1,25(OH)
2
D
3
 on Th17-related cytokines, such as IL-17A, TNFα 
and IL-22, can be augmented through combination with dexamethasone (DEX).11 DEX is 
a synthetic glucocorticoid (GC) which is clinically used for fast resolution of inflammation 
and is often combined with vitamin D supplements to prevent the osteoporotic side effects 
of the drug.12
Given the immunomodulatory capacities of both DEX and 1,25(OH)
2
D
3
, we here 
investigated whether this combination could suppress CCR6+ memTh cells, RASF and 
their interaction. Furthermore, the potential use of these findings for improving current 
anti-TNFα therapy is explored.
MATERIALS AND METHODS
Subjects
Healthy control peripheral blood mononuclear cells (PBMC) were obtained from 
buffycoats (Sanquin, Amsterdam, the Netherlands). For validation of findings in healthy 
PBMC, RA PBMC were isolated from treatment-naïve RA patients who were embedded 
in the tREACH study, which was ethically approved by the METC Rotterdam. Relevant 
clinical information is summarized in table S1. RA synovial fibroblasts (RASF) were 
grown from synovial explants after joint replacement surgery. All patients signed 
informed consent.
Cell sorting
PBMC were isolated from peripheral blood using ficoll-based cell separation 
and frozen in liquid nitrogen until use. For sorting of CCR6+ memTh cells 
(CD4+CD45RO+CCR6+CD25low/int), PBMC were stained using antibodies against CD4, 
CCR6, CD25 (BioLegend, San Diego, CA, USA) and CD45RO (BD Biosciences, San 
Diego, CA, USA). Before sorting CCR6+ memTh cells, the cells were pre-purified using 
CD4 microbeads via automated magnetic-activated cell sorting (Miltenyi Biotec, Leiden, 
The Netherlands). Dead cells were excluded using 4’6-Diamidino-2-Phenylindole Dilactate 
(DAPI) and CCR6+ memTh cells were sorted on a FACSAriaIII sorter (BD Biosciences).
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Cell culture
RA synovial fibroblasts (RASF) were obtained by culturing small synovial biopsies in a 
culture flask with Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Waltham, MA, 
USA), supplemented with 10% fetal calf serum (FCS, Gibco) and 100 IU/ml penicillin/
streptomycin (pen/strep, Lonza, Verviers, Belgium). After RASF were grown out of the 
synovial biopsies, cells were passaged and used for experiments between passage 3 and 
8. For co-culture with sorted T cells or stimulation experiments, RASF were plated at a 
density of 1x104 cells/well in a 96-well plate, 24 hours before the T cells or stimulation 
medium were added. Where indicated, RASF were stimulated with 2 ng/ml recombinant 
TNFα and 5 ng/ml recombinant IL-17A (R&D Systems, Minneapolis, MN, USA).
Sorted CCR6+ memTh cells were stimulated with 300 ng/ml soluble anti-CD3 and 
400 ng/ml soluble anti-CD28 (Sanquin, Amsterdam, the Netherlands), at a density of 
2,5x104 cells/ml in Iscove’s Modified Dulbecco’s Medium (IMDM, Gibco) supplemented 
with 10% FCS, 100 IU/ml pen/strep, 2mM L-glutamine and 50 μM β-mercaptoethanol 
(Sigma-Aldrich, St. Louis, MO, USA). Cells were treated with or without 1,25(OH)
2
D
3
 
(Leo Pharmaceutical Products, Ballerup, Denmark), dexamethasone (Sigma-Aldrich) 
and etanercept (anti-TNFα, Pfizer, New York, NY, USA) dissolved in 100% ethanol at 
indicated concentrations. Control conditions contained an equal volume of 100% ethanol 
which never exceeded 0,1%. 
Flow cytometry
Cultured cells were restimulated with 50 ng/ml phorbol 12-myristate 13 acetate (PMA), 
500 ng/ml ionomycin (Sigma-Aldrich) and GolgiStop (BD Biosciences) for 4 hours. 
Cells were then stained with Fixable Viability Dye eFluor506 (eBioscience, San Diego, 
CA, USA), fixated with 2% paraformaldyhyde and permeabilized using 0,5% saponine. 
Intracellular cytokines were stained with monoclonal antibodies against IL-17A, IL-22 
(eBioscience) and IFNγ (BioLegend).
Apoptosis was assessed using 7AAD/AnnexinV staining, performed following 
manufacturer’s instructions (eBioscience). All samples were measured on the FACSCantoII 
Flow Cytometer (BD Biosciences).
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ELISA
In culture supernatant after three days of culture, the concentration of IL-17A, IL-22, 
IFNγ, TNFα, IL-10, IL-6, IL-8 (Ready-Set-Go, eBioscience), MMP1, MMP3 (DuoSet 
ELISA, R&D Systems) and PGE2 (Prostaglandin E2 Parameter Assay Kit, R&D Systems) 
were measured using ELISA. Manufacturer’s protocols were followed.
Statistical analysis
Differences between experimental treatment groups were tested using ANOVA with 
Bonferroni post-tests. Analyses were performed using Prism software version 6.01 
(GraphPad Software, La Jolla, CA, USA). 
RESULTS
1,25(OH)2D3-DEX combination treatment suppresses TNFα production from 
CCR6+ memTh cells
As a first step to examine the potential use of 1,25(OH)
2
D
3
 and DEX to inhibit synovial 
inflammation, CCR6+ memTh cells were sorted from healthy controls and cultured for 
three days with 1,25(OH)
2
D
3
, DEX or both. In line with the previous studies, treatment 
with 1,25(OH)
2
D
3
 reduces the percentage of cells producing IL-17A, IL-22 and IFNγ. 
On the other hand, treatment with DEX hardly affected pro-inflammatory cytokine 
production in these cultures. Combining 1,25(OH)
2
D
3
 and DEX had a similar effect 
as 1,25(OH)
2
D
3
 single treatment (figure 1A-B). Notably, treatment with DEX reduced 
the amount of IL-17A and IFNγ that was produced during the three-day culture period 
(figure 1C). Since DEX is known to induce cell death, the treatment effect on apoptosis 
was investigated. However, the minimal increase in apoptosis upon 1,25(OH)
2
D
3
, DEX 
or combination exposure could not explain the difference between flow cytometry and 
ELISA (figure S1). Although no additive effect was observed with 1,25(OH)
2
D
3
-DEX 
combination treatment on IL-17A, IL-22 or IFNγ, TNFα was most strongly inhibited by 
the combined exposure (figure 1C). Since 1,25(OH)
2
D
3
 can induce an anti-inflammatory 
phenotype in the CCR6+ memTh cells (W. Dankers et al., submitted manuscript), the 
combinatory effects of 1,25(OH)
2
D
3
 and DEX on IL-10 were also assessed. However, DEX 
did not affect IL-10 production nor did it augment the induction of IL-10 by 1,25(OH)
2
D
3
 
(figure 1C). Overall, these data show that 1,25(OH)
2
D
3
 is the main modulator of IL-17A, 
IL-22, IFNγ and IL-10 production by CCR6+ memTh cells, but that the combination of 
1,25(OH)
2
D
3
 of DEX has provides additional value through TNFα inhibition.
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Figure 1. 1,25(OH)
2
D
3
 and DEX additively suppress pro-inflammatory cytokines secreted by CCR6+ memTh 
cells. CCR6+ memTh cells were sorted from healthy individuals and cultured for three days under stimulation 
with anti-CD3 and anti-CD28, with or without 100 nM 1,25(OH)
2
D
3
 and 1000 nM DEX. (A) Representative 
flow cytometry plots of IL-17A-, IL-22- and IFNγ-producing cells. (B) quantification of flow cytometry as in 
A for 6 donors. (C) Cytokine production in the culture medium as measured by ELISA. Data show mean ± 
SEM for n=6-10 healthy individuals, representative of at least 3 independent experiments. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001
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Figure 2. 1,25(OH)
2
D
3
 and DEX additively suppress the pro-inflammatory feedback loop between CCR6+ 
memTh cells and RASF. CCR6+ memTh sorted from healthy individuals were cultured with RASF for three 
days. The cells were stimulated with anti-CD3 and anti-CD28 and treated with or without 100 nM 1,25(OH)
2
D
3
 
and 1000 nM DEX. After three days, cytokine production was measured in the culture supernatant using 
ELISA. Mean ± SEM are given for n=10 healthy donors grown on RASF from 2 different donors. Data are 
representative of at least 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
1,25(OH)2D3 and DEX additively suppress the pro-inflammatory feedback loop 
between CCR6+ memTh cells and RASF
Since 1,25(OH)
2
D
3
 and DEX had additive effects in blocking TNFα and they were both 
capable of reducing the level of IL-17A that is produced by CCR6+ memTh cells, we 
hypothesized that the combination treatment would augment inhibition of the pro-
inflammatory loop between CCR6+ memTh cells and RASF when compared to either 
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compound alone. Similar to the effects of 1,25(OH)
2
D
3
 and DEX on CCR6+ memTh cell 
cultures, treatment of the CCR6+ memTh-RASF co-cultures reduced IL-17A, IL-22 and 
IFNγ production, especially with 1,25(OH)
2
D
3
. However, the production of TNFα was 
stimulated upon treatment with DEX, whereas it was still inhibited with the combination 
treatment. Furthermore, IL-10 was upregulated in response to DEX and the combination 
of DEX and 1,25(OH)
2
D
3
, but not 1,25(OH)
2
D
3
 alone (figure 2).
Despite the differences in modulation of T cell-derived cytokines by DEX and 
1,25(OH)
2
D
3
, they equally inhibit the RASF-derived factors IL-6, IL-8 and PGE2. 
For IL-6 and IL-8 there was also a trend towards additive inhibition in response to the 
combination of 1,25(OH)
2
D
3
 and DEX. Interestingly, DEX was a stronger inhibitor of 
the tissue-destructive enzymes MMP1 and MMP3 than 1,25(OH)
2
D
3
. These data suggest 
that, although no strong additive effect of 1,25(OH)
2
D
3
 and DEX is found on individual 
cytokines, the two compounds cooperate to reduce the pro-inflammatory milieu at an 
inflammatory synovial site by each targeting different players in the inflammation. 
Furthermore, the increased production of IL-10 potentially mediates anti-inflammatory 
effects on other immune cells.
DEX already modulates unstimulated RASFs, while 1,25(OH)2D3 requires 
cytokine stimulation
The finding that DEX strongly modulates RASF-derived factors, but not T-cell 
derived cytokines, in the CCR6+ memTh-RASF co-cultures suggests a direct effect 
of DEX on RASF. In order to investigate this, RASF were cultured with or without 
stimulation of TNFα, IL-17A or both for three days and treated with 1,25(OH)
2
D
3
, DEX 
or the combination (figure 3). Without stimulation, 1,25(OH)
2
D
3
 did not affect cytokine 
production by RASF, whereas DEX reduced the levels of IL-6 and IL-8. Upon stimulation 
with TNFα, IL-17A or both, 1,25(OH)
2
D
3
 reduces the expression of IL-6 and IL-8, but 
not MMP1 and MMP3. DEX is in these cultures a strong repressor of IL-6, IL-8, MMP1 
and MMP3. Together with our previous findings, these data suggest that, although DEX 
and 1,25(OH)
2
D
3
 can affect both T cells and RASF, DEX acts most strongly on RASF 
whereas the main effect of 1,25(OH)
2
D
3 
is mediated via the T cells.
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Figure 3. The effect of 1,25(OH)2D3 is stable upon restimulation with pro-inflammatory cytokines. CCR6+ 
memTh were sorted and cultured as in figure 1A. After these cultures, cells were washed and restimulated 
using various type of T cell stimulation and exogenous cytokines. The cells were cultured for another three 
days with or without 1,25(OH)2D3 to get the control, 1,25(OH)2D3 and withdrawal conditions as described 
for figure 1B-D. Cytokine expression was measured using ELISA (A) or flow cytometry (representative plot 
in (B) and summary of multiple donors in (C)). Data is depicted as mean ± SEM of n=6 healthy donors. Data 
are representative for at least two independent experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
Low dose of 1,25(OH)2D3 and DEX improves the effects of TNFα blockade in 
CCR6+ memTh-RASF co-cultures
Since 1,25(OH)
2
D
3
 and DEX additively inhibit the pro-inflammatory loop between CCR6+ 
memTh cells and RASF, it was next studied whether 1,25(OH)
2
D
3
-DEX combination can 
enhance the anti-inflammatory effect of TNFα blockade in this model system. To make 
these experiments more physiologically relevant, the dosages of 1,25(OH)
2
D
3
 and DEX 
were reduced to 0,1 nM and 10 nM, respectively. At 10 nM, DEX still inhibited IL-6, IL-8 
and MMP1 in CCR6+ memTh-RASF co-cultures, but 0,1 nM 1,25(OH)
2
D
3
 only slightly 
affected these pro-inflammatory factors (figure S2). Therefore, also 10 nM was taken along 
for 1,25(OH)
2
D
3
. CCR6+ memTh cells were sorted from healthy controls and cultured 
together with RASF while being exposed to various combinations of 1,25(OH)
2
D
3
, DEX 
and the TNFα-blocking agent etanercept. Inhibition of IL-17A, IL-6, IL-8, MMP1 and 
MMP3 is shown as heatmaps in figure 4 and more detailed in figure S3. 
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Figure 4. Suppression of RASF activation by TNFα blockade is enhanced by adding DEX and 1,25(OH)
2
D
3
. 
CCR6+ memTh-RASF co-cultures as described for figure 2 were exposed to 10 nM DEX, 0.1 or 10 nM 
1,25(OH)
2
D
3
, 0, 0.1, 1 or 10 μg/ml etanercept or combinations of the compounds as indicated. After three 
days, synovial fibroblast activation was measured through cytokine detection using ELISA. Arrows indicate 
increasing concentrations. Heatmaps are constructed using the mean inhibition in each condition of n=6 
healthy donors cultured on RASF from 2 different RA patients. 
For IL-17A, etanercept dose-dependently inhibits cytokine expression, but this effect 
is stronger (darker shades) when the cells are also treated with 10 nM of 1,25(OH)
2
D
3
. 
Combining DEX with this dose of 1,25(OH)
2
D
3
 further suppresses IL-17A and leaves little 
added effect for etanercept. IL-6 and IL-8 are more strongly inhibited by etanercept and 
show a clear dose-response (left column of the heatmap, top to bottom). Adding increasing 
dosages of 1,25(OH)
2
D
3
 augments the effects of etanercept, but the optimal effect is 
reached when 10 nM DEX, 10 nM 1,25(OH)
2
D
3
 and etanercept are combined. Notably, 
there is almost no difference anymore between 0.1 or 10 µg/ml etanercept. MMP1 and 
MMP3 show a similar pattern of inhibition as IL-6 and IL-8, except that the effect of DEX 
is stronger even without additional 1,25(OH)
2
D
3
 or etanercept. These data suggest that 
combining 1,25(OH)
2
D
3
 and especially DEX with etanercept has strong additive effects 
compared to etanercept alone. 
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Since the cells from healthy controls that were used in figure 4 and S3 may react differently 
to treatment than the cells from RA patients, the experiment was repeated using sorted 
CCR6+ memTh cells from treatment-naïve early RA patients cultured with RASF, serving 
as a proof of principle (figures 5 and S4). Due to large variation between patients (figure 
S4), there was a less clear dose-dependent inhibition of IL-17A in response to etanercept. 
However, 10 nM 1,25(OH)
2
D
3
 still enhanced the effects of etanercept and IL-17A inhibition 
was again further increased when 10 nM DEX was added. The inhibition of IL-6 and 
IL-8 by etanercept was stronger in the CCR6+ memTh cells from RA patients than from 
healthy individuals and showed a clear dose-dependent inhibition. Similar to the results 
for the healthy controls, 1,25(OH)
2
D
3
 enhanced the effects of etanercept and DEX was 
an even stronger modulator of especially IL-6. MMP1 and MMP3 were inhibited by 
etanercept, although the dose-response was less clear than for IL-6 and IL-8. However, 
similar to the data from the healthy cells, DEX strongly suppressed the expression of the 
tissue-destructive enzymes (figure 5).
10
1
0.1
0
0 20 40 60 10080
% inhibition
IL-17A
E
ta
n
er
ce
p
t 
(μ
g
/m
l)
0 nM DEX 10 nM DEX
0 0.1 10 0 0.1 10
 (nM)
IL-6
0 nM DEX 10 nM DEX
IL-8
0 nM DEX 10 nM DEX
MMP1
0 nM DEX 10 nM DEX
MMP3
0 nM DEX 10 nM DEX
0 0.1 10 0 0.1 10 0 0.1 10 0 0.1 10
0 0.1 10 0 0.1 10
 (nM)
0 0.1 10 0 0.1 10
 (nM) (nM)1.25(OH)2D3 (nM)
10
1
0.1
0
10
1
0.1
0
10
1
0.1
0
10
1
0.1
0
E
ta
n
er
ce
p
t 
(μ
g
/m
l)
1.25(OH)2D3 1.25(OH)2D3
1.25(OH)2D3 1.25(OH)2D3
Figure 5. Additive effects of DEX and 1,25(OH)
2
D
3
 on the inhibition of RASF activation by TNFα blockade 
are verified for treatment-naïve RA patients. Co-cultures were set up as described for figure 4 using RASF 
from established RA patients and allogeneic CCR6+ memTh cells sorted from PBMC of treatment-naïve early 
RA patients. Cytokine expression was measured using ELISA after three days of culture. Arrows indicate 
increasing concentrations and heatmaps represent the mean inhibiton per condition, for n=2-4 treatment-naïve 
early RA patients. 
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Altogether, the data from figures 4 and 5 show that combination with DEX, and to a lesser 
extent 1,25(OH)
2
D
3
, provide a beneficial effect over TNFα blockade alone in a model for 
synovial inflammation.
DISCUSSION
This study showed that 1,25(OH)
2
D
3
 and DEX can additively inhibit synovial inflammation 
modelled by CCR6+ memTh-RASF co-cultures. Furthermore, combining low doses DEX 
and 1,25(OH)
2
D
3
 with TNFα blockade demonstrated added value over TNFα blockade 
alone.
Similar to our previous results in PBMC and memTh cells11, 1,25(OH)
2
D
3
 was a stronger 
modulator of IL-17A, IL-22, IFNγ and IL-10 in CCR6+ memTh cells than DEX. This 
could be due to the reported resistance of CCR6+ memTh cells to cytokine inhibition and 
apoptosis induction by glucocorticoids (GC) 13. Interestingly, in asthma, GC resistance is 
increased with decreasing vitamin D serum levels.14 Since the vitamin D receptor (VDR) 
can enhance the activity of the glucocorticoid receptor at promoter sites, 1,25(OH)
2
D
3
 may 
be able to overcome GC resistance through this mechanism.15 Notably, in Crohn’s disease 
Th17.1 cells, one of the subpopulations within CCR6+ memTh cells, are the most GC-
resistant cells.16 Since these cells can also be found at the site of inflammation in juvenile 
idiopathic arthritis17 and RA (unpublished observations), further research into cell type-
specific modulation by GC may further elucidate its immunosuppressive actions in RA.
Independent of the differences in modulation of cytokines derived from CCR6+ memTh 
cells, either cultured alone or together with RASF, both 1,25(OH)
2
D
3
 and DEX inhibited 
the activation of synovial fibroblasts as demonstrated by the decreased IL-6, IL-8, MMP1, 
MMP3 and PGE2. These data suggested that DEX has strong direct effects on RASF, 
which was then confirmed by RASF only cultures. Although others have shown that 
1,25(OH)
2
D
3
 can inhibit MMP1 and MMP3 from RASF under IL-1β stimulation18, this was 
not observed in our cultures with stimulation of TNFα and IL-17A. Based on other studies 
that show that the VDR and GR can cooperate to enhance each other’s functions15,19, we 
expected synergistic effects of 1,25(OH)
2
D
3
 and DEX also in CCR6+ memTh cells or 
RASF. However, this synergy was not observed, except that TNFα could only be inhibited 
when 1,25(OH)
2
D
3
 and DEX were combined. Instead, the data indicate that 1,25(OH)
2
D
3
 
and DEX additively suppress inflammation through targeting different inflammatory 
pathways. 1,25(OH)
2
D
3
 indirectly reduces RASF activation through modulation of IL-17A 
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and could reduce activation of other immune cells, such as macrophages, by inhibiting 
IFNγ.20 DEX on the other hand directly affects the RASF and reduces immune cell 
activation, immune cell attraction and tissue destruction through regulation of IL-6, IL-8 
and MMPs, respectively. Finally, 1,25(OH)
2
D
3
 and DEX both are capable of inducing the 
anti-inflammatory cytokine IL-10, in CCR6+ memTh cell mono cultures or in co-culture 
with RASF, which could further contribute to inhibiting synovial inflammation.
Because of the strong immunomodulatory effects of 1,25(OH)
2
D
3
 and DEX, we postulated 
that they could be beneficial in the treatment of autoimmune diseases. This study 
demonstrated that especially DEX could augment the effect of TNFα blockade on RASF 
activation, even up to the point that no differences could be seen between the lowest and 
highest dose of anti-TNFα. Adding 0,1 nM 1,25(OH)
2
D
3
 did not contribute to this effect, but 
10 nM enhanced the effects of DEX and TNFα blockade. Although 0,1 nM is considered 
a physiological concentration, the actual concentration of 1,25(OH)
2
D
3
 in the synovium 
is unknown. Since it has been reported that immune cells are capable of converting 
25(OH)D
3
 into 1,25(OH)
2
D
3 
21,22, the local concentration at the site of inflammation of 
active vitamin D may be higher than 0,1 nM and therefore could contribute to the anti-
inflammatory effects of DEX and anti-TNFα.
Although these data indicate that combination of DEX and TNFα blockade could be 
beneficial in the treatment of RA, some limitations of this study should be considered. 
First of all, the current study has focused on an in vitro culture model with only T cells and 
RASF, whereas an inflamed joint also contains other cell types.23 Although 1,25(OH)
2
D
3
 
and DEX are both known for their wide range of immunomodulatory properties12,24, the 
exact effects that combining these with TNFα blockade may have not been investigated. 
Furthermore, the data suggest that dosage reduction of TNFα blockade could be possible 
upon combination with DEX, since there is no dose-dependent effect anymore. It should 
be noted that the physiological concentration of etanercept in the synovial fluid is not 
elaborately studied. One study found in two patients receiving 50 mg etanercept every 2 
weeks that after 5 weeks, so in between two dosages, the concentration of etanercept in 
the synovial fluid was around 20 ng/ml.25 However, one patient who received 50 mg every 
week had a concentration of 100 ng/ml after 5 weeks, suggesting that the concentration 
shortly after etanercept injection is in the range of the 0,1 µg/ml that was used in this 
study.25 The inhibitory effects of RASF activation by this dose of etanercept have been 
drastically enhanced by DEX and 1,25(OH)
2
D
3
.
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A final point to consider is that TNFα blockade has more effects than only suppressing 
RASF activation.26 Therefore, it is possible our in vitro model overlooks interactions that 
may arise between the compounds and a more complex environment. In order to study 
this, a clinical trial should be designed in which a low dose of DEX is combined with 
TNFα blockade. Due the perceived immunomodulatory effects of 1,25(OH)
2
D
3
, adding 
vitamin D supplements to this treatment will not only prevent the osteoporotic side effects 
of DEX, but it may also further enhance the therapeutic effects.
In conclusion, this study suggests an added value of combining 1,25(OH)
2
D
3
 with DEX for 
inhibiting synovial inflammation in RA patients through their distinct cell type-specific 
modulation properties. Furthermore, the findings in the CCR6+ memTh-RASF functional 
co-culture model provide a rationale for a clinical trial combining low dose of 1,25(OH)
2
D
3
 
and DEX with TNFα blockade to improve disease management in RA.
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Figure S1. 1,25(OH)
2
D
3
 and DEX minimally affect apoptosis in CCR6+ memTh cells. Sorted CCR6+ memTh 
cells were cultured for three days with or without 100 nM 1,25(OH)
2
D
3
 and 1000 nM DEX under stimulation of 
anti-CD3 and anti-CD28. On day 3, apoptosis was measured using 7AAD-AnnexinV staining. Early apoptosis 
is defined as AnnexinV+7AAD-, late apoptotic cells are AnnexinV+7AAD+ and the total percentage apoptotic 
cells is depicting all AnnexinV+ cells. The data show mean ± SEM of n=5 healthy controls, representative of 2 
independent experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
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Figure S2. Low doses of 1,25(OH)
2
D
3
 and DEX still modulate RASF activation by CCR6+ memTh cells. Co-
cultures of healthy CCR6+ memTh cells and RASF were treated with various concentrations of 1,25(OH)
2
D
3
 
or DEX, while the cells were stimulated with anti-CD3 and anti-CD28. After three days cytokine production 
was assessed using ELISA. Results represent n=2-3 healthy donors and show mean ± SEM. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001
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Figure S3. Complete data behind the heatmaps of figure 4. CCR6+ mTh-RASF co-cultures as described for figure 
2 were exposed to 10 nM DEX, 0.1 or 10 nM 1,25(OH)
2
D
3
, 0, 0.1, 1 or 10 μg/ml etanercept (anti-TNFα) or combina-
tions of the compounds as indicated. After three days, synovial fibroblast activation was measured through cytokine 
detection using ELISA. Data represent mean ± SEM for n=6 healthy donors on RASF from 2 different RA patients. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
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Figure S4. Complete data behind the heatmaps of figure 5. Co-cultures were set up as described for figure 4 
using RASF from established RA patients and allogeneic CCR6+ mTh cells sorted from PBMC of treatment-
naïve early RA patients. Cytokine expression was measured using ELISA after three days of culture. The 
graphs show mean ± SEM for n=2-4 treatment-naïve early RA patients. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001
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Parameters n=4
Age (years) 66.0 (11)
Female, n (%) 3 (75)
RF positive, n (%) 3 (75)
ACPA positive, n (%) 3 (75)
DAS 5.1 (0.6)
VAS global 63.8 (36.0)
ESR (mm/hr) 42 (29)
CRP 22 (17)
TJC44 19.8 (10.8)
SJC44 17.5 (7.0)
Disease duration (days) 155 (90)
Table S1. Characteristics of patients used in this study. Data are represented as mean (SD) unless otherwise 
indicated. Abbreviations: DAS, disease activity score for 44 joints; VAS, visual analogue scale; ESR, eryth-
rocyte sedimentation rate; CRP, c-reactive protein; TJC44, tender joint count of 44 joints; SJC44, swollen 
joint count of 44 joints.
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ABSTRACT
Background
In vitro studies have shown that vitamin D enhances the effects of etanercept in inhibiting 
synovial inflammation. Therefore, this study investigates if etanercept response is related 
to serum vitamin D (25(OH)D) levels in RA patients.
Methods
Data were used from the multicenter stratified single blinded randomized clinical trial 
(tREACH). RA patients, fulfilling the 2010 classification criteria, starting etanercept 
within the first 12 months of the study were included. Serum 25(OH)D levels were 
determined at start and after 3 months of treatment. Correlation coefficients between 
serum 25(OH)D, disease activity score (DAS) and EULAR response criteria were 
calculated.
Results
67 patients were included, of which 82% were female and respectively 67% and 73% 
were rheumatoid factor and ACPA positive. DAS after 3 months was weakly inversely 
correlated with serum 25(OH)2D3 after 3 months (r=-0.29, p=0.02) and the change in 
25(OH)2D3 during treatment (r=-0.25, p=0.04). EULAR response rate was lower in 
patients who were vitamin D-deficient at start of treatment (34.6% vs 59.4%) and in 
patients with decreasing 25(OH)D levels during treatment (39.2% vs 57.7%).
Conclusions
RA patients with a serum 25(OH)D level <50 nmol/L at start of etanercept or decreasing 
levels during treatment have a lower EULAR response rate. Therefore, vitamin D 
supplementation in vitamin D-deficient patients who start etanercept could increase their 
chance of adequate treatment response.
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INTRODUCTION
The treatment of rheumatoid arthritis (RA) has significantly improved since the 
introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). 
Although the variety of different modes of action that can be targeted with bDMARDs 
is increasing, the agents blocking tumor necrosis factor alpha (TNFα) are still the most 
widely used. Most patients respond well to these agents, but there is still a large group with 
an inadequate treatment response.1 It is currently unknown why some patients respond 
well and others do not, and how the response rate could be improved.
Vitamin D is a secosteroid hormone that is known for the extraskeletal effects, but is 
increasingly recognized for its other functions, including modulation of the immune 
system.2 Due to its wide array of immunomodulatory effects, it has also been linked to 
RA. Polymorphisms in the vitamin D receptor are associated with the risk of developing 
RA.3 Furthermore, the serum vitamin D level, as measured by 25-hydroxy-vitamin D3 
(25(OH)D3), is generally lower in RA patients than in healthy individuals and is negatively 
correlated with disease activity.4,5 
Interestingly, in vitro studies using a simplified model of synovial inflammation 
demonstrate that the active vitamin D metabolite 1,25(OH)
2
D
3
 optimizes the effect of 
etanercept, one of the TNFα blocking agents.6 This suggests that vitamin D could improve 
the response to etanercept in RA patients. In inflammatory bowel diseases it was already 
demonstrated that patients with low serum 25(OH)D levels have a decreased remission 
rate upon anti-TNFα treatment.7 Therefore, our aim is to investigate whether serum 
25(OH)D levels are associated with the initial etanercept response in RA patients.
METHODS
Patients
For this study, patients from the Treatment in the Rotterdam Early Arthritis Cohort 
(tREACH), a multicenter, stratified single-blinded randomized clinical trial, were used. 
The complete trial description has been previously published.8 In short, patients were 
included if age ≥18 years, arthritis ≥1 joint and symptom duration <1 year. They were 
stratified into low-, intermediate- and high-probability groups for their likelihood of 
progressing to persistent arthritis. Patients of the high-probability group were randomized 
into three initial treatment arms with or without a combination of conventional synthetic 
DMARDs, which always included MTX. Patients were examined every 3 months and a 
8
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disease activity score (DAS) was calculated for 44 joints. A treat-to-target approach was 
used, aiming for a DAS<2.4. If DAS>2.4, treatment was intensified, starting with MTX 
+ etanercept (50 mg/week, subcutaneously) and followed by other bDMARDs if DAS 
was still >2.4. The study protocol was approved by the medical ethics committee of all 
participating centers. For the present study, patients from the high-probability group who 
fulfilled the 2010 classification criteria for RA and started with etanercept during the first 
year of follow-up were included. 
Vitamin D measurements
Serum from patients at the start of etanercept (Tstart) and 3 months thereafter (Tstart+3) 
were stored at -80°C until 25(OH)D levels were determined. Serum 25(OH)D levels were 
measured using the Liaison 25 OH vitamin D TOTAL assay (DiaSorin, Stillwater, MN, 
USA) following manufacturer’s protocol in the LIAISON Analyzer (DiaSorin). 
Statistical analysis
Correlation between variables was determined by Pearson’s correlation coefficient. 
The relation between DAS and vitamin D levels were investigated with univariate and 
multivariate regression analyses. In the multivariate regression we corrected for DAS 
and serum vitamin D at Tstart. Treatment response was defined by the EULAR response 
criteria, which is determined with the attained DAS and its change from start.9 Differences 
in EULAR response rates per 25(OH)D stratum were analyzed using the Chi-Square test. 
Difference between vitamin D at Tstart and Tstart+3 was tested with Student’s T test. 
Statistical analyses were performed using STATA software version 15.1, and a p-value 
<0.05 was considered statistically significant.
RESULTS
In total 91 patients from the high-probability group started on etanercept within the first 
12 months after enrollment. In our study we included 67 patients of whom paired serum 
25(OH)D measurements at start of etanercept (Tstart) and 3 months thereafter (Tstart+3) 
were available (figure 1). Patient characteristics of the 67 included patients at Tstart and 
Tstart+3 are shown in table 1. Mean 25(OH)D levels were 55.0 ± 19.7 nmol/L and 51.0 
± 20.2 nmol/L for Tstart and Tstart+3, respectively, and were not significantly different 
(p=0.06). After 3 months of etanercept treatment, respectively 53.7%, 17.9% and 28.4% 
were classified as non-, moderate-, or good-responders according to the EULAR response 
criteria.
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Tstart (n=67) Tstart+3 (n=67)
Patient characteristics
Age, mean (SD) 53.8 (13.5)
Female gender, n (%) 55 (82.1)
Symptom duration (days) 282 (212-406) 
RF positive, n (%) 45 (67.2)
ACPA positive, n (%) 48 (72.6)
Disease activity
DAS(44) 3.0 (2.6-3.2) 2.4 (1.6-2.9)
TJC44 8 (5-13) 6 (2-9)
SJC44 4 (3-8) 2 (0-5)
VAS global 50 (35-69) 33 (20-52)
ESR (mm/hr) 17 (8-25) 12 (7-21)
Serum 25(OH)D (nmol/L), mean (SD) 55.0 (19.7) 51.0 (20.2)
Other medication
MTX, n (%) 64 (95.5)
Other csDMARD, n (%) 5 (7.5)
Corticosteroids, n (%) 5 (7.5)
Vitamin D supplements, n (%) 2 (3.0)
EULAR treatment response
No response, n (%) 36 (53.7)
Moderate response, n (%) 12 (17.9)
Good response, n (%) 19 (28.4)
Table 1. Demographics and patient characteristics  
Data reported are median (IQR) unless otherwise stated. Abbreviations: SD, standard deviation; IQR, 
interquartile range; RF, rheumatoid factor; ACPA, anti-citrullinated protein antibody; DAS(44), disease ac-
tivity score for 44 joints; TJC, tender joint count; SJC, swollen joint count; VAS, visual analog scale; ESR, 
erythrocyte sedimentation rate; MTX, methotrexate; csDMARD; conventional synthetic disease modifying 
antirheumatic drug
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Assessed for eligibility (n=797)
Randomized (n=568)
Study population (n=91)
Patients analyzed (n=67)
Declined to participate  n=115
Not meeting criteria   n=59
Not eligible due to recruitment stop n=30
Lost to follow-up   n=25
Patient selection:
 1. High probability stratum
 2. Rheumatoid arthritis according to 2010 criteria
 3. Starting etanercept during the 1st year of follow-up
Drop out (n=24):
 - No serum at Tstart (n=9)
 - No serum after 3 months (n=9)
 - No serum at either timepoint (n=6)
Figure 1. Flowchart of the study. 
There was no linear correlation between 25(OH)D at Tstart and DAS at Tstart+3 (r=-
0.08, p=0.51). However, vitamin D deficient patients (<50 nmol/L) at Tstart had a lower 
EULAR response rate than patients with higher 25(OH)D levels (figure 2A). EULAR 
none, moderate and high response was respectively seen in 65.4%, 19.2% and 15.4% of 
vitamin D deficient patients, compared to respectively 40.6%, 15.6% and 43.8% in patients 
with a 25(OH)D>50 nmol/L at Tstart.
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Figure 2. EULAR treatment response is decreased in vitamin D-deficient patients and patients with decreas-
ing serum 25(OH)D. (A) Percentage of EULAR non- (black), moderate (gray) and good (white) responders, 
stratified by serum 25(OH)D level below or above 50 nmol/L at Tstart. (B) as in (A), but stratified by decreasing 
or increasing serum 25(OH)D level during the treatment period. **p<0.01, ***p<0.001 by Chi-Square test.
Interestingly, the serum 25(OH)D levels at Tstart+3 were inversely correlated with the 
DAS at that timepoint (r=-0.29, p=0.02) even after correcting for DAS and 25(OH)D at 
Tstart (β=-0.011, p=0.03). This could be explained by the inverse correlation between 
the change in 25(OH)D during the treatment period and the DAS at Tstart+3 (r=-0.25, 
p=0.04), which was still found after correcting for DAS and 25(OH)D at Tstart (β=-0.015, 
p=0.03). As a result, patients whose 25(OH)D level decreased at Tstart+3 compared to 
Tstart (difference <0) had a lower rate of EULAR response than the patients whose 
25(OH)D levels increased (difference ≥0) (figure 2B). The EULAR response rates for 
none, moderate and good response were respectively 61.0%, 22.1% and 17.1% for patients 
with decreasing levels and 42.3%, 11.5% and 46.2% for patients with increasing 25(OH)
D levels.
DISCUSSION
In this study we found that both the serum 25(OH)D level after three months of etanercept 
treatment and the change in 25(OH)D during that period were inversely correlated with 
the DAS after three months of treatment. Furthermore, patients on etanercept who were 
vitamin D-deficient at the start of treatment or had decreasing 25(OH)D levels during 
treatment had a lower response rate.
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One study previously investigated a correlation between vitamin D and response to 
anti-TNFα therapy in RA by using a Mendelian randomization approach. They found a 
weak association between the change in DAS28 after anti-TNFα therapy and one of the 
SNPs that is related to serum 25(OH)D levels.10 The current study is the first to directly 
investigate the relation between serum 25(OH)D and the response to TNFα-blocking 
treatment in RA. 
There are several factors which may influence the results obtained in this study. Firstly, 
etanercept may directly affect serum 25(OH)D levels. However, this seems unlikely 
since two other TNFα-neutralizing agents, infliximab and adalimumab, do not affect 
serum 25(OH)D levels.11,12 Another factor that could play a role is the MTX treatment 
which most patients also use. Although it cannot be completely excluded that 25(OH)D 
influences MTX efficacy, all patients were on MTX before etanercept treatment and had 
an inadequate response. This points towards a relation with etanercept rather than MTX. 
Finally, it could be argued that  seasonal variation in 25(OH)D influence study results. 
Since patients were enrolled in the study throughout the year, seasonal variation may play 
a role in the change in 25(OH)D level during treatment. Similarly, a higher disease activity 
could may be related to reduced outdoor activities. However, if etanercept response and 
serum 25(OH)D are causally linked, it is not directly important whether the 25(OH)D 
levels are attained through sunlight exposure or another source.  
The finding that patients with vitamin D deficiency at initiation of etanercept of  have a 
lower response rate, indicates that vitamin D increases etanercept effectiveness. However, 
a causal relation can only be demonstrated by performing vitamin D supplementation 
studies. The few trials that have been performed give inconclusive results.2 One of the 
difficulties with such trials is that the threshold level of serum 25(OH)D for immunological 
effects is unknown. For healthy calcium metabolism, for example, the current guideline 
recommends a serum 25(OH)D level of at least 75 nmol/L.13 From the current study it 
seems that 50 nmol/L already increases therapeutic efficacy of etanercept, although the 
levels were generally low in this study and etanercept response might be even better 
with higher 25(OH)D levels. To address these questions, large multi-center clinical trials 
should be designed where patients are supplemented with vitamin D to reach (multiple) 
predefined serum 25(OH)D levels.
The data presented here support the in vitro findings that vitamin D augments the effects 
of etanercept.6 In this model, which contains T-helper-17 cells and RA synovial fibroblasts 
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(RASF), 1,25(OH)
2
D
3
 contributes to etanercept-mediated inhibition of RASF activation by 
efficiently suppressing Th17 cell pathogenicity. However, other cells in the inflamed joint, 
such as macrophages, can also respond to TNFα and 1,25(OH)
2
D
3
 and could therefore 
also be additively suppressed by vitamin D and etanercept.2,14
Overall, we demonstrated a relation between serum 25(OH)D levels and the initial 
etanercept response in RA patients. Importantly, RA patients who are vitamin D deficient 
have a lower response rate than those with a level higher than 50 nmol/L. Therefore, 
increasing the serum 25(OH)D level in vitamin D deficient patients could be important 
to optimize the treatment effects of TNFα blocking therapy.
8
220
Chapter 8
REFERENCES
1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388(10055):2023-38.
2. Dankers W, Colin EM, van Hamburg JP, et al. Vitamin D in Autoimmunity: Molecular 
Mechanisms and Therapeutic Potential. Front Immunol 2016;7:697.
3. Tizaoui K, Hamzaoui K. Association between VDR polymorphisms and rheumatoid arthritis 
disease: Systematic review and updated meta-analysis of case-control studies. Immunobiology 
2015;220(6):807-16.
4. Lee YH, Bae SC. Vitamin D level in rheumatoid arthritis and its correlation with the disease 
activity: a meta-analysis. Clin Exp Rheumatol 2016;34(5):827-33.
5. Lin J, Liu J, Davies ML, et al. Serum Vitamin D Level and Rheumatoid Arthritis Disease 
Activity: Review and Meta-Analysis. PLoS One 2016;11(1):e0146351.
6. van Hamburg JP, Asmawidjaja PS, Davelaar N, et al. TNF blockade requires 1,25(OH)2D3 
to control human Th17-mediated synovial inflammation. Ann Rheum Dis 2012;71(4):606-12.
7. Winter RW, Collins E, Cao B, et al. Higher 25-hydroxyvitamin D levels are associated with 
greater odds of remission with anti-tumour necrosis factor-alpha medications among patients 
with inflammatory bowel diseases. Aliment Pharmacol Ther 2017;45(5):653-59.
8. Claessen SJ, Hazes JM, Huisman MA, et al. Use of risk stratification to target therapies in 
patients with recent onset arthritis; design of a prospective randomized multicenter controlled 
trial. BMC Musculoskelet Disord 2009;10:71.
9. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin 
Exp Rheumatol 2005;23(5 Suppl 39):S93-9.
10. Yarwood A, Viatte S, Plant D, et al. Testing the role of vitamin D in response to antitumour 
necrosis factor alpha therapy in a UK cohort: a Mendelian randomisation approach. Ann 
Rheum Dis 2014;73(5):938-40.
11. Welsh P, Peters MJ, McInnes IB, et al. Vitamin D deficiency is common in patients with RA 
and linked to disease activity, but circulating levels are unaffected by TNFalpha blockade: 
results from a prospective cohort study. Ann Rheum Dis 2011;70(6):1165-7.
12. Augustine MV, Leonard MB, Thayu M, et al. Changes in vitamin D-related mineral 
metabolism after induction with anti-tumor necrosis factor-alpha therapy in Crohn’s disease. 
J Clin Endocrinol Metab 2014;99(6):E991-8.
13. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention 
of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol 
Metab 2011;96(7):1911-30.
14. Vasanthi P, Nalini G, Rajasekhar G. Role of tumor necrosis factor-alpha in rheumatoid 
arthritis: a review. APLAR Journal of Rheumatology 2007;10(4):270-74.
221
Improved etanercept response with non-deficient or increasing serum vitamin D levels in RA
8
Chapter 9
General discussion
Chapter 9
General discussion
224
Chapter 9
In the past decades the treatment of RA has drastically improved, but a large group 
of patients does not sufficiently respond or becomes resistant to treatment over time.1 
Therefore, there is still a need for new therapeutic targets and improvement of current 
treatment strategies. CCR6+ memory T-helper (memTh) cells, including Th17 and Th17.1 
cells, are pro-inflammatory IL-17A-producing Th cells, which are thought to play a role 
in RA pathogenesis through activation of synovial fibroblasts2, aberrant stimulation of 
B cells leading to pathogenic antibody production3 and secretion of pro-inflammatory 
cytokines such as TNFα and IFNγ that activate other immune cells.4 Therefore, these 
cells provide interesting targets for therapeutic modulation. In this thesis we studied the 
modulation of murine Th17 cells and human CCR6+ memTh cells by the active vitamin 
D metabolite 1,25(OH)
2
D
3
 and how this could be applied for improving current therapies. 
This chapter discusses the results obtained with regards to the molecular mechanisms 
that have been elucidated (figure 1) and the therapeutic potential that can be derived from 
these studies.
Molecular mechanisms behind 1,25(OH)2D3-mediated Th17 modulation
The role of IL-4 and IL-10 in the effects of 1,25(OH)2D3 on murine Th17 cells from CII-
immunized mice
We and others have previously demonstrated the capacity of 1,25(OH)
2
D
3
 to suppress the 
pathogenicity of IL-17A-producing T helper cells.5-7 On the other hand, it has also been 
shown that 1,25(OH)
2
D
3
 can promote the development of Th2 cells and regulatory T cells 
(Tregs) from naïve CD4+ T cells or the total CD4+ T cell population.5,8-11 In chapter 
3 we show that in CD4+ T cells 1,25(OH)
2
D
3
 can induce IL-4 and IL-10, associated 
with Th2 cells and Tregs, respectively, under Th17 polarizing conditions. Interestingly, 
this induction was only observed when the CD4+ T cells were cultured in a splenocyte 
culture enriched for CD4+ T cells, but not when either CD62L+ Th or TEFF/EM cells were 
cultured separately. This suggests an indirect induction of IL-4 and IL-10 by 1,25(OH)
2
D
3
, 
in which it modulates other cells in the splenocyte culture that subsequently promote 
IL-4 and IL-10 production in the Th cells. Although T cells produce both IL-4 and 
IL-10 in response to IL-4 itself12, it not likely that IL-4 from other splenocytes causes 
this induction because the cells were cultured in the presence of an IL-4-neutralizing 
antibody. Production of IL-4 and IL-10 can also be promoted upon interaction between 
Inducible T-cell Costimulator (ICOS) on T cells and ICOS-ligand on for example antigen-
presenting cells.13 However, there is currently no data on the effects of 1,25(OH)
2
D
3
 on 
either ICOS or ICOS-ligand. Therefore, this is an interesting angle for future research 
into the immunomodulatory effects of 1,25(OH)
2
D
3
.
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Figure 1. Schematic overview of the current ideas on 1,25(OH)
2
D
3
-mediated inhibition of CCR6+ memTh 
cells and RASF activation.
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From the data in chapter 3 it could not be concluded that 1,25(OH)
2
D
3
 directly promotes 
a Th2-like phenotype in Th17 cells. Interestingly, we did observe that IL-4 can augment 
the effects of 1,25(OH)
2
D
3
 through VDR upregulation, whereas IL-10 does not play a role 
in IL-17A and IL-17F inhibition.  Combined with previous findings that VDR stimulation 
decreases IL-4 production, but also that IL-4 is diminished in VDR-deficient mice, the 
data from this study indicate a regulated balance between IL-4 and VDR.14,15 Such a 
balance would not only explain the findings in this study that adding more IL-4 above 
a certain level is not beneficial anymore, but also provides some insight into the debate 
surrounding the effects of 1,25(OH)
2
D
3
 on IL-4.16
Whether the induction of IL-4 on T cells, either direct or indirect, contributes to the 
1,25(OH)
2
D
3
-mediated suppression of disease in CIA and other autoimmune models 
remains to be determined. In EAE, 1,25(OH)
2
D
3
 cannot prevent disease in IL-4-deficient 
mice but this has been attributed to natural killer T (NKT)-cell-derived IL-4 production. 
Since NKT cell activation has proven beneficial in CIA, this may also be a mechanism 
for 1,25(OH)
2
D
3
 to suppress autoimmune arthritis.17 Also for human RA, it needs to be 
studied whether IL-4 can augment the effects of 1,25(OH)
2
D
3
 similar to mouse cells, and 
whether this mechanism is specific for arthritis or can also be found in other autoimmune 
diseases and healthy conditions.
Pathogenicity of IL-17A-producing CCR6+ memTh subpopulations in RA
In human peripheral blood, Th17 cells are found within the CCR6-expressing memory 
Th cells, which also contain Th17.1, CCR4/CXCR3 double-positive (DP) and CCR4/
CXCR3 double-negative (DN) cells.4 In autoimmune disease such as MS and Crohn’s 
disease there is increasing evidence suggesting that Th17.1 rather than Th17 cells are 
the pathogenic cell types.18,19 In rheumatoid arthritis it is not entirely clear whether all 
subpopulations are pathogenic and should be targeted to reduce joint inflammation. 
Therefore, we studied whether there is a difference in potential of CCR6+ memTh cells 
to activate RASF (chapter 4). 
Despite differences in expression of cytokines such as IL-17A and IFNγ, all subpopulations 
could activate RASF. Interestingly, they did differ in the level of individual factors they 
stimulated in the RASF. It is not completely clear where these differences come from, but 
it could be through cytokine expression. For example, IL-17A is a more potent inducer 
of IL-6 than of MMP1 (chapter 7) and could therefore explain some of the differences 
between Th17 and Th17.1 cells. Furthermore, since 1,25(OH)
2
D
3
 inhibits all memTh-
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derived cytokines (except GM-CSF), it is also possible that a combination of cytokines 
is required for the full pro-inflammatory loop. However, even in the cultures that were 
treated with 1,25(OH)
2
D
3
 there was still some activation of RASF compared to baseline, 
suggesting that cell-cell interaction is an important part of the pro-inflammatory feedback 
loop in the CCR6+-RASF co-cultures.
Interestingly, the differences between CCR6+ memTh subpopulations in terms of cytokine 
induction in RASF are less pronounced when studying the cells from treatment naïve 
early RA patients. This suggests that, although they follow roughly the same pattern in 
expression of IL-17A, IFNγ, RORC and TBX21, the cells from RA patients are different 
from those of healthy individuals. Considering the hypothesis that cell-cell interaction 
via adhesion molecules is an important part of the pro-inflammatory loop between 
RASF and CCR6+ memTh cells, it would be interesting to study the differences in for 
example VCAM-1 and VLA-1 between cells from RA patients and healthy individuals. 
Furthermore, using techniques such as RNA-sequencing could provide more clues on the 
differences between the cells from RA patients and healthy individuals.
Since all subpopulations can activate RASF, these data do not indicate that Th17.1 cells 
would be particularly pathogenic in the context of RA. Therefore, it is of clinical interest 
to block all CCR6+ memTh subpopulations and their interaction with RASF. In chapter 
4 we explored briefly which factors could be targeted and found that blocking IL-17A, but 
not IFNγ or T-bet, reduced RASF activation even in Th17.1-RASF cultures where IL-17A 
levels were low. However, blocking IL-17A did not stop the activation of the T cells by 
RASF, because T cell-derived cytokines were not diminished. Interestingly, 1,25(OH)
2
D
3
 
did reduce both RASF activation and T cell cytokine production in all subpopulations, 
suggesting that either multiple cytokines together drive the pro-inflammatory loop or 
that cell-cell interaction is a mechanism that is also targeted by 1,25(OH)
2
D
3
. Of course, 
it could also be a combination of these scenarios. 
A mechanism that was not studied here was the role of TNFα in the activation of RASF by 
the individual subpopulations. Previous studies have shown that TNFα does play a role in 
the pro-inflammatory loop between RASF and CCR6+ memTh cells.6 Furthermore, TNFα 
and IL-17A enhance each other in RASF activation which could state a more pathogenic 
role for those cells that express both.20 Therefore, it may be interesting to study TNFα 
expression within the subpopulations.
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The finding that all CCR6+ memTh subpopulations have pathogenic potential does 
not mean that it is not interesting anymore to study them separately. First of all, the 
model for synovial inflammation that was used here is simplified, with only RASF and 
CCR6+ memTh cells. Of course, the inflamed joint harbours many more cell types 
than just these two, and they all interact to perpetuate chronic synovial inflammation.21 
Therefore we cannot definitively conclude that the subpopulations contribute equally to 
synovial inflammation, since certain subpopulations may be more potent activators or 
other lymphocytes, myeloid cells or osteoclasts. Another consideration to keep studying 
separate subpopulations is that it was found in Crohn’s disease that Th17.1 cells expressed 
higher levels of MDR1, making them resistant to glucocorticoid treatment.18 Such a 
difference could also be present within cells in RA patients and could also be of clinical 
interest. Interestingly, studies in asthma have shown that vitamin D serum levels are 
inversely correlated with glucocorticoid response.22 Furthermore, 1,25(OH)
2
D
3
 reversed 
drug resistance in leukemic cell lines via inhibition of MDR1 and MRP1.23 These data 
implicate that 1,25(OH)
2
D
3 
could reduce the drug resistance in T cells and thereby make 
therapy more efficient. 
Overall, chapter 4 clearly demonstrates that all CCR6+ memTh subpopulations could play 
a role in RA pathogenesis and should be targeted. Furthermore, since all subpopulations 
are effectively modulated by 1,25(OH)
2
D
3
, these data further support the interest for the 
immunomodulatory actions of 1,25(OH)
2
D
3
 on CCR6+ memTh cells in the context of RA.
Shift from a pro- to an anti-inflammatory phenotype in 1,25(OH)2D3-treated human 
CCR6+ memTh cells
Since it was clear from chapter 4 that all CCR6+ memTh cells should be modulated to 
fully suppress synovial inflammation, we further studied the changes that are induced 
upon 1,25(OH)
2
D
3
 treatment in the complete  CCR6+ memTh population in chapter 5. 
Others have previously shown that 1,25(OH)
2
D
3
 promotes the differentiation of regulatory 
T cells (Tregs) within the total CD4+ population9,24, and in chapter 3 we found that 
1,25(OH)
2
D
3
 elevates IL-10 in Th17 cells. Therefore, we investigated whether 1,25(OH)
2
D
3
 
could induce a regulatory phenotype in human CCR6+ memTh cells. 
Interestingly, in the sorted human CCR6+ memTh cells from both healthy individuals 
and treatment-naïve early RA patients not only IL-10 was induced, but also other markers 
associated with Tregs and type 1 regulatory T (Tr1) cells (chapter 5). Importantly, the 
activation of a regulatory-like gene signature was accompanied by functional suppressive 
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capacities since 1,25(OH)
2
D
3
-treated CCR6+ memTh cells inhibited proliferation of 
autologous CD3+ T cells (chapter 5). 
The finding that committed pro-inflammatory memory Th cells are capable of transitioning 
into anti-inflammatory cells with functional suppressive capacity is something that is 
not only novel in the context of 1,25(OH)
2
D
3
-mediated immunomodulation, but also in 
the concepts of human T cell biology. Th cells are generally considered to be highly 
plastic, where for example Th17 cells easily acquire Th1- or Th2-like characteristics and 
Tregs start producing IL-17A upon the right stimulation.25 Furthermore, it was shown in 
murine self-resolving inflammation that IL-17A-producing cells start producing IL-10 
and contribute to the resolution of inflammation.26 Also, it is known that human CCR6+ 
memTh cells can produce IL-10 and limit their own proliferation under suboptimal TCR 
stimulation and low IL-2 availability.27 Here we show for the first time that is possible to 
switch the phenotype of fully stimulated CCR6+ memTh cells from pro-inflammatory 
to anti-inflammatory, with functional regulatory capacity. Since our data indicate that 
1,25(OH)
2
D
3
 induces this change in CCR6+ memTh cells, this could be one of the 
mechanisms through which 1,25(OH)
2
D
3
 normalizes an immunological imbalance, 
contributes to resetting the pro-inflammatory environment and thereby prevents the 
progression of arthritis as shown in murine models.
Assuming that 1,25(OH)
2
D
3
 actually contributes to resolution of inflammation through 
modulation of pro-inflammatory cells, this is a mechanism that could be hijacked to serve 
as a therapeutic target. For that, it is crucial to understand the molecular mechanisms 
behind the change in cell phenotype. This could be of interest for autoimmune and 
inflammatory diseases in which the immune response is not properly controlled and the 
shift from pro- to anti-inflammatory cells needs to be promoted.28 On the other hand, in 
cancer the problem is usually the other way around with too much Tregs and not enough 
Th17 and other pro-inflammatory cells, leading to tumour growth.29 In these situations, 
exploiting the knowledge on the mechanism that alters the T cell balance from pro- to anti-
inflammatory could help to prevent development of anti-inflammatory cells and thereby 
reduce tumour growth.
An important consideration for investigating the mechanism is whether all CCR6+ memTh 
cells can acquire this anti-inflammatory phenotype. In chapter 4 we have shown that 
the subpopulations do not differ in their capability of RASF activation and that they 
were all influenced by 1,25(OH)
2
D
3
, but the induction of IL-10 in all of these subsets was 
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not yet investigated. It is also of interest to determine whether the change induced by 
1,25(OH)
2
D
3
 is really a conversion from IL-17A-producing cells towards IL-10-producing 
cells, or rather an expansion of the already existing IL-10-producing CCR6+ memTh cells. 
Defining which cells are capable of converting towards anti-inflammatory cells is not 
only important for understanding the mechanism, but also for the potential therapeutic 
application which will be discussed later in this chapter. Furthermore, detailed gene 
expression analysis should provide more insight into which molecules are changed by 
1,25(OH)
2
D
3
 that are responsible for the anti-inflammatory phenotype. It would be of 
interest to see if these are molecules similar to the ones that distinguish pathogenic from 
non-pathogenic Th17 cells in mice.30
Overall, the data in chapters 3 and 5 show that 1,25(OH)
2
D
3
 does not directly induce a 
Th2-like phenotype in Th17 cells, but that it can switch them towards a functional anti-
inflammatory phenotype with regulatory capacity resembling Tr1 and Treg cells.
Stability of the 1,25(OH)2D3-induced phenotype in CCR6+ memTh cells in vitro
For the phenotypical changes described in this thesis to be beneficial in vivo, the cells 
should not switch back to a pro-inflammatory program when 1,25(OH)
2
D
3
 is absent or 
immune-stimulating conditions are encountered. In chapter 6 we demonstrated that the 
reduction of pro-inflammatory cytokines induced by 1,25(OH)
2
D
3
 is stable upon exposure 
to various types of restimulation, including low- and high-strength TCR signalling, the 
Th17-stimulating cytokines IL-1β and IL-23 and RA synovial fluid. Importantly, the 
1,25(OH)
2
D
3
-treated cells also retained their suppressive capacity in the presence of RA 
synovial fluid (chapter 5). 
Although this seems promising for the in vivo suppressive capacity of 1,25(OH)
2
D
3
-
treated CCR6+ memTh cells, it should be kept in mind that the conditions in synovial 
fluid may not reflect those in synovial tissue.31 However, synovial fluid can represent 
disease-specific conditions, since the protein in fluid from RA patients is different from 
that of osteoarthritis patients.32  Another issue to take into account is that IL-1β, but also 
some RA synovial fluids, increased the amount of IL-17A that was secreted in the culture 
supernatant. This is probably due to its effects on the cells that did not lose their IL-17A-
producing capacity and are still susceptible to the IL-1β-mediated modulation. These 
findings further emphasize the need to investigate exactly which populations within the 
CCR6+ memTh cells switch to an anti-inflammatory cell and which populations are not 
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affected. Furthermore, in vivo studies are required to fully elucidate the extent of the 
stability of the 1,25(OH)
2
D
3
-induced phenotype.
The phenotype of Th cells is not only directed by transcription factors and exogenous 
cytokines, but also by the epigenetic landscape at the level of histones and DNA.33,34 
Interestingly, 1,25(OH)
2
D
3
 affects the expression of histone demethylase genes and also 
can affect gene expression, including IL-17A, through modulation of DNA methylation 
and histone modification.7,35,36 In line with these data, we found in chapter 6 that the 
recruitment of HDAC is required for 1,25(OH)
2
D
3
 to inhibit not only IL-17A, but also 
IL-17F, IL-22 and IFNγ. Since IL-17A and IL-17F are located on chromosome 6 while 
IL-22 and IFNγ are encoded on chromosome 12, this indicates that the recruitment of 
HDAC is a general mechanism by which 1,25(OH)
2
D
3
 alters gene transcription. The 
epigenetic changes caused by these HDACs may underlie the stability of 1,25(OH)
2
D
3
-
induced phenotype. To investigate this, analysis of histone modifications is required after 
treatment, but also after withdrawal of 1,25(OH)
2
D
3
. Ideally, this would be done using 
chromatin immunoprecipitation followed by sequencing (ChIP-seq) for specific histone 
modifications such as H3K4me3 and H3K27Ac. However, this requires large numbers of 
primary CCR6+ memTh cells that can only be obtained after in vitro expansion, which 
slightly alters the phenotype of the cells and possibly also the epigenetic marks. For 
example, using the expansion method described in chapter 4 for studying the shRNA-
mediated knockdown of TBX21 the cells retain their cytokine production, but 1,25(OH)
2
D
3
 
cannot modulate IFNγ expression anymore. Therefore, this method may not be useful 
for studying the epigenetic modifications that were made by 1,25(OH)2D3. Another 
possibility is to perform an assay for transposase-accessible chromatin using sequencing 
(ATAC-seq), which requires much less cells and gives an indication of which sites are 
accessible at a given time.37 Thereby, it is an indirect measure of the histone modifications 
and the functional changes in the accessibility of gene loci upon 1,25(OH)
2
D
3
 treatment.
Aside from HDAC, also other histone modifiers may play a role in the effects of 
1,25(OH)
2
D
3
 and DNA methylation may also be involved. Another epigenetic mechanism 
that should not be overlooked is micro-RNA (miRNA)-mediated gene regulation. The 
small pieces of RNA, generally 19-21 nucleotides in length, target specific messenger 
RNAs and thereby destabilize the mRNA and prevent their translation into protein. In a 
rat model for MS, 1,25(OH)
2
D
3
 changed the pattern of miRNA expression together with 
a shift in the DNA methylation.38 Also in rheumatoid arthritis, miRNAs are thought 
to play a role and certain miRNAs are associated with the risk for progressing from 
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systemic autoimmunity to RA.39,40 Functionally, it was shown that 1,25(OH)
2
D
3
 inhibited 
proliferation and cytokine production of synovial fibroblasts at least partially via inhibition 
of miR-22.41 
Extensive studies are required to examine the epigenetic changes induced by 
1,25(OH)
2
D
3
 and how they contribute to the altered phenotype of CCR6+ memTh 
cells. This will elucidate the molecular mechanisms involved in 1,25(OH)
2
D
3
-mediated 
immunomodulation and provide opportunities to exploit these processes for treatment of 
RA and other autoimmune disease.
Suppression of RA through 1,25(OH)2D3-treated CCR6+ memTh cells 
The finding that 1,25(OH)
2
D
3
 induces a stable anti-inflammatory phenotype in Th17 cells 
led us to the question whether these cells could potentially contribute to suppression of 
synovial inflammation. Although the chemokine receptor profile of 1,25(OH)
2
D
3
-treated 
CCR6+ memTh cells differed from the control-treated cells, they still migrate towards 
synovial fluid and hence can still go towards the site of synovial inflammation (chapter 5). 
The big question that remains is whether this hold true in vivo, since chemokine receptors 
are usually not exclusively associated with a specific anatomical site. Many chemokine 
receptors are expressed on the surface of both treated and untreated CCR6+ memTh cells, 
and the ratio within these receptors is likely what determines where they will migrate to.42 
An interesting observation in our data is that CCR7 is increased in 1,25(OH)
2
D
3
-treated 
CCR6+ memTh cells from both RA patients and healthy individuals. CCR7 is important 
for homing to secondary lymphoid organs and it is required for Tregs to perform their 
suppressive function.43 Therefore it is possible that 1,25(OH)
2
D
3
-treated CCR6+ memTh 
not only migrate towards synovial fluid, but also to the lymph node. A recent study has 
shown that Th17 cells in the secondary lymphoid organs contribute to the development 
of pathogenic antibodies through IL-22-mediated B cell activation.3 Since 1,25(OH)
2
D
3
 
also reduces the amount of IL-22 by CCR6+ memTh cells, treated cells that migrate to 
the joint also cannot stimulate pathogenic antibody production anymore. What these 
changes effectively mean in the in vivo context of an autoimmune diseases remains to 
be determined.
Inside the rheumatic joint, one of the pathogenic functions of CCR6+ memTh is the 
activation of synovial fibroblasts (RASF).2 Assuming that 1,25(OH)
2
D
3
-treated CCR6+ 
memTh cells migrate towards the joints, it is important that they do not activate RASF 
anymore to prevent perpetuation of the synovial inflammation. In chapter 6 we 
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demonstrate that CCR6+ memTh cells that have been exposed to 1,25(OH)
2
D
3
 are less 
capable of activating RASF than untreated cells. However, there is still a higher level of 
IL-6, IL-8 and MMPs than unstimulated RASF produce (see also chapter 7). It could be 
that some of the treated cells still express IL-17A and other factors that are important for 
RASF activation. Therefore, studying exactly which populations within CCR6+ memTh 
cells convert to anti-inflammatory cells as mentioned in previous parts of this discussion 
is required before this mechanism can be used for therapeutic purposes.
Together, these findings and the data from previous studies show that the three most 
important pathogenic roles of CCR6+ memTh cells, i.e. production of pro-inflammatory 
cytokines, aberrant B cell stimulation and RASF activation, are potentially all addressed 
through treatment with 1,25(OH)
2
D
3
.5-7 
Therapeutic potential of vitamin D
Improvement of treatment response through vitamin D
Given the plethora of immunomodulatory effects of 1,25(OH)
2
D
3
, not just on T cells 
but on all immune cells, it would seem like an attractive agent to improve therapeutic 
response in patients (chapter 2). Based on our own and published data, direct vitamin 
D supplementation cannot be seen as an independent therapy, but it could potentially be 
used as an additive to improve the current treatment strategies.
Previously, we have shown that 1,25(OH)
2
D
3
 and DEX can cooperate to inhibit cytokine 
production from memTh cells. Using the functional co-culture model containing RASF 
and CCR6+ memTh cells we investigated the interaction between 1,25(OH)
2
D
3
 and DEX 
in chapter 7. These experiments demonstrated that while 1,25(OH)
2
D
3
 predominantly 
modulates the Th cells, DEX has its strongest effects on RASF. Due to this additive 
effect 1,25(OH)
2
D
3 
and DEX could also improve the effects of anti-TNFα. Interestingly, 
DEX was much more potent than etanercept in inhibiting RASF activation, especially 
for MMP1 and MMP3. This could be an explanation for the strong beneficial effects of 
glucocorticoids on the progression rate in RA.44
Although our study revealed that a low dose of DEX is already enough to exert the potent 
suppression of RASF activation, long-term treatment with DEX or other glucocorticoids 
is still associated with side effects.45,46 Similar to what is being done with vitamin D, it has 
also been studied how the beneficial effects of glucocorticoids can be exploited without 
the metabolic side effects. Thereby glucorticoid-induced leucine zipper protein (GILZ) 
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was identified as a primary glucocorticoid target, which was subsequently demonstrated 
to be important for the development of various autoimmune diseases including RA.47 If 
GILZ has similar effects on RASF as DEX, then it may be worth investigating targeting 
this protein in combination with current bDMARDs, instead of using DEX.
From the data described in chapter 7 regarding the triple-treatment with etanercept, 
DEX and 1,25(OH)
2
D
3
 it seems that the addition of 1,25(OH)
2
D
3
 has little beneficial 
immunomodulatory effects with regards to RASF activation. Although DEX treatment 
will always be combined with vitamin D supplementation to prevent osteoporotic side 
effects, it is also still likely that vitamin D has additional immunomodulatory properties 
that can contribute to the resolution of inflammation. Firstly, 1,25(OH)
2
D
3
 was the most 
potent inhibitor of T cell derived cytokines in the RASF-CCR6+ coculture. This is not 
only for IL-17A, but also other pro-inflammatory cytokines such as IL-22 and IFNγ 
which may stimulate other immune cells at the site of inflammation such as B cells and 
macrophages.3,48 Furthermore, as described in chapters 5 and 6, 1,25(OH)
2
D
3
 switches 
the pro-inflammatory CCR6+ memTh cells into stable anti-inflammatory cells. This could 
normalize the immunological balance and thereby not only reduce the acute inflammation 
but potentially also provide a long-term effect. Finally, as discussed in the previous 
section, 1,25(OH)
2
D
3
 might be beneficial by overcoming glucocorticoid resistance and 
thereby make DEX even more potent.
Although these studies seem promising for a clinical trial investigating the combination 
of DEX, vitamin D and TNF-blockade, we have to keep in mind that the culture model 
of RASF and CCR6+ memTh is a simplified representation of synovial inflammation, 
as stated before. Therefore, the effect of TNFα blockade could be underestimated due 
to the absence of for example myeloid cells, given its broad immunomodulatory effect 
in patients.49 On the other hand, almost all immune cells that are present in the joint 
have been reported to be modulated by 1,25(OH)
2
D
3
 as described in chapter 2. DEX 
also has potent immunosuppressive effects on other immune cells, including myeloid 
cells and B cells.50 This led us to the conclusion that there is a rationale to combine 
low dose glucocorticoids, such as DEX, with a TNFα-blocking agent and vitamin D 
supplementation.
As a first glance on what increasing serum 25(OH)D
3
 levels would do to the treatment 
response for TNFα blockade, we studied the correlation between serum 25(OH)D
3
 levels 
and response to etanercept (chapter 8). There we found that the response rate upon 
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etanercept treatment is lower in both patients who were vitamin D-deficient at the start of 
treatment and in patients who had decreasing serum 25(OH)D
3
 levels during the 3-month 
treatment period.
The first question that comes to mind with these data is whether the 25(OH)D
3
 is 
determined by the amount of inflammation and is thus a consequence of therapeutic 
efficacy rather than a contributing factor. This could explain the correlation between 
the change in 25(OH)D
3
 and the disease activity score (DAS). However, treatment with 
adalimumab did not affect circulating 25(OH)D
3
 levels (46.3 nmol/L vs. 47.5 nmol/L) 
despite a decrease in overall disease activity.51 Furthermore, the finding that the starting 
25(OH)D
3
 seems important for the etanercept response rate suggest that there may a 
causative relation. Supplementation studies could be used to investigate this, but as 
described in chapter 2, these will need to be large multicentre trials that supplement 
vitamin D to reach a certain serum level rather than give a fixed dose to each patient.
Although the current study suggests that a serum 25(OH)D
3
 above 50 nmol/L is associated 
with a higher response rate, this does not mean that this is the optimal level for everyone. 
One thing that should be taken into account is calcium intake, since a higher intake 
reduces serum parathyroid hormone (PTH), which leaves more 25(OH)D
3
 available for 
conversion to 1,25(OH)
2
D
3
 and hence immunomodulatory effects.52 The clinical trials 
mentioned before that aim at a fixed serum level should provide more insight into this 
matter.
Overall, the data from chapters 7 and 8 provide grounds for at least vitamin D 
supplementation in vitamin D-deficient patients upon start with etanercept. Furthermore, 
adding a low dose of DEX may further improve the therapeutic response. 
The transfer of autologous 1,25(OH)2D3-treated CCR6+ memTh cells as a therapy
As mentioned previously, 1,25(OH)
2
D
3
 does not only affect CCR6+ memTh cells, 
but also many other cell types within the immune system. In that context, it has been 
demonstrated that 1,25(OH)
2
D
3
 induces an irreversible tolerogenic phenotype in DCs.53,54 
As a result, antigen-specific DCs that have been treated with 1,25(OH)
2
D
3
 and DEX are 
now investigated as a therapeutic possibility in autoimmune diseases, including RA.55,56 
A phase I clinical trial has demonstrated that these tolDCs were safe and are interesting 
for future investigation for therapeutic efficacy.57 Therefore, it is tempting to consider a 
similar approach with 1,25(OH)
2
D
3
-treated CCR6+ memTh cells, in which the cells are 
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isolated from peripheral blood from patients, treated with 1,25(OH)
2
D
3
in vitro and then 
given back to the patients. However, there are some hurdles to overcome before this can 
be brought into clinical trials. 
First of all, we need to make sure that the effects of 1,25(OH)
2
D
3
 are stable in vivo and 
that the cells actually contribute to inhibiting synovial inflammation. This should be done 
in murine arthritis models, such as collagen-induced arthritis. A difficulty with these 
kinds of studies is the low number of CCR6+ memTh cells you can get from the spleen of 
immunized mice, let alone from the peripheral blood. Therefore, before this can be tested 
we require a protocol to expand the CCR6+ memTh cells in vitro without changing their 
phenotype, which could also be applied to the human situation.
Another point of concern is that not all CCR6+ memTh cells seem to be affected by 
1,25(OH)
2
D
3
, as proven by the finding that there are still IL-17A-producing and IFNγ-
producing cells within the treated cultures. To avoid the clinical use of these pro-
inflammatory cells that can still respond to pro-inflammatory stimuli, the cells that have 
been affected need to be selected. One way to do that is to generate T cell clones from 
treated CCR6+ memTh cells and screen them for the desired properties.58 This would also 
overcome the limitation of cell numbers, since Th clones expand rapidly under the right 
conditions. For this to be applicable, it may be important to select the proper TCR for 
the antigens that are fuelling the synovial inflammation, similar as is being investigated 
for the tolDCs. That being said, in CIA transfer in vitro-expanded polyclonally activated 
Tregs reduced disease activity.59
Overall it seems that the therapeutic delivery of 1,25(OH)
2
D
3
-treated T cells is at the 
moment far from clinical application. However, the potential benefits warrant extensive 
studies to explore this field as an independent therapy, but possibly also in combination 
with the delivery of tolDCs.
General remarks
In this thesis we explored the modulation of CCR6+ memTh and Th17 cells by the active 
vitamin D metabolite 1,25(OH)
2
D
3
 and how this could be exploited for therapeutic use. 
Aside from the issues discussed previously, there are a few general points that need to be 
kept in mind when interpreting the data.
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An important issue that has arisen during the past years is the debate about the role 
of Th17 cells in RA. Despite all the in vitro and murine in vivo indications that Th17 
cells should be targeted in RA patients, the clinical trials blocking the IL-17A-signaling 
pathway have been disappointing in RA.60-63 This could be due to the selection of patients, 
which were established RA patients, but it could also mean that IL-17A and the related 
pathways are mainly important at earlier stages in the disease. Considering the data that 
Th17 cells are important for the development of pathogenic autoantibodies and for the 
activation of RASF, it can be hypothesized that these cells are mainly important in the 
onset of systemic and synovial inflammation and not necessarily in the perpetuation of 
the disease. Another explanation for the disappointing effects of IL-17A blockade in RA is 
that cytokine secretion is not the only way through which Th17, or other CCR6+ memTh 
cells contribute to synovial inflammation, as implicated in chapters 4 and 7. Cell-cell 
interaction between the Th cells and RASF also contributes to this activation, and may 
also need to be targeted to get full resolution of inflammation.
Another point of consideration is that in most of the in vitro studies the cells from healthy 
individuals instead of RA patients were used due to the limited availability of RA cells 
and the high number of cells required for experiments. In chapter 3 and 4 we had the 
possibility to compare gene expression levels between healthy and RA cells. Although 
we did not find substantial differences, RA cells are generally more activated and the 
RA CCR6+ memTh subpopulations appear different in their capacity to activate RASF.2,5 
Furthermore, the effects of 1,25(OH)
2
D
3
 might be slightly different between the cells from 
healthy individuals and RA patients, since for example IL-23R was not downregulated in 
the healthy cells but was inhibited in the RA cells. This could be due to the heightened 
activation of the RA cells, since 1,25(OH)
2
D
3
 is an immunomodulator rather than an 
immunosuppressor. Furthermore, the comparisons were made between microarray data 
for RA patients and RT-PCR for healthy individuals, which are two different methods 
of measuring gene expression and could therefore account for differences. However, 
in general it seems that Th cells from RA patients respond similarly to 1,25(OH)
2
D
3
 
treatment as cells from healthy individuals. Therefore, we believe that the findings in 
this thesis will also apply to CCR6+ memTh cells from RA patients, although more 
experiments are required to definitively confirm that. 
Related to this is the applicability of the findings in this thesis for other autoimmune 
diseases in which Th17 cell populations or their cytokines play a pathogenic role, such 
as multiple sclerosis (MS), inflammatory bowel diseases (IBD) and systemic lupus 
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erythematosus (SLE). Previous studies have shown that 1,25(OH)
2
D
3
 is also related to the 
disease severity in these diseases, and therefore our findings may also be applicable in these 
settings (chapter 2). In terms of the molecular mechanism of 1,25(OH)
2
D
3
 it is of great 
interest to see if the CCR6+ memTh cells of other autoimmune diseases can also switch 
stably towards an anti-inflammatory phenotype. Furthermore, their migratory potential 
towards relevant inflammatory sites should be addressed, such as the cerebrospinal fluid 
in MS and the gut in IBD. Similar to RA, vitamin D could be considered as an additive 
to improve current therapies. Importantly, in IBD is was already shown that patients 
with a higher vitamin D levels have a higher remission rate upon anti-TNFα, suggesting 
an opportunity for vitamin D supplementation.64 In MS a clinical trial with vitamin 
D supplementation in addition to normal therapy has already been performed. After 
20.000 IU of vitamin D were given weekly to patients on IFNβ treatment the vitamin 
D-treated patients had lower MRI disease activity.65 Altogether, the modulation of Th17 
cell populations by 1,25(OH)
2
D
3
 should also be studied in other autoimmune diseases, 
which would assist in better understanding the effects of 1,25(OH)
2
D
3
 under various 
circumstances and may help in improving current therapies in those disease.
Conclusion
Taking all the considerations and discussions into account, this thesis has solved another 
piece of the puzzle on how 1,25(OH)
2
D
3
 modulates the immune system to suppress the 
autoimmune reaction in RA (figure 1). 1,25(OH)
2
D
3
 has the potential of switching pro-
inflammatory CCR6+ memTh cells towards anti-inflammatory cells with regulatory 
capacity, which are stable upon various pro-inflammatory restimulations. IL-4 could 
assist in this process through upregulation of the VDR, making the Th cells more 
susceptible to 1,25(OH)
2
D
3
. Further elucidating the underlying mechanisms may yield 
new therapeutic options, including the transfer of autologous 1,25(OH)
2
D
3
-treated Th 
cells. Furthermore, the data in this thesis suggest that the immunomodulatory effects of 
1,25(OH)
2
D
3
 can be utilized in clinical practice through vitamin D supplementation in 
addition to TNFα blockade. This could potentially be enhanced by combining this with 
a low dose of dexamethasone. Increasing the knowledge on how 1,25(OH)
2
D
3
 modulates 
the immune system and how current treatments could benefit from combination with 
vitamin D supplements will further improve the therapeutic options and thereby enhance 
the quality of life for RA patients.
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SUMMARY
Since the introduction of the biological disease modifying antirheumatic drugs 
(bDMARDs) and the application of new therapeutic strategies, the treatment of 
rheumatoid arthritis (RA) has significantly improved. Although this increased the quality 
of life for RA patients, there is a large group of patients who does not achieve sustained 
remission with the current therapies. Therefore, there is still a need for new therapies and 
improvement of current treatment strategies. This requires a better understanding of the 
underlying RA pathogenesis and how important players in this process can be modulated.
In RA, but also other autoimmune diseases, the immune system is aberrantly activated. As 
a result, there is an immunological imbalance between pro- and anti-inflammatory cells 
which results in an uncontrolled chronic inflammation. Although the exact mechanisms 
that contribute to this imbalance and the development of RA are not yet elucidated, it is 
thought that pro-inflammatory IL-17A-producing T helper (Th) cells play an important 
role. IL-17A-producing Th cells have a memory phenotype and are characterized by 
the transcription factor RORC and the chemokine receptor CCR6. Furthermore, next 
to IL-17A they also produce other pro-inflammatory cytokines such as IL-17F, IL-22, 
IFNγ and GM-CSF. CCR6+ memory Th (memTh) cells are heterogeneous and consist of 
different Th17 populations including Th17 and Th17.1 cells. They can contribute to the 
chronic synovial inflammation in RA through activation of synovial fibroblasts, aberrant 
activation of B cells leading to the production of pathogenic autoantibodies and activation 
of other immune cells via their pro-inflammatory cytokines. 
Considering these pathogenic functions of CCR6+ memTh cells and their elevated levels 
and activity in the blood of treatment-naïve early RA patients compared to healthy 
controls, modulating these cells could restore the immunological balance in autoimmune 
diseases such as RA. Previously, we and others have shown that the active vitamin D 
metabolite 1,25(OH)
2
D
3
 is a potent suppressor of the pro-inflammatory properties of 
CCR6+ memTh cells. Therefore, we explored in this thesis how the CCR6+ memTh 
cells are modulated by 1,25(OH)
2
D
3
 and touch upon how this knowledge could be used 
in clinical practice.
In chapter 3 we examined the mechanisms contributing to the effects of 1,25(OH)
2
D
3
 
on Th17 polarization of Th cells derived from collagen type II-immunized mice, an 
experimental model used to study arthritis. Using in vitro cultures, we found that 
1,25(OH)
2
D
3
 indirectly induces the production of IL-4 and IL-10 within Th17 cells. 
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Although IL-10 is known as an anti-inflammatory cytokine, it is not required for the 
1,25(OH)
2
D
3
-mediated suppression of Th17 differentiation. In contrast, IL-4 augments the 
effects of 1,25(OH)
2
D
3
 on IL-17A and IL-17F. Mechanistically, we demonstrated that IL-4 
induces vitamin D receptor (VDR), making the cells more susceptible to 1,25(OH)
2
D
3
.
Starting from chapter 4 we studied the effects of 1,25(OH)
2
D
3
 in human CCR6+ memTh 
cells. As described above, CCR6+ memTh cells represent a heterogeneous population 
containing various subpopulations. Since it is unknown whether all subpopulations could 
contribute to RA pathogenesis, four subpopulations were studied; Th17, Th17.1, CCR4/
CXCR3 double-negative (DN) and CCR4/CXCR3 double-positive (DP, also named Th17/
Th1) cells. In chapter 4 it was shown that all CCR6+ memTh populations produce IL-17A, 
although at different levels, and that they all express equal levels of RORC. Functionally, 
all subpopulations could contribute to synovial inflammation by activating RA synovial 
fibroblasts (RASF), creating a pro-inflammatory feedback loop in which also the Th cells 
became more activated. RASF activation could be inhibited through IL-17A blockade, but 
not by IFNγ neutralization or knockdown of T-bet. The full pro-inflammatory feedback 
loop could be inhibited by 1,25(OH)
2
D
3
, independent of the CCR6+ memTh subpopulation. 
From this, we concluded that, since all CCR6+ memTh subpopulations can play a role in 
synovial inflammation and that they are all modulated by 1,25(OH)
2
D
3
, it made sense to 
study the effect of 1,25(OH)
2
D
3
 on the total population of CCR6+ memTh cells.
Therefore, we further studied the phenotype changes induced by 1,25(OH)
2
D
3
 within 
CCR6+ memTh cells in chapter 5. In CCR6+ memTh cells of both healthy individuals 
and RA patients, the suppression of pro-inflammatory cytokines such as IL-17A and 
IFNγ is accompanied by induction of the anti-inflammatory cytokine IL-10. Furthermore, 
genes associated with a regulatory phenotype, including FOXP3 and CTLA4, are induced 
in these cells. In line with this gene signature, 1,25(OH)
2
D
3
-treated CCR6+ memTh 
cells suppress the proliferation of autologous CD3+ T cells similar to classical Tregs. 
Importantly, the modulated CCR6+ memTh cells are still capable of migrating towards 
synovial fluid and they retain their suppressive capacity in this environment. As described 
in chapter 6, also the reduced pro-inflammatory properties in 1,25(OH)
2
D
3
-treated CCR6+ 
memTh cells are stable, even upon restimulation through the TCR or via pro-inflammatory 
cytokines. Since we found that the effects of 1,25(OH)
2
D
3
 on CCR6+ memTh cells were 
dependent on the recruitment of histone deacetylases, it is likely that the long-lasting 
change in phenotype is due to epigenetic modifications. Overall, these data show that it is 
possible to switch pro-inflammatory memory Th cells into anti-inflammatory cells with 
10
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functional regulatory capacities. This could be a mechanism through which 1,25(OH)
2
D
3
 
normalizes the immunological balance in RA patients.
Therapeutically, it is not possible to directly supplement patients with high doses of 
1,25(OH)
2
D
3
 due to the risk of severe side effects. Therefore, we studied the potential 
therapeutic value of vitamin D in RA patients in chapters 7 and 8. Previously, we and 
others have shown that combining 1,25(OH)
2
D
3
 with dexamethasone (DEX), a clinically 
used glucocorticoid, has additive effect in modulating immune cells, such as monocytes 
and Th cells, compared to either compound alone. Furthermore, 1,25(OH)
2
D
3
 augments 
the effects of etanercept, a TNFα blocking bDMARD, in the co-culture of CCR6+ memTh 
cells and RASF. In this thesis we found that 1,25(OH)
2
D
3
 and DEX additively suppress 
the pro-inflammatory feedback loop in the CCR6+ memTh-RASF co-culture (chapter 
7). Importantly, a physiologically low dose of DEX significantly improves the effects of 
etanercept on the CCR6+ memTh-RASF coculture. A low dose of 1,25(OH)
2
D
3
 could add 
to this combination through further inhibition of the pathogenicity of CCR6+ memTh 
cells.
The findings from chapter 7 combined with the previously published data that 1,25(OH)
2
D
3
 
augments the effects of etanercept in CCR6+ memTh-RASF cocultures, prompted an 
explorative clinical study to see if vitamin D could actually affect the therapeutic response 
to etanercept. Therefore, we studied the serum vitamin D levels (25(OH)D) in RA patients 
who were treated with etanercept for three months (chapter 8). In this group, we found 
that patients whose 25(OH)D level decreased during the treatment period had a lower 
response rate than those who had an increased 25(OH)D level. Moreover, patients who 
started treatment with a serum 25(OH)D level below 50 nmol/L (classified as vitamin 
D-deficient) had a lower response rate than those with a higher 25(OH)D level at the start 
of etanercept treatment. Although these data do not demonstrate causality, they suggest 
a beneficial role for vitamin D in the treatment response to etanercept.
Overall, this thesis has elucidated some key concepts in the 1,25(OH)
2
D
3
-mediated 
suppression of the immune system in autoimmune diseases such as RA. Future efforts 
should concentrate on further elucidating the phenotypic changes in CCR6+ memTh 
cells, as this could yield new therapeutic opportunities. Another area to investigate is 
the supplementation of vitamin D and combination with DEX in the treatment with 
etanercept, an potentially other TNFα-targeting drugs, to improve the response in patients 
with RA.
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SAMENVATTING
De behandeling van reumatoïde artritis (RA) is sterk verbeterd sinds de introductie van 
biologische Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) en het implementeren 
van nieuwe behandelingsstrategieën. Hoewel dit de kwaliteit van leven verbeterde voor 
veel patiënten, is er nog steeds een grote groep patiënten die niet in remissie komen of die 
resistent worden tegen de huidige behandelingen. Het is daarom van belang om nieuwe 
therapieën en behandelstrategieën te ontwikkelen. Hiervoor moeten we beter begrijpen 
welke processen ten grondslag liggen aan de ontwikkeling van RA en hoe belangrijke 
spelers in die processen kunnen worden gemoduleerd.
In RA, maar ook in andere auto-immuunziekten, is het immuunsysteem verkeerd 
geactiveerd. Hierdoor is er een immunologische disbalans tussen de pro- en anti-
inflammatoire cellen, wat leidt tot een ongecontroleerde chronische ontsteking. Hoewel 
de precieze mechanismen die bijdragen aan deze disbalans nog niet bekend zijn, wordt 
gedacht dat pro-inflammatoire IL-17A-producerende T-helper (Th) cellen een belangrijke 
rol spelen. IL-17A-producerende Th cellen hebben een geheugen (memory) fenotype en 
worden gekarakteriseerd door de transcriptiefactor RORC en de chemokine receptor 
CCR6. Verder maken ze naast IL-17A ook andere pro-inflammatoire cytokines, zoals 
IL-17F, IL-22, IFNγ en GM-CSF.  Deze CCR6+ geheugen Th (memTh in dit proefschrift) 
cellen zijn heterogeen en bestaan uit verschillende Th17 celpopulaties, zoals Th17 en 
Th17.1 cellen. CCR6+ memTh cellen kunnen bijdragen aan de chronische synoviale 
ontstekingen in RA door het activeren van synoviale fibroblasten, het verkeerd activeren 
van B cellen waardoor zij pathogene auto-antilichamen gaan maken en het activeren van 
andere immuuncellen door het produceren van pro-inflammatoire cytokines.
Gezien de pathogene functies van CCR6+ memTh cellen en hun verhoogde aanwezigheid 
en activiteit in het bloed van onbehandelde vroege RA patiënten vergeleken met 
gezonde individuen, zou het moduleren van deze cellen de immunologische balans in 
auto-immuunziekten zoals RA kunnen herstellen. Eerder hebben wij en anderen laten 
zien dat de actieve vorm van vitamine D, 1,25(OH)
2
D
3
 effectief de pro-inflammatoire 
eigenschappen van CCR6+ memTh cellen onderdrukt. Daarom hebben we in dit 
proefschrift onderzocht hoe CCR6+ memTh cellen gemoduleerd worden door 1,25(OH)
2
D
3
 
en gaan we kort in op hoe dit gebruikt kan worden in de klinische praktijk.
In hoofdstuk 3 hebben we onderzocht welke mechanismen een rol spelen in de effecten 
van 1,25(OH)
2
D
3
 op Th17 polarisatie van Th cellen geïsoleerd uit collageen type II-
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geïmmuniseerde muizen, een experimenteel model wat gebruikt wordt voor het bestuderen 
van artritis. In deze in vitro celkweken, vonden we dat 1,25(OH)
2
D
3
 indirect de productie 
van IL-4 en IL-10 in Th17 cellen stimuleert. Hoewel IL-10 bekend staat als een anti-
inflammatoire cytokine, was deze niet nodig voor de suppressie van Th17 polarisatie 
door 1,25(OH)
2
D
3
. Daarentegen vergrootte IL-4 de effecten van 1,25(OH)
2
D
3
 op IL-17A 
en IL-17F. Mechanistisch hebben we aangetoond dat IL-4 de transcriptie van de vitamine 
D receptor (VDR) stimuleert, waardoor de cellen gevoeliger worden voor 1,25(OH)
2
D
3
.
Vanaf hoofdstuk 4 hebben we de effecten van 1,25(OH)
2
D
3
 op humane CCR6+ memTh 
cellen onderzocht. Zoals hierboven beschreven zijn CCR6+ memTh cellen heterogeen 
en bevatten ze verschillende subpopulaties. Omdat het onbekend is of alle subpopulaties 
kunnen bijdragen aan de pathogenese in RA, zijn vier CCR6+ memTh subpopulaties 
onderzocht; Th17, Th17.1, CCR4/CXCR3 dubbel-negatieve (DN) en CCR4/CXCR3 dubbel-
positieve (DP, ook wel Th17/Th1 genoemd) cellen. In hoofdstuk 4 werd beschreven dat 
alle CCR6+ memTh subpopulaties IL-17A maken, hoewel de hoeveelheid verschilde, 
en dat ze allemaal evenveel RORC tot expressie brengen. Functioneel gezien konden 
alle subpopulaties bijdragen aan synoviale ontsteking door het activeren van synoviale 
fibroblasten uit RA patienten (RASF) en daardoor het aanzetten van een pro-inflammatoire 
feedback loop waarin ook de Th cellen extra geactiveerd raken. De activatie van RASF 
kon worden geremd door het blokkeren van IL-17A, maar niet door het remmen van IFNγ 
of T-bet. De volledige pro-inflammatoire loop kon worden geremd door 1,25(OH)
2
D
3
, 
onafhankelijk van de CCR6+ memTh subpopulatie. Hieruit concludeerden we dat, omdat 
alle CCR6+ memTh subpopulaties een rol kunnen spelen in synoviale ontsteking en ze 
allemaal geremd worden door 1,25(OH)
2
D
3
, het logisch was om het effect van 1,25(OH)
2
D
3
 
op de gehele CCR6+ memTh populatie te bestuderen.
Daarom hebben we in hoofdstuk 5 de veranderingen in het fenotype van de gehele CCR6+ 
memTh populatie door 1,25(OH)
2
D
3
 verder bestudeerd. In de CCR6+ memTh cellen van 
zowel gezonde individuen als RA patiënten wordt de onderdrukking van pro-inflammatoire 
cytokines zoals IL-17A en IFNγ vergezeld door inductie van het anti-inflammatoire 
cytokine IL-10. Bovendien worden genen die geassocieerd zijn met een regulatoir 
fenotype, zoals FOXP3 en CTLA4, geïnduceerd in deze cellen. In overeenstemming met 
deze veranderingen kunnen 1,25(OH)
2
D
3
-behandelde CCR6+ memTh cellen even goed de 
proliferatie van autologe CD3+ T cellen remmen als klassieke Tregs. Belangrijk hierbij te 
vermelden is dat de gemoduleerde CCR6+ memTh cellen nog steeds naar synoviaal vocht 
kunnen migreren en hun suppressieve capaciteiten behouden in deze omgeving. Zoals 
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in hoofdstuk 6 wordt beschreven is ook de onderdrukking van de pro-inflammatoire 
eigenschappen van de gemoduleerde CCR6+ memTh cellen stabiel, zelfs na restimulatie 
van de TCR of met pro-inflammatoire cytokines. Aangezien we hebben gevonden dat de 
effecten van 1,25(OH)
2
D
3
 op CCR6+ memTh cellen afhankelijk zijn van het aantrekken 
van histon deacetylases, is het aannemelijk dat de langdurige aanpassing van het fenotype 
in deze cellen veroorzaakt wordt door epigenetische modificaties. Samenvattend laten deze 
data zien dat het mogelijk is om pro-inflammatoire geheugen Th cellen om te schakelen 
naar anti-inflammatoire cellen met functionele regulatoire capaciteiten. Dit zou een van 
de mechanismen kunnen zijn waarmee 1,25(OH)
2
D
3
 de immunologische balans in RA 
patiënten kan herstellen.
Het is niet mogelijk om patiënten direct te behandelen met een hoge dosis 1,25(OH)
2
D
3
 
in verband met het risico op ernstige bijwerkingen. Daarom hebben we de mogelijke 
therapeutische waarde van vitamine D in RA patienten onderzocht in hoofdstuk 7 en 
8. Eerder hebben wij en anderen al laten zien dat de combinatie van 1,25(OH)
2
D
3
 met 
dexamethason (DEX), een glucocorticoïde die vaak wordt gebruikt in de behandeling 
van patiënten, een toegevoegde waarde heeft in het moduleren van verschillende cellen 
van het immuunsysteem, zoals monocyten en T cellen, vergeleken met een van de twee 
stoffen alleen. Bovendien vergroot 1,25(OH)
2
D
3
 de effecten van etanercept, een TNFα 
blokkerende DMARD, in een gecombineerd kweekmodel van CCR6+ memTh cellen en 
RASF. In dit proefschrift hebben we ontdekt dat 1,25(OH)
2
D
3
 en DEX een additief effect 
hebben in de pro-inflammatoire feedback loop in deze CCR6+ memTh-RASF kweken 
(hoofdstuk 7). Verder vonden we dat een fysiologisch lage dosis van DEX de effecten 
van etanercept in het kweekmodel significant verbeterde. Als hieraan een lage dosis 
1,25(OH)
2
D
3
 wordt toegevoegd kan dit leiden tot verdere remming van de pathogeniciteit 
van CCR6+ memTh cellen.
De bevindingen van hoofdstuk 7, gecombineerd met de eerder gepubliceerde data dat 
1,25(OH)
2
D
3
 de effecten van etanercept verbetert in CCR6+ memTh-RASF kweken, leidde 
tot een verkennende klinische studie om te zien of vitamine D inderdaad de reactie op 
etanercept kon verbeteren. Hiervoor hebben we het serum vitamine D gehalte, gemeten 
als 25(OH)D, bepaald in RA patiënten die 3 maanden met etanercept zijn behandeld 
(hoofdstuk 8). In deze groep vonden we dat patiënten wiens 25(OH)D gehalte toenam 
tijdens de behandelperiode beter reageerden dan degenen bij wie het 25(OH)D gehalte 
af nam. Ook patiënten die bij het starten van de behandeling een 25(OH)D gehalte hoger 
dan 50 nmol/L hadden (geclassificeerd als vitamine D deficiënt), reageerden beter op de 
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behandeling met etanercept dan degenen met een lager 25(OH)D gehalte. Hoewel deze 
data geen causaliteit aangeven, suggereren ze dat er een positieve rol voor vitamine D is 
bij de behandeling met etanercept.
Met het bovenstaande onderzoek heeft dit proefschrift enkele belangrijke concepten 
verhelderd met betrekking tot de onderdrukking van het immuunsysteem door vitamine 
D in auto-immuunziekten zoals RA. In de toekomst zal de aandacht moeten uitgaan naar 
het verder uitzoeken van de fenotypische verandering in CCR6+ memTh cellen, omdat 
dit mogelijk nieuwe therapeutische mogelijkheden zal bieden. Een ander aandachtsgebied 
is het onderzoeken van vitamine D supplementatie en de combinatie met DEX in 
behandelingen met etanercept, en mogelijk andere medicijnen die TNFα remmen, om de 
behandelingen voor RA patiënten te verbeteren.
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DANKWOORD 
Klaar! Soms heb ik getwijfeld of het ooit ging lukken, maar nu ligt mijn proefschrift 
dan toch echt voor je. Als ik de afgelopen 6,5 jaar moet omschrijven is ‘achtbaan’ toch 
wel het beste woord. Hele diepe dalen, maar ook heel veel mooie, leuke, gezellige en 
grappige momenten. Dit boekje had hier niet gelegen zonder alle fantastische mensen 
om me heen, dus die wil ik hier graag bedanken.
Ten eerste wil ik natuurlijk mijn promotor Prof. Hazes bedanken. Mieke, bedankt dat 
je me de mogelijkheid hebt gegeven om bij de Reumatologie te promoveren. Je zorgt er 
altijd voor dat we de klinische relevantie van ons onderzoek niet uit het oog verliezen, 
en ik ben blij dat we met de laatste twee hoofdstukken een stapje in die richting hebben 
kunnen zetten.
En dan uiteraard mijn co-promotor Erik. Je hebt het aangedurfd om mij aan het uitdagende 
vitamine D-project te laten werken. In de afgelopen jaren heb ik met veel plezier met je 
gediscussieerd over hoe het project verder moest en hoe we de data completer konden 
maken, en ik heb veel geleerd van je eindeloze stroom ideeën. Ik kon ook altijd bij je 
binnen lopen om iets te bespreken en je steun tijdens de moeilijke, maar ook euforische, 
momenten hebben het mogelijk gemaakt dat mijn boekje er toch echt is gekomen. Bedankt 
voor alles en ik hoop dat we blijven samenwerken!
Ik wil ook graag de rest van mijn commissie bedanken. Professor Katsikis, professor 
Tak en dr. Samsom, bedankt voor het kritisch lezen van het proefschrift. Professor 
Toes, professor Hintzen en dr. Damoiseaux, bedankt voor het plaatsnemen in de grote 
commissie.
Hoewel hij niet in mijn officiële commissie zit, wil ik toch ook graag Edgar bedanken. Je 
bent altijd actief betrokken geweest bij mijn onderzoek en daarom ook co-auteur op alle 
hoofdstukken in dit boekje. Je enthousiasme voor onderzoek doen werkt aanstekelijk en 
ik hoop dat je dit blijft doorgeven aan nieuwe studenten. Bedankt!
Als je aan het promoveren bent, breng je zoveel tijd door op je werk dat je collega’s 
vrienden worden. Gelukkig had ik de meest fantastische labgenoten die je kunt bedenken, 
dus die wil ik natuurlijk ook graag bedanken. 
Ten eerste de analisten, zonder wiens organisatie- en pipetteerskills al het labonderzoek 
compleet in het honderd zou lopen. Nadine, je hebt deze FACS- en ELISA-kneus flink wat 
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moeten leren, maar ik denk dat het je toch redelijk gelukt is. Zonder jouw hulp met onder 
andere sort-dagen, qPCRs en ELISAs waren alle hoofdstukken in dit boekje er echt nog 
lang niet geweest! Het was altijd gezellig om met jou te werken, te squashen of gewoon 
te kletsen. Misschien ook omdat jouw vrijdagmiddag-buien zich regelmatig uitstrekten 
over de rest van de week. Je moet alleen echt nog even het verschil leren tussen de baas 
zijn en gelijk hebben, maar daar gaan we nog wel aan werken want we blijven natuurlijk 
contact houden. Ik ben blij dat je mijn paranimf bent!
Patrick, wat hebben we een hoop uren doorgebracht bij de sort, soms tot ’s avonds laat. 
Je hulp hierbij, maar ook bij het muizen immuniseren, de fibroblasten kweken en het 
inpipetteren van de ELISA-verdunningen de laatste maanden was super! Je eerlijkheid, 
humor en de gesprekken over koken, eten en je tuin maakten die lange dagen gewoon 
weer leuk. Anne-Marie, hoewel we niet heel erg veel samen in het lab gestaan hebben, 
staan vooral je enorme snelheid bij het buffy’s opwerken en je hulp bij de grote ELISAs de 
laatste maanden me bij. Maar ik kon ook altijd bij je terecht voor het regelen van labzaken 
en natuurlijk om gewoon even (of iets langer dan even) te kletsen over allerlei (on)zinnige 
zaken. Eddy, helaas hebben we nooit in het lab samengewerkt, maar we hebben wel heel 
veel gelachen. Chicken breasts worden nooit meer normaal in mijn hoofd ben ik bang.
Degenen die het beste weten wat je meemaakt als promovendus zijn natuurlijk je mede-
promovendi. Laat ik beginnen bij mijn andere paranimf; Sandra. Je was net iets eerder 
begonnen dan ik, dus we konden mooi alles samen doen. Dingen als de statistiekcursus, 
de memorabele MolMed cursus en alle congressen werden zo een stuk gezelliger. Ook 
de Boudewijn borrels en etentjes waren leuk, en dat moeten we zeker weer doen als ik 
in Nederland ben. Niet onbelangrijk; ik vind het ook nog altijd super dat ik een tijdje in 
je appartement mocht overnachten. Het is super om te zien dat je nu een baan hebt die 
helemaal bij je past en dat je een prachtig gezinnetje vormt met Jan Piet en Tim. Bedankt 
dat je mijn paranimf wilt zijn, met jou en Nadine naast me moet het helemaal goed komen!
Odilia, je was al halverwege je promotie toen ik kwam en ik ben nog steeds onder de 
indruk van de hoeveelheid werk die jij kon/kan verzetten op een experimentdag. Ik denk 
toch dat die 4 uur extra levenservaring een wereld van verschil maken ;). Laten we snel 
weer banoffee pie maken (en opeten)!
Marlieke, je hebt niet een heel makkelijk promotieproject gehad, maar je hebt zoveel 
geleerd de afgelopen jaren dat je binnenkort vast een mooi boekje gaat afleveren. Bedankt 
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voor al het sparren en de kletspraatjes tussendoor! Wida, je was een fantastische student 
en ik ben blij dat je daarna in het lab bent blijven werken. Ik vond het heel gezellig met 
jou op de kamer de laatste paar jaar en ik zal onze gesprekjes missen. Heel veel succes 
met de laatste maanden, je kunt het! Xiaofei, it was great to learn a bit more about Chinese 
culture and habits from you. Best of luck with finishing your project! Hannah, je bent 
al mijn tweede superstudent die bij het lab blijft hangen, en dat ondanks mijn duivelse 
begeleiding ;). Je bent pas net begonnen, maar wat ik nu kan zien gaat dat helemaal goed 
komen. Bedankt voor al je hulp en je waardevolle klinische inzichten het afgelopen jaar, 
en heel veel succes met je project!
Naast Wida en Hannah heb ik het geluk gehad om met nog meer getalenteerde studenten te 
werken. Sahar, Priyanca en Claudia; thanks for all the work you have done, the good times 
in the lab and I wish you all luck and happiness in the rest of your (professional) lives.
Natuurlijk is er ook een oud-labgenoot die ik hier niet moet vergeten. Jan Piet, toen ik in 
het lab kwam heb jij me meteen op sleeptouw genomen om de eerste experimenten op te 
zetten en uit te voeren. Ik heb veel van je geleerd en ben blij met de input die je altijd wilt 
geven. Bedankt hiervoor, voor dat ik op je huis mocht passen (en dus een paar uur van 
m’n wekelijkse reistijd kon afhalen) toen je in de VS was en ook voor alle gezelligheid 
en borrels natuurlijk. 
Tenslotte ook alle andere (oud-)labgenoten; Amy, Dennis, Desiré, Franka, Heleen, Hoyan, 
Henrique, Maarten, Nazike, Nazila, Radjesh, Saynur en Zahide, bedankt voor jullie 
gezelligheid!
De afdeling Reumatologie bestaat niet alleen uit het lab, dus ik wil ook graag de rest van 
de afdeling bedanken. Ten eerste natuurlijk Joyce, onze fantastische organisator van alle 
afdelingsactiviteiten, maar ook altijd bereid om te helpen en geïnteresseerd in hoe het met 
mensen gaat. Je bent top! Radboud, je doet niet alleen ontzettend fascinerend onderzoek, 
je altijd kritische blik heeft menig onderzoek op de afdeling vooruit gebracht. Ik kijk ook 
met veel plezier terug op je betrokkenheid en onze gesprekken tussen het werk door en 
op congressen, bedankt! Pascal, je ongeremde enthousiasme werkt aanstekelijk. Je kennis 
van de tREACH data en statistische analyses heeft het laatste hoofdstuk in dit boekje 
mogelijk gemaakt, bedankt daarvoor! Albert, Annemarie, Angelique, Anke, Annelieke, 
David, Esther, Florentien, Hetty, Hilal, Jenny, Kim, Maren, Margot, Marijn, Martijn, 
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Myrthe, Petra, Philomine, Ron, Rosaline en Sylvia, ook jullie ontzettend bedankt voor 
alle input en gezelligheid de afgelopen jaren!
Naast de Reumatologie heb ik ook veel tijd doorgebracht bij de afdeling Immunologie. 
Daarom wil ik ook graag alle collega’s van de Immunologie bedanken. In het lab waren 
Wouter, Marie-José, Anne, Annette, Inge en Marjan altijd behulpzaam bij alle vragen 
over apparaten en reagentia. Harm en Peter, bedankt voor jullie geduld bij alle sorts van 
het laatste jaar! Marvin, bedankt voor de leuke samenwerking op het project voor de MS 
stichting en het net-gepubliceerde paper in Brain! De borrels, labdagen en PhD retreats 
waren toch ook wel hoogtepunten van de samenwerking met de Immunologie. Martine, 
Chris, Michèle en Maarten, I had a great year with the GMO’s! Prisca en Alice, bedankt 
voor het leuke jaar als PhD-commissie! Jenna, I’m glad that we became friends over 
the years you worked in Rotterdam. I’m looking forward to your wedding, our vacation 
plans in California (we may need to plan a few months) and we should definitely meet in 
Hawaii. Natuurlijk ook alle andere PhDs bedankt voor de heerlijke en memorabele PhD 
retreats en de gezelligheid tijdens de borrels (en nu hoop ik dat ik niemand vergeet…); 
Anne, Britt, Chris, Christina, Fabian, Hannah, Jamie, Jeroen, Jorn, Karin, Liza, Malou, 
Marieke, Marjolein, Matti, Naomi, Prayer, Simar, Willem-Jan, Wouter en Zana.
Tijdens mijn promotie heb ik ook samen gewerkt met collega’s buiten onze afdelingen. 
Sjoerd en Sandra, bedankt voor jullie onmisbare hulp bij het meten en interpreteren van 
de vitamine D levels. I also got the awesome opportunity to work at the NIH in Bethesda. 
Dr. O’Shea, John, thank you so much for the amazing time in your lab. It was fantastic to 
learn from such a great scientist and I’m glad we still keep in touch. Yuka, thank you for 
all the help with the ChIP-seq experiments and showing me around in the lab. 
Hoewel een promotie veel van je tijd in beslag neemt, blijft er gelukkig ook wel wat tijd 
over voor alle fantastische mensen buiten het werk. Zij hebben allemaal gezorgd voor de 
broodnodige ontspanning, ondersteuning en gezelligheid, waar ik niet zonder zou kunnen!
Tera, ik weet niet goed hoe ik de zwaarste tijd van mijn leven had doorstaan zonder jouw 
constante steun, met elke dag whatsappjes en een schouder of afleiding wanneer ik het 
nodig had. Al sinds de middelbare school kunnen we goed praten en vooral heel veel 
lachen; je bent fantastisch! Ik ben vereerd dat jij als award-winning artiest de omslag van 
dit boekje hebt willen ontwerpen en painten, en dat Alexandra daar ook nog zo’n mooie 
foto van heeft weten te maken. Bedankt allebei! En dan de rest van onze Eetclub; Suzanne, 
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Claire, Anne-Marie en Anke. Ook jullie ken ik al sinds de middelbare school, laten we 
maar niet gaan terugrekenen hoe lang dat geleden is. Bedankt voor alle fantastische 
herinneringen, gezelligheid, het verrassingsweekendje, het we-worden-allemaal-30-
weekendje… teveel om op te noemen. Ook al ben ik eventjes aan de andere kant van de 
wereld, ik ga er vanuit dat we gewoon contact houden en dat we snel sushi gaan eten als 
ik weer in Nederland ben.
Alex, Marian, Jens, Ties en Fedde, mijn familie die niet officieel familie is, ik voel 
me altijd thuis bij jullie. Marian, we denken over zoveel dingen hetzelfde dat het altijd 
makkelijk is om met je te kletsen en om samen leuke dingen te doen. Laten we zeker een 
etentje, film of musical inplannen als ik in Nederland ben! Alex, dankzij jou wordt een 
dikke deken in de kast nooit meer hetzelfde en blijf ik voor altijd dol op Flügel. Bedankt 
voor de goede gesprekken en je gezelligheid. Lieve Jens, Ties en Fedde, ik kan niet geloven 
hoeveel groter, slimmer en leuker jullie iedere keer weer worden. Ik ben dol op jullie!
Hanneke, Jurgen, Tamara, Sjoerd, Annemieke, Michel en Floris; we kennen elkaar al heel 
erg lang maar het is gewoon nog steeds leuk! Onze weekjes en weekendjes in Centerparcs 
en later de Ardennen waren altijd heerlijke ontspanning en ik hoop dat we dit zeker blijven 
doen. Bedankt voor alles!
Jolanda, mijn studiemaatje uit Enschede, het is eigenlijk een wonder dat we onze studie 
überhaupt gehaald hebben als je kijkt naar het aantal college-uren dat we doorbrachten 
op mijn kamer met bugles en films. Onze vriendschap is moeiteloos, we kunnen kletsen, 
naar Guus Meeuwis of gewoon ontspannen films kijken met chocolade-fondue ernaast, 
het maakt eigenlijk niet uit. Ik kijk uit naar nog veel meer zulke avondjes!
Maarten en Saskia, natuurlijk kenden we elkaar al sinds ik samen was met Thomas, 
maar in de afgelopen 4 jaar zijn jullie echt goede vrienden geworden. Ik ben blij met 
jullie vriendschap, niet alleen door alles wat we samen hebben meegemaakt, maar ook 
de heerlijke vakantie in Frankrijk en alle gezellige tijden daarna. Bedankt!
Paul, Lucia, Bernadette, Bauke, Stephan, Michelle, Richard en Emi, wat is er toch allemaal 
gebeurd? Ik snap het soms nog steeds niet helemaal, maar ik weet wel dat ik blij ben met 
hoe we ermee omgaan en dat we nog steeds contact hebben met elkaar. Ik voel me nog 
steeds thuis bij jullie en ik hoop dat dat zo blijft. Dankjulliewel!
259
Addendum
Rob, Monique en Remco, ik vind het nog steeds zo bijzonder dat ik meteen mee mocht 
naar Indonesië! Het was een heerlijke reis, en ook daarna bleef het gezellig. Bedankt 
hiervoor, en hopelijk jullie snel langs in Australië!
En dan mijn ‘kleine’ zussie! Joyce, we spreken elkaar niet wekelijks, maar ik weet dat je 
er altijd bent als het nodig is. Als we elkaar zien is het ook altijd gezellig en ik ben blij 
dat je mijn zusje bent!
Papa en mama, bedankt voor jullie onvoorwaardelijke steun waardoor ik kon studeren, in 
Rotterdam kon werken zonder iedere avond terug naar Enschede te moeten en uiteindelijk 
dit boekje er dus ligt. Het is altijd leuk om weer even ‘thuis’ te komen en lekker met z’n 
allen te gourmetten, barbecueën of uit eten te gaan. Bedankt voor alles!
Lieve Thomas, wat is het verschrikkelijk oneerlijk dat je er niet meer bent. Dankzij jou ben 
ik geworden wie ik ben en had ik het vertrouwen om te beginnen aan dit promotietraject. 
Ik ben dankbaar dat ik bijna 10 jaar deel van je leven mocht zijn, en ik mis je.
En last but not least natuurlijk mijn fantastische verloofde Jasper. Samen met jou is alles 
leuker, van lekker uit eten tot foodfestivals tot korfballen tot op vakantie gaan tot samen 
op de bank hangen. Dankzij jouw steun ben ik niet gillend gek geworden de afgelopen 
maanden en ligt er nu echt een proefschrift. Ik kan niemand bedenken met wie ik liever 
het avontuur van verhuizen naar Australië zou willen aangaan. Ik hou van je en kijk uit 
naar onze toekomst samen.
10
260
Chapter 10
PORTFOLIO
 
Name PhD student: Wendy Dankers 
Erasmus MC Department Rheumatology 
Research School: Molecular Medicine
PhD period: 2011-2018 
Promoter: Prof. Dr. J.M.W. Hazes 
Supervisor: Dr. E. Lubberts
1. PhD training Year Workload (ECTS)
Courses
- Presenting skills for scientists 2011 1
- Molecular Immunology 2012 3
- Biostatistcial methods I: basic principles 2012 5.7
- Course on molecular medicine 2012 0.7
- Laboratory animal science 2014 3
- Time management for PhD students and postdocs 2015 1
- Biomedical English writing 2015 2
(Inter)national conferences
Oral presentations
- NVVI annual meeting 2011, 2012 2
- NVR annual meeting 2012, 2016 2
- MolMed Day 2012, 2015 2
- Vitamin D workshop 2015 1
- EULAR 2012 1
Poster and pitch presentations
- European Workshop for Rheumatology Research 2012, 2013, 2015, 2016, 
2017
5
- Dublin Cytokines meeting 2012 1
- MolMed day 2013, 2016 2
- ICIS annual meeting 2013 1
- EULAR annual meeting 2013 1
- NVVI annual meeting 2014, 2015, 2016 3
- ACR annual meeting
- EWIMID
2014, 2016
2017
2
1
Other
- Immunology journal club 2011-2015 2
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2. Teaching Year Workload (ECTS)
Supervising Master theses
-  Master’s student Biopharmaceutical Sciences (Leiden University), 
7 months
2014 10
- Master’s student Molecular Medicine (Erasmus MC), 10 months 2016-2017 20
Supervising internships
- Master’s student Infection and Immunity (Erasmus MC), 5 months 2012 10
-  Bachelor’s student Hoger Laboratorium Onderwijs  
(Avans Hogeschool Breda), 7 months
2012-2013 14
- Master’s student Molecular Medicine (Erasmus MC), 8 months 2016-2017 16
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PUBLICATIONS
 
This thesis 
Vitamin D in autoimmunity: molecular mechanisms and therapeutic potential 
Wendy Dankers, Edgar M. Colin, Jan Piet van Hamburg, Erik Lubberts 
Frontiers in Immunology, 2017, 7:697
IL-4 enhances 1,25(OH)
2
D
3
-mediated inhibition of Th17 polarization through 
upregulation of the vitamin D receptor  
Wendy Dankers, Jan Piet van Hamburg, Wida Razawy, Nadine Davelaar, Adriana 
M.C. Mus, Patrick S. Asmawidjaja, Louis Boon, Edgar M. Colin, Erik Lubberts 
Submitted
CCR6+ memory T-helper subpopulations, including Th17 and Th17.1 cells, activate 
synovial fibroblasts from rheumatoid arthritis patients and can be modulated by 
1,25(OH)
2
D
3 
Wendy Dankers, Hannah den Braanker, Sandra M.J. Paulissen, Jan Piet van 
Hamburg, Nadine Davelaar, Edgar M. Colin, Erik Lubberts 
Manuscript in preparation 
Human memory Th17 cell populations change into anti-inflammatory cells with 
regulatory capacity upon exposure to active vitamin D 
Wendy Dankers, Nadine Davelaar, Jan Piet van Hamburg, Jeroen van de Peppel, 
Edgar M. Colin, Erik Lubberts 
Submitted
1,25(OH)
2
D
3
 uses histone modifications for long-term suppression of IL-17A, IL-22 and 
IFNγ in CCR6+ T-helper memory cells 
Wendy Dankers, Nadine Davelaar, Edgar M. Colin, Erik Lubberts 
Submitted
1,25(OH)
2
D
3
 and dexamethasone additively suppress synovial fibroblast activation by 
CCR6+ Th memory cells and enhance the effect of TNFα blockade 
Wendy Dankers, Claudia González-Leal, Nadine Davelaar, Patrick S. Asmawidjaja, 
Adriana M.C. Mus, Johanna M.W. Hazes, Edgar M. Colin, Erik Lubberts 
Submitted
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Improved response to etanercept with non-deficient or increasing serum vitamin D 
levels in rheumatoid arthritis 
Wendy Dankers, Pascal H.P. de Jong, Sandra Heil, Sjoerd A.A. van den Berg, 
Angelique E. Weel, Johanna M.W. Hazes, Edgar M. Colin, Erik Lubberts 
Submitted
Other 
The role and modulation of CCR6+ Th cell populations in rheumatoid arthritis 
Sandra M.J. Paulissen, Jan Piet van Hamburg, Wendy Dankers, Erik Lubberts 
Cytokine, 2015, 74:43
Th17.1 cells associate with multiple sclerosis disease activity: perspectives for early 
intervention 
Jamie van Langelaar, Roos M. van der Vuurst de Vries, Malou Janssen, Annet F. 
Wierenga-Wolf, Isis M. Spilt, Theodora A. Siepman, Wendy Dankers, Georges M. 
Verjans, Helga E. de Vries, Erik Lubberts, Rogier Q. Hintzen, Marvin M. van Luijn 
Brain, 2018, 141(5):1334
Nothern Lights Assay: A versatile method for comprehensive detection of DNA 
damage 
Bjarki Gudmundsson, Hans G. Thormar, Albert Sigudssron, Wendy Dankers, Margret 
Steinarsdottir, David Olafsson, Anna M. Halldorsdottir, Stephen Meyn, Jon J. Jonsson 
Submitted
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